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SUMMARY 
Cancer is the second cause of death after cardio-vascular diseases in economically developed 
countries. Two of the most commonly used anti-cancer therapies are chemo and radiotherapy. 
Despite the remarkable advances made in term of delivery and specificity of these two anti-tumor 
regimens, their toxicity towards healthy tissue remains a limitation. A promising approach to 
overcome this obstacle would be the utilization of therapeutic peptides that specifically augment 
the sensitivity of tumoral cells to treatments. Lower therapeutical doses would then be required to 
kill malignant cells, limiting toxic effects on healthy tissues. 
It was previously shown in our laboratory that the caspase-3 generated fragment N2 of RasGAP 
is able to potentiate the genotoxin-induced apoptosis selectively in cancer cells. In this work we 
show that fragment N2 strictly requires a cytoplasmic localization to deliver its pro-apoptotic 
effect in genotoxin-treated cancer cells. 
The tumor sensitizing capacity of fragment N2 was found to reside within the 10 amino acid 
sequence 317-326. Our laboratory earlier demonstrated that a peptide corresponding to amino 
acids 317 to 326 of RasGAP fused to the TAT cell permeable moiety, called TAT-RasGAP317-326, 
is able to sensitize cancer cells, but not normal cells, to genotoxin-induced apoptosis.   
In the present study we describe the capacity of TAT-RasGAP317-326 to sensitize tumors to both 
chemo and radiotherapy in an in vivo mouse model. The molecular mechanism underlying the 
TAT-RasGAP317-326-mediated sensitization starts now to be elucidated. We demonstrate that 
G3BP1, an endoribonuclease binding to amino acids 317-326 of RasGAP, is not involved in the 
sensitization mechanism. We also provide evidence showing that TAT-RasGAP317-326 potentiates 
the genotoxin-mediated activation of Bax in a tBid-dependent manner.  
Altogether our results show that TAT-RasGAP317-326 could be potentially used in cancer therapy 
as sensitizer, in order to improve the efficacy of chemo and radiotherapy and prolong the life 
expectancy of cancer patients. Moreover, the understanding of the TAT-RasGAP317-326 mode of 
action might help to unravel the mechanisms by which cancer cells resist to chemo and 
radiotherapy and therefore to design more targeted and efficient anti-tumoral strategies. 
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RÉSUMÉ 
Le cancer est la cause principale de mortalité dans les pays économiquement développés. Malgré la 
grande hétérogénéité qui existe au sein des différents cancers, le manque de contrôle de prolifération ainsi 
que l’impossibilité de mourir par apoptose représentent les prérequis essentiels pour l’établissement et le 
développement du cancer. Deux des thérapies anti-cancéreuses les plus utilisées sont la chimiothérapie et 
la radiothérapie. Malgré les progrès remarquables effectués en termes de spécificité et d’acheminement de 
ces deux stratégies, leur toxicité envers les tissus sains reste une limitation pour leur utilisation. Une 
stratégie prometteuse afin de surmonter cet obstacle serait d’utiliser des peptides thérapeutiques qui 
augmentent spécifiquement la sensibilité des cellules tumorales aux traitements, ce qui permettrait de 
diminuer les doses utilisées et réduirait ainsi les effets secondaires toxiques sur les tissus sains.    
Notre laboratoire a démontré précédemment que le fragment N2, résultant du clivage de RasGAP par la 
caspase-3, avait la propriété de potentialiser l’apoptose induite par des génotoxines, et ceci spécifiquement 
dans les cellules cancéreuses. Dans cette étude, nous montrons que le fragment N2 requiert une 
localisation strictement cytoplasmique afin d’avoir une action pro-apoptotique dans les cellules 
cancéreuses traitées aux génotoxines.  
L’effet de sensibilisateur tumoral que possède le fragment N2 est toujours conservé dans une séquence 
minimale de 10 acides aminés à l’intérieur du fragment N2, la séquence 317 à 326. Notre groupe de 
recherche a démontré précédemment qu’un peptide correspondant aux acides aminés 317 à 326 de la 
protéine RasGAP fusionné au peptide de perméabilisation TAT, appelé TAT-RasGAP317-326, avait le 
pouvoir de sensibiliser les cellules cancéreuses, mais pas les cellules saines, à la mort induite par les 
génotoxines. 
Dans cette étude, nous décrivons le pouvoir du peptide TAT-RasGAP317-326 à sensibiliser les tumeurs à la 
chimio- et à la radiothérapie in vivo à l’aide d’un modèle murin. Les mécanismes moléculaires à la base de 
cette sensibilisation commencent désormais à être élucidés. Nous avons démontrés que G3BP1, une 
endoribonucléase connue pour se lier aux acides aminés 317-326 de RasGAP, n’était pas impliquée dans 
cette sensibilisation. Nous avons aussi amené la preuve que TAT-RasGAP317-326 potentialise l’activation 
de Bax induite par des génotoxines  dépendamment de la protéine tBid. 
Pris ensemble, nos résultats montrent que TAT-RasGAP317-326 pourrait potentiellement être utilisé dans un 
contexte de chimio- ou radiothérapie comme sensibilisateur. Ceci dans le but d’améliorer l’efficacité des 
traitements utilisés actuellement et de prolonger l’espérance de vie de patients atteints du cancer. De plus, 
la compréhension du mode d’action de TAT-RasGAP317-326 pourrait aider à définir les mécanismes par 
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lesquels les cellules cancéreuses acquièrent une résistance aux chimio- et radiothérapies, et ainsi inventer 
des stratégies anti-tumorales plus efficaces et ciblées.  
4
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 INTRODUCTION 
Cancer hallmarks 
Cancer is a class of genetic diseases that, in spite of their high heterogeneity, share some common 
traits. Ten years ago six features common to most cancers were pointed out by Hanahan and 
Weinberg in the renowned review entitled ‘The Hallmarks of Cancer’: self-sufficiency in growth 
signal, insensitivity to anti-growth signal, evasion of apoptosis, unlimited replicative potential, 
angiogenesis and metastasis [1] (Figure 1). During the last decade two new hallmarks were 
associated to cancers: reprogramming of the cellular metabolism and immune destruction 
evasion. All these cellular alterations, arising from genetic mutational events occurring for 
example in oncogenes or tumor-suppressor genes, are accumulated stepwise during the neoplastic 
transformation and each of them confers to tumor cells a selective growth or survival advantage. 
[2-4].   
 
Figure1. The Hallmarks of cancer. Illustration of the six hallmark capabilities originally proposed by Hanahan and 
Weinberg. Adapted from Hanahan D. and Winberg, R.A., Cell, 2011.   
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Activated growth signaling 
Proliferation of normal cells is tightly regulated by the growth factor availability within tissues. 
Cancer cells have developed different strategies to evade this strict control ensuring tissue 
homeostasis and therefore to reduce their dependence or to render themselves independent of 
growth signals. One is represented by the over-expression of growth factor receptors that allows 
cancer cells to become sensitive to the basal growth factor levels present in the tissue that 
normally would not stimulate proliferation [5-7]. Another mechanism allowing cancer cells to 
provide themselves with proliferating signals is the acquired ability to produce growth factors for 
which they express the cognate receptors, generating in this way a positive feedback often 
denominated autocrine stimulation [8-10]. Growth factor receptors can also be mutated in their 
cytoplasmic portion generating persistent proliferation signals without the need of their 
engagement by the respective ligands. One representative example is the EGFR (Epidermal 
Growth Factor Receptor), a receptor tyrosine kinase often bearing mutations in the kinase domain 
that result in an increased kinase activity and therefore in a hyperactivation of downstream 
proliferative pathways [11]. Alternatively, growth receptor-activated signaling pathways are often 
misregulated in cancer, leading to a constitutive activation of the proliferative signals 
downstream of the receptors. Ras and c-Myc oncoproteins are two of the most know examples of 
mutated/deregulated factors operating within the growth receptor-activated proliferative circuits 
[12-17].  
Normal tissue proliferation is regulated both by proliferative signals that allow the cell population 
within the tissue to expand and by growth arrest signals that re-establish steady-state conditions. 
Therefore if transformed cells acquire independence of proliferation, on the other hand they 
8
 should also be able to ignore anti-proliferative signals. One of the most common anti-
proliferative factors is TGF-β, a soluble factor that, by the binding to its cognate receptor on the 
cell surface, starts an anti-proliferative program [18;19]. Cancers are often able to elude this 
TGF-β -mediated anti-growth signal by mutating either its specific receptor or components of the 
intra-cellular circuitry that translates its anti-proliferative signals [20]. At the molecular level the 
irresponsiveness to growth arrest signals that characterizes tumor cells is often due to the 
inactivation of tumor suppressor genes such as retinoblastoma protein (Rb) [21-23], a protein 
controlling the cell cycle entry, or PTEN, a phosphatase that counteracts the PI3-kinase-mediated 
proliferative signals [24].  
Overriding anti-cancer barriers 
After acquiring the proliferative independence, cancer cells must win immortality in order to 
generate macroscopic tumors. Indeed normal cells undergo a limited number of replication cycles 
after which they irreversibly enter a quiescent but viable phase called senescence [25]. The main 
cellular event leading to the entrance to this non-proliferative state is the progressive telomere 
shortening, taking place at each cycle of cell division, as a direct consequence of the lack of 
telomerase in normal somatic cells. Telomerase is the enzyme that counteracts telomere erosion 
by adding new TTAGGG repeats to the 3’ ends of chromosomes [26], however it is only active in 
cells during the embryonic development and in cells belonging to the germination line [27;28].  
Interestingly about 90% of human cancers express telomerase that enable transformed cells to 
overcome the telomere shortening process and the activation of the senescence program, 
therefore allowing them to become immortal [29]. Senescence is by now considered as one of the 
two cell-imposed barriers against carcinogenesis by virtue of the fact that it restrains the 
replicative potential of normal cells [30].  
9
 The second anti-cancer barrier normal cells raise against tumoral transformation is represented by 
the apoptotic cell death process [31]. Apoptosis is a physiological process of programmed cell 
death aimed at the elimination of damaged and harmful cells [32;33]. The genetic damages 
cancer cells accumulate during carcinogenesis activate the apoptotic cell death program with the 
final goal of eliminating damaged cells before they become dangerous for the organism. In order 
to counteract the DNA-damage induced cell death signals, cancer cells resort to apoptosis elusion 
to secure their own viability and clonal expansion.  
Angiogenesis 
Tumor expansion requires continuous supplies of oxygen and nutrient to support the high 
proliferation rate of cancer cells that therefore must acquire the ability to promote the synthesis of 
vasculature during the macroscopic tumoral mass formation [34]. Angiogenesis is a physiological 
process that consists in the growth of new blood vessels from pre-existing vessels. This process is 
normally active during embryogenesis whereas in the adult it only takes place under particular 
physiological or pathological conditions (e.g. during wound healing) [35]. Conversely, during 
tumor progression an angiogenic program, called angiogenesis switch, is constitutively on, 
sustaining the tumor expansion [36;37]. Well know angiogenic inducers are the members of the 
vascular endothelial growth factors family (VEGFs) [38]. The mechanism underlying the 
angiogenic switch can vary from tumor to tumor. Indeed some reports indicate that the oncogenes 
expressed within the tumor cells can up-regulate the expression of angiogenic factors [39;40] 
while other reports show that tumor surrounding or tumor infiltrated cells, such as mast cells and 
macrophages, are instructed by tumoral cells to promote the angiogenic switch [41;42]. 
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 Metastasis  
The leading cause of death in cancer suffering patients has to be attributed to metastasis [43]. 
Metastasizing refers to the ability of cancer cells to leave the primary tumor mass and to invade 
new sites within the body. The metastatic process consists of different phases. In the initial phase 
malignant cells acquire the ability to invade the surrounding tissue towards blood and lymphatic 
vessels where they intravasate to enter the circulation (intravasation) and disseminate throughout 
the body. The following step, called extravasation, allows cancer cells to exit the circulation, 
reach the new colonization site and form small nodules (micrometastasis) that finally grow into 
new macroscopic tumoral masses [43] (Figure 2).  
 
Figure 2. The metastatic process. Illustration of the multistep process of metastasis formation. Adapted from 
Hunter et al., Breast Cancer Research, 2008.   
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 The main molecular events leading to the cancer cell reprogramming that underlies this multistep 
process start now to be understood, and it seems that the initial cellular change driving metastasis 
is the so called ‘epithelial-mesenchymal transition’ (EMT). The EMT is characterized by the loss 
of surface molecules that mediate cell to cell adhesion (e.g. E-cadherin) that promotes the 
capacity of tumor cells to escape the primary tumor site. There are reports indicating that, once 
disseminated to distal organs, malignant cells undergo the reverse program, the mesenchymal-
epithelial transition (MET) allowing them to form new tumor colonies [44;45]. 
Alteration of glucose metabolism 
Cellular energy metabolism is one of the main processes that are affected during the transition 
from normal to cancer cells. In particular, glucose metabolism is very often altered in tumor cells. 
Glycolysis is a catabolic process that converts one molecule of glucose into two pyruvates with 
the production of two ATP and two reduced nicotinamide adenine dinucleotide (NADH) 
molecules. Pyruvate in the presence of oxygen undergoes oxidation to CO2 and H2O in the 
oxidative phosphorylation pathway, resulting in the production of approximately 36 molecules of 
ATP. Alternatively, in the absence of oxygen, pyruvate is transformed into lactic acid in the 
anaerobic glycolysis pathway. However, conversion of glucose to lactic acid can occur in the 
presence of oxygen and this is known as the Warburg effect or aerobic glycolysis. Interestingly, 
most cancer cells produce large amounts of lactate regardless of the availability of oxygen. The 
altered glucose metabolism characterizing malignant cells was the subject of a review I wrote and 
that was published in Current Opinion in Clinical Nutrition and Metabolic Care. This review can 
be found at the end of the introduction. 
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 Genomic instability 
 The genetic and molecular mechanisms allowing the sequential acquisition of mutations during 
carcinogenesis, and therefore the onset of the above described hallmarks, have been intensively 
studied in the last two decades. It is now clear that cancer cells exhibit a marked genomic 
instability that explains the higher mutational rate of malignant cells compared to normal cells 
[46;47]. Therefore genomic instability has been recently defined as a cancer enabling 
characteristic that would increase the chances of spontaneous mutational events, whose fixation 
in the genome is translated into the acquisition of the aforementioned tumor hallmarks [2]. The 
question the scientific community raised long time ago was: where does this genomic instability 
peculiar to malignant cells originate from?  
Mutator hypothesis or oncogenic stress?  
There are two different theories potentially explaining why cancer cells exhibit high mutation 
rate. The first is the so called ‘mutator hypothesis’ stating that the genomic instability in pre-
cancerous lesions is to be attributed to defects in the ‘caretaker genes’, that are the genes 
responsible for DNA repair and mitotic checkpoint [3;48-51].  Indeed improper DNA damage 
repair or uncontrolled progression through the cell cycle can increase the basal mutation rate in 
pre-cancerous cells, thus generating this characteristic genomic instability that then drives tumor 
development. To support this theory is the evidence that some hereditary cancers, such as 
HNPCC (hereditary non-polyposis colon cancer), show mutation in the DNA repair genes and 
that inherited mutations within caretaker genes, such as BRCA1/2, predispose to the development 
of breast cancer [52;53]. However recent high-throughput analysis of human cancer genomes 
failed to identify caretaker genes that were frequently mutated in sporadic cancers. Genes 
13
 emerging as the most frequently mutated were known oncogenes, such as Ras and EGFR, and 
tumor suppressor genes, PTEN, NF1, p16INK4A and p53 [54-59]. 
 
Figure 3. Oncogenic stress model. DNA replication stress causes genomic instability that drives the progression 
from pre-malignant lesion to cancer. Adapted from Halazonetis T., et al., Science, 2008. 
 
The high mutation rate of p53 and the fact that it could also be considered a caretaker gene, 
because it serves as DNA damage checkpoint protein, seems to be in favor of the mutator 
hypothesis. Nevertheless it has been demonstrated, both in mouse and human models, that p53 
deletion does not cause genomic instability and that genomic instability is present in pre-
malignant cells before the onset of p53 mutations [60;61]. In addition the finding that the over-
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 expression of oncogenes generates DNA replication stress led to the ‘oncogenic stress’ model 
formulation [31;62]. This model states that in pre-cancerous lesion the gain of function mutation 
of an oncogene or the loss of function mutation of a tumor suppressor generates the replication 
stress. This is defined as the condition in which DNA undergo a replicative overload triggering 
replication forks collapse. DNA replication stress, and so the collapse of replicative forks was 
shown to be the cause of DNA double strands breaks (DBS) and DNA-damage induced 
activation of p53, triggering in turn either senescence or apoptosis [31;62]. Therefore, in sporadic 
cancer, the sustained DNA replication stress associated with oncogene activation increases the 
rate of DBS, provoking genomic instability, which in turn generates a selective pressure for p53 
mutation, required for the breaching of the two anti-cancer barriers represented by senescence 
and apoptosis (Figure 3). This selective pressure would therefore explain the high  
p53 mutation rate found in malignant cells. Additionally the replicative stress also favors the 
accumulation of additional mutations required for cancer progression. 
Apoptosis 
Apoptosis, or programmed cell death, is a physiological process required to remove damaged or 
redundant cells during development and for the maintenance of tissues homeostasis [33]. 
Cells can undergo apoptosis through the extrinsic pathway, initiated by death receptors exposed 
on the cell surface or the intrinsic pathway, activated as result of exposition to cellular insults 
(e.g. genotoxins, radiation, UV and growth factor deprivation) (Figure 4). 
The extrinsic pathway involves the engagement of membrane death receptors, such as TNFR1 or 
Fas, by their cognate binding factors (TNF, FasL/CD95L), leading to the trimerization of the 
receptors and to the assembly at their intracellular domains of a caspase activation platform 
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 called DISC. The DISC (death-inducing signalling complex) mediates the activation of initiator 
caspases 8 and 10 that in turn activate effector caspases (caspase 3/6/7) [63;64]. Effector caspases 
then cleave a number of different nuclear and cytoplasmic substrates determining the cellular 
demise.   
 
 
Figure 4. Intrinsic and extrinsic apoptosis. Schematic illustration of the death receptor- mediated and 
mitochondrial-mediated apoptotic pathways. Adapted from Youle R., J. and Strasser A., Nature Reviews, 2008. 
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 The intrinsic pathway is characterized by the disruption of the mitochondrial membrane integrity 
[65]. The loss of mitochondrial integrity causes the release in the cytoplasm of apoptogenic 
factors such as cytochrome c, AIF (apoptosis inducing factors) and Smac (second-mediated 
activator of caspase) [66]. Cytochrome c, once released, promotes the formation of a complex 
called apoptosome. The apoptosome, formed by cytochrome c, the protein Apaf-1 and the 
caspase 9, triggers the activation of the caspase 9 that in turn activates, by proteolitic cleavage, 
executioner caspases (caspase 3/6/7) [67].   
 
Figure 5. The three functional subgroups of the Bcl-2 family members. Sensors: BH3-only proteins in the text; 
Guardians: pro-survival proteins in the text. BH: Bcl-2 homology; TM region: trans-membrane region. Adapted 
from Strasser A., et al., EMBO J., 2011 
 
The mitochondrial integrity is tightly controlled by proteins belonging to the Bcl-2 family. All the 
Bcl-2 family members share a close homology in up to four domains called BH (Bcl-2 
Homology) and they can be divided on the basis of their pro-survival and pro-apoptotic function. 
17
 The pro-survival proteins are Bcl-2, Bcl-w, Bcl-XL, Mcl-1 and A1. The pro-apoptotic proteins 
consist of two sub-classes of proteins: the first includes Bax and Bak, that are able to directly 
induce cytochrome c release, and the second includes the so called BH3-only proteins that are 
Bad, Bim, Bid, Bik, Bmf, Hrk, Noxa and Puma [65;68](Figure 5). However the mechanisms by 
which Bax and Bak get activated and induce the MOMP (mitochondrial outer membrane 
permeabilization), required for the cytochrome c release, are still a matter of controversy. Two 
main models, known as the ‘direct model’ and the ‘indirect model’ of activation of Bax and Bak, 
have been proposed. 
Direct model 
The direct model classifies the BH3-only proteins into two sub-groups: activators and sensitizers. 
The activators are Bim, Bid and probably Puma, the sensitizers are the other members of the BH3 
group (e.g. Bik and Noxa). The activators have the ability to bind to and directly activate Bax and 
Bak, whereas sensitizers are envisaged to displace the activators from the pro-survival proteins 
(Figure 6). The first evidence in favour of the direct model is that Bax and Bak, under normal 
conditions, are not thought to be complexed to anti-apoptotic proteins. In fact it has been shown 
that both Bax and Bak BH3 domain, responsible for the binding to the Bcl-2 family pro-apoptotic 
members, is buried in absence of stress. This observation implies that in healthy cells, Bax and 
Bak are not complexed to the pro-survival proteins [69;70]; in particular, Bax is a cytoplasmic 
monomer whereas Bak is constitutively localized at the mitochondrial membrane. Evidence 
supporting the direct model was also provided by Martinou’s laboratory that showed that 
truncated Bid was able to induce Bax conformational changes and activation [71] with the 
consequent release of cytochrome c from mitochondria. Many reports confirmed and extended 
these observations to Bim and Puma, whereas other BH3-only proteins (e.g. Bik and Noxa) were 
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 shown not to trigger Bax and Bak activation and mitochondrial membrane integrity disruption 
[72-77]. Another observation supporting the direct model is that mutations on Bax and Bak 
preventing them from binding to Bcl-2, Bcl-XL and Mcl-1, do not result in their constitutive 
activation, suggesting that mechanisms other than the pro-survival protein-mediated repression 
are required for Bax and Bak activation [78]. Finally an NMR study characterized, for the first 
time, the interaction between a Bim BH3-derived peptide and Bax [79]. This study not only 
described the interaction site for the direct Bax activation mediated by BH3-only protein 
activators, but also helped to unravel the multistep mechanism of Bax activation [76;79;80] 
Indirect model 
The indirect model postulates that the Bax and Bak are kept in check by the anti-apoptotic 
members of the Bcl-2 family in order to prevent them from triggering the apoptotic program. 
Upon an apoptotic stimulus, the BH3 only members neutralize the anti-apoptotic proteins to 
favour the release of Bax and Bak[81] (Figure 6). 
The indirect model excludes any kind of Bim/Bid-mediated Bax and Bak direct activation. The 
first evidence in favour of the indirect model comes from David Huang’s group that showed no 
direct binding of the BH3 activators to Bak and Bax. By contrast the binding of BH3-only 
members with the anti-apoptotic proteins of the Bcl-2 family has been widely reported [82;83]. 
Moreover some BH3-only proteins, such as Bim and Puma, are more potent than other at binding 
the anti-apoptotic members. Indeed Bim, Puma and Bid have been shown as able to bind with the 
same affinity to all the anti-apoptotic players, explaining why they are the most effective 
apoptosis inducers among the BH3 only members [82].                  
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 Direct vs Indirect 
The direct model, as mentioned, theorize that Bim and Bid directly activate Bax and Bak. If this 
model is correct, mice lacking Bim and Bid should have a phenotype similar to the phenotype of 
mice lacking Bax and Bak that die in utero. By contrast mice Bim-/- Bid-/- appear largely normal. 
Moreover fibroblast derived from Bim-/- Bid-/- mice remained sensitive to apoptotic stimuli and 
Bax activation normally occurs. According to the direct model Bad and Noxa are ‘sensitizers’, 
i.e. they cannot directly activate Bax and Bak, but together have the capacity to neutralize all the 
anti-apoptotic members. When they are over-expressed in fibroblast lacking Bim and Bid, Bax 
activation and cytochrome c release normally occur [83]. This shows that Bid and Bim are 
dispensable for the induction of apoptosis and that only neutralizing the anti-apoptotic players it 
is possible to trigger the activation of Bax. Additionally it has been observed that when Bid was 
mutated in order to abrogate its ability to bind Bak and Bak but not the anti-apoptotic proteins, 
cells were still able to undergo apoptosis [83]. At this point it might be argue that despite the 
absence of Bid and Bim there is still Puma that could directly activates Bax, even if the role of 
Puma as direct Bax activator is still controversial,  explaining why Bim-/- Bid-/-  KO cells remain 
sensitive to apoptotic stimuli. Recently, a triple Bim/Bid/Puma KO mouse was generated, that 
phenocopied the Bax/Bak KO mouse [84]: the dispute on direct or indirect model is then solved 
in favour of the direct model? Not really! A consistent part of the scientific community does 
think that there are still substantial differences of phenotype between the Bax/Bak knock-out 
mice and the Bim/Bid/Puma KO mice [85] 
To conclude there is strong evidence in favour of both models, even if neither the indirect nor the 
direct model can fully explain all the described results. It might be argued that that these two 
mechanisms are both valid, they might even coexist in the cell and be complementary as 
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 proposed by David Andrews and collaborators in the so called ‘embedding together model’ 
which tries to fuse elements from both the direct and indirect model [86;87].  
 
Figure 6. Direct and Indirect models of Bax/Bak activation. In the direct activation model, the activator BH3-only 
proteins (Bim, tBid and probably Puma), via their BH3 domain (red triangle), can directly engage and activate Bax 
(or Bak). In healthy cells the pro-survival family members (referred to as ‘Bcl-2 et al’) prevent this by sequestering 
the BH3-only activators. After an apoptotic signal, the sensitizer BH3-only proteins (e.g. Bad, Noxa, Bik) displace 
the activators from the anti-apoptotic proteins to activate Bax or Bak. (B) In the indirect activation model, the BH3-
only proteins displace Bax and Bak from the inhibitory binding to the Bcl-2 family anti-apoptotic proteins, triggering 
their activation. Adapted from Strasser A., et al., EMBO J., 2011. 
 
A new way of activating Bax: the ‘Trap and Release’ Mechanism 
Recently, Philippe Juin and collaborators showed that the anti-apoptotic protein Bcl-XL is able by 
itself, without the participation of the BH3-only proteins, to prime Bax and maintain it in an 
active conformation. The displacement of Bax from Bcl-XL is then translated into Bax-mediated 
mitochondrial membrane disruption, cytochrome c release and apoptosis (Figure 7). The exact 
molecular mechanisms underlying this Bcl-XL-mediated Bax activation, referred to as ‘Trap and 
Release’ model, are not fully understood. It has been speculated that Bcl-XL facilitates the 
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 exposure of the Bax BH3 domain that is then neutralized by the BH3-binding hydrophobic 
groove of Bcl-XL. The exposure of the BH3 domain might be then accompanied by a general 
conformational change of the Bax molecule that, once Bax is displaced from Bcl-XL, leads to its 
insertion into the outer mitochondrial membrane and oligomerization. Alternatively, Bcl-XL 
binds to Bax molecules that spontaneously underwent conformational change and maintains 
activated Bax molecules in a safety status. These data are of particular interest because they 
unravel a new and revolutionary level of regulation of the Bcl-2 family members and might 
facilitate the understanding of how Bcl-XL prevents cell death [88]. 
 
Figure 7. ‘Trap and Release’ Bax activation mechanism. Model for Bax activation via its interaction with and 
then release by Bcl-XL. Adapted from Gautier F., et al., Molecular and Cellular Biology, 2011. 
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 Caspases 
Caspases (cysteine-dependent aspartate-specific protease) are proteases that cleave aspartic acid-
containing polypeptides using their cysteine side chain, playing a central role in apoptosis 
[89;90]. For long time since their discovery, caspases were believed to participate only in the 
apoptotic cell death process, with the exception of caspase 1, known to be a pro-inflammatory 
effector.  
In the last decade mounting observations seemed to invalidate the paradigm of caspases only 
being cell death mediators and the scientific community has now accepted that caspases are also 
involved in life-maintaining processes, namely cell differentiation and survival [91-94]. Indeed, 
to all the conventionally considered pro-apoptotic caspases has been attributed at least one non-
apoptotic function [95]. Anyway, the initial distinction between pro-apoptotic and inflammatory 
caspases can be still useful for a general classification (Figure 8). The pro-apoptotic caspases are 
divided into two groups: initiators and effectors. Initiator caspases (8 and 10 for the extrinsic 
pathway and 9 for the intrinsic pathway) are also called apical caspases because they initiate the 
apoptotic cascade. They exist as inactive monomers; they are characterized by a long prodomain 
and activated by the dimerization stimulated by their recruitment to the respective activation 
platform: DISC for caspase 8-10 and apoptosome for caspase 9. Using these classification 
parameters, also the caspase 2 could be considered an initiator caspase as it bears a long 
prodomain and it is activated by a molecular platform called PIDDosome; however the activation 
mechanism and the exact function of caspase 2 still remain to be fully elucidated. 
23
  
Figure 8. Caspases classification. Caspases can be classified in pro-apoptotic and inflammatory caspases. Pro-
apoptotic caspases are further divided into initiator caspases (8-10 and probably 2), activated by dimerization, and 
effector caspases (3-6-7), activated by intra-domain cleavage. Inflammatory caspases are caspase 1/4/5. Adapted 
from Salvesen G., S., et al. Cell, 2011. 
 
Executioner caspases, caspase 3, 6 and 7, are so called by virtue of the fact that they execute the 
apoptotic process by integrating the apoptotic signalling into cell dismantling. They exist as 
inactive dimers that are activated by initiator caspase-mediated proteolytic cleavage [96-99]. All 
the knowledge about the mechanism of activation of executioner caspases comes from the crystal 
structure of caspase 7, where it was possible to observe a conformational change of the active site 
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 after such a proteolytic cleavage [100]. Finally, inflammatory caspases (caspase1-4-5), whose 
role is to mediate the maturation of specific cytokines required by the immune system, are 
probably activated in a fashion similar to the initiator caspases [101]. 
Ras signaling 
The Ras protein was identified as the transforming gene of the Harvey and Kirsten strains of rat 
sarcoma viruses [102;103]. Ras is a protein belonging to the small GTPase family that is involved 
in the cellular signal transduction downstream of growth factor associated receptors that controls 
distinct cellular processes such as proliferation, migration and apoptosis [104]. Ras cycles 
between an active state, when bound to GTP, and an inactive state, when bound to GDP [105], 
and its cycling is tightly controlled by two classes of proteins: GEFs and GAPs. GEFs (guanine 
exchange factor) enhance the rate of GDP dissociation [106], whereas GAPs (GTPase activating 
protein), like p120-RasGAP (from now on referred to as RasGAP), accelerate the intrinsic 
GTPase activity of the small GTPases to promote their inactivation [107].  
RasGAP 
RasGAP is a well-known GAP protein that functions as a negative regulator of Ras signaling 
[108;109]. It is a 120-kDa cytosolic protein ubiquitously expressed and highly conserved across 
species [108;110] (Figure 9). The N-terminal region contains a Src Homology 3 domain (SH3) 
flanked by two Src Homology 2 domains (SH2), followed by a pleckstrin homology (PH) and by 
a calcium-dependent phospholipid-binding domain (CaLB/C2) [111;112]. SH2 domain binds 
phosphorylated tyrosines containing sequences, such as the cytoplasmic portion of tyrosine 
kinase–associated receptors, the PH domain binds to the cytoplasmic membrane phospholipids 
such as phosphatidylinosotol 4-5 biphosphate and the CaLB/C2 is responsible for protein-protein 
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 interactions. SH3 domains are known to bind proline-rich motifs (PxxP). Interestingly the 
RasGAP SH3 was proposed not to bind proline-rich motif, suggesting that RasGAP may interact 
with its binding partners through unconventional SH3 domain interactions [110;113]. The 
catalytic domain GAP that stimulates the hydrolysis of Ras-bound GTP is localized in the C-
terminal region [107;114].  
 
Figure 9. RasGAP structure. PPP:proline-rich region; SH2: Src homology domain 2; SH3: Src homology          
domain 3; PH: pleckstrin homology domain; C2: calcium-dependent lipid domain and GAP:GTPase activating 
protein domain. 
 
RasGAP not only as GTP-ase activating protein 
RasGAP was also described to act as Ras effector in functions related to proliferation, 
differentiation and apoptosis, independently of its GAP activity. 
Several reports support this role for RasGAP. For example, Ras oncogenic mutants do not 
respond to RasGAP, but when they were mutated in the effector binding site (aa 30-40), known 
to be also the RasGAP binding site [115], they lost their transforming activity. Moreover a 
mutation within the RasGAP binding domain of Ras that does not affect their reciprocal 
interaction (Ala 39) does not result in the loss of Ras transforming activity [116]. Hence this 
report provides evidence in favour of RasGAP being a component of the Ras signalling pathway. 
This hypothesis was corroborated by a study showing that the N-terminal domain of RasGAP 
(nGAP, residues 1-666) was able to abolish oncogenic Ras activity but not normal Ras therefore 
acting as a competitive antagonist for the endogenous Ras/RasGAP complex and so preventing 
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 the Ras signalling [117]. Another study, showing that the opening of the muscarin receptor-
activated potassium channel can be inhibited by the Ras/RasGAP complex, demonstrated that the 
SH2-SH3 region of RasGAP, residing in its N-terminal part, mediates this inhibition [118]. It is 
also important to mention that disruption of the RasGAP gene (Rasa1) leads to embryonic 
lethality at day 10.5 due to aberrant cardiovascular development [119].  In conclusion, all this 
piece of evidence support a role for the N-terminal portion of RasGAP in some of the Ras-
mediated biological response. 
G3BP1 
In 1996, the laboratory of Bruno Tocque, in search of RasGAP interacting proteins potentially 
acting as Ras effectors, discovered a new protein binding to its SH3 domain that was called 
G3BP1 (GAP SH3 Binding Protein 1) (Figure 10). G3BP1 is a 68 kDa cytosolic protein whose 
binding site on the RasGAP SH3 domain encompasses residues 317-326 [120]. Interestingly, this 
binding, mediated by the NTF2-like domain of G3BP1 [113], only takes place in serum-
stimulated cells, whereas, in quiescent cells, G3BP1 re-localizes into the nucleus showing 
hyperphosphorylation on serine residues. Furthermore, in the absence of RasGAP, G3BP1 
phosphorylation was abrogated. After the cloning it turned evident that G3BP1 was related to 
RNA-binding proteins, indeed, it bears two ribonucleoprotein (RNP) motifs, RNP1 and RNP2, 
forming the RNA consensus recognition motif (RRM) [121]. Consistently with this observation, 
it has been proved later that G3BP1 harbours an intrinsic endoribonuclease activity, in particular, 
it is able to cleave the 3’-untranslated region (3’-UTR) of the human c-myc RNA transcript [122] 
negatively regulating its stability. Moreover the G3BP1 ability to cleave mRNA was found to be 
positively regulated by its phosphorylation status. Conceivably, G3BP1 was believed to enable 
the accumulation of c-myc mRNA in proliferating cells, where it is associated to RasGAP and 
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 dephosphorylated, and to mediate c-myc degradation in resting cells, where it is 
hyperphosphorylated and its endoribonuclease activity is on. Therefore G3BP1 seems to couple 
extracellular proliferative stimuli to c-myc mRNA metabolism through its binding to RasGAP, 
reinforcing the notion of RasGAP as a Ras effector.  
 
Figure 10. G3BP1 Structure. Schematic representation of the G3BP1 protein structure. NTF2-like: nuclear 
transport factor 2-like domain; RRM: RNA recognition motif and RGG:arginine-glycine rich box. 
 
RasGAP as caspase substrate 
The RasGAP N-terminal part plays also a role in apoptosis (Figure 11). Indeed RasGAP was 
discovered to bear two caspase 3 consensus cleavage sites that are sequentially targeted, during 
the apoptotic process, as caspase 3 activity increases [123;124]. When caspase 3 activity is very 
low, RasGAP is cleaved at position 455 to generate an N-terminal fragment (called fragment N) 
and a C-terminal fragment (called fragment C) [125]. Interestingly fragment N protects cells from 
several different apoptotic stimuli when over-expressed in cells, through a pathway engaging the 
Ras/PI3K/AKT signalling arm [126]. It is pertinent to mention that caspase-3 is the only caspase 
able to cleave RasGAP, as demonstrated using caspase-3 knock-out mouse embryonic fibroblasts 
[127]. When caspase-3 activity augments, fragment N is further cleaved at position 157, leading 
to the generation of two distinct fragment that were called fragment N1 and N2, the latter 
containing the SH2-SH3-SH2 motif [125]. Importantly, this second cleavage at position 157 was 
shown to abolish the anti-apoptotic properties of the fragment N [125]. Intriguingly fragment N2 
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 has pro-apoptotic functions in cancer cells, but not in normal cells, by sensitizing them to 
genotoxin-induced apoptosis, while having no effect by itself [128]. 
Cancer Treatment 
The most commonly used anti-cancer treatments are surgery, chemotherapy, based on the 
utilization of drugs that kill cancer cells, and radiotherapy, which uses high energy radiation to 
kill malignant cells. Surgery is the oldest modality of cancer treatment. The earliest report of a 
surgical treatment of cancer was written in Egypt circa 1600 B.C. Nowadays surgery is the most 
currently used kind of therapy of solid tumors while chemo and radiotherapy are rarely used as 
primary therapies but rather as adjuvant or neoadjuvant therapies. Adjuvant therapy is any 
treatment given after primary therapy, whereas neoadjuvant is any treatment given before the 
primary therapy. Adjuvant therapies, introduced during 1970s, are mainly represented by 
systemic therapies, i.e. therapies that use substances that travel through the bloodstream reaching 
and killing cancer cells all over the body, such as chemotherapy. They are aimed at the 
elimination of residual cancer cells that were not removed by surgery within the primary tumor 
site or that might have spread to colonize new tumor sites, causing recurrence of the tumor. To 
this respect, a recent report showed that adjuvant chemotherapy for early-stage breast cancer 
reduces the rate of tumor recurrence and the mortality of patients [129].  
Neo-adjuvant therapies, experimented for the first time by Bonadonna and collaborators in 1975 
[130], rely on the utilization of chemo and/or radiotherapy to shrink tumors that are inoperable at 
their current state, to render them resectable. There are reports showing that in breast cancer the 
utilization of neoadjuvant therapy allows breast-conserving surgery instead of mastectomy 
(surgical removal of the breast) [131] and that neo-adjuvant radiotherapy improves the survival in 
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 patients with resectable pancreatic cancer [132;133]. Finally, the mortality of cancer has been 
declining since 1990, due both to prevention and early diagnosis and to the advances made by the 
modern medicine in cancer treatment [134]. 
TAT-RasGAP317-326: a tumor sensitizer 
Cancer treatment is limited by two major concerns: intrinsic or acquired resistance to therapies, 
particularly to radio and chemo-therapy, and side effects, generated when the therapeutical dose 
exceeds the toxic dose. The development of therapeutical strategies aimed at restoring the normal 
sensitivity of malignant cells or at increasing their responsiveness to treatments, would allow the 
reduction of the effective doses with a consequent limitation of side effects. One promising 
approach is represented by the utilization of therapeutic peptides acting as sensitizers selectively 
in tumor cells.   
The RasGAP caspase 3-generated fragment N2 favours the genotoxin-induced apoptotic cell 
death selectively in cancer cells. In order to make fragment N2 a therapeutical tool for cancer 
treatment, its shortest amino acid sequence still bearing sensitizing activity, found out to reside in 
the amino acids 317-326, was fused to a cell penetration sequence from the TAT protein of HIV 
virus. The resulting TAT-RasGAP317-326 peptide efficiently enters tumor cells in vitro and 
sensitizes several cancer cell lines to genotoxic compounds towards apoptosis [135]. Relatively 
little is known on its mode of action and on its selectivity for tumoral cells. The first mechanistic 
study showed that TAT-RasGAP317-326-mediated sensitization to apoptosis requires an intact 
p53/Puma axis to occur, and that the increased apoptotic response has to be attributed to an 
increased mitochondrial membrane depolarization and caspase 3 activation [136]. 
30
  
Figure 11. Model for the role of RasGAP cleavage fragments in the regulation of apoptosis. 
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Purpose of review
Cancer cells alter their metabolism in order to support their rapid proliferation and
expansion across the body. In particular, tumor cells, rather than fueling glucose in the
oxidative phosphorylation pathway, generally use glucose for aerobic glycolysis. In this
review, we discuss some of the mechanisms thought to be responsible for the
acquisition of a glycolytic phenotype in cancer cells and how the switch towards
glycolysis represents a selective growth advantage.
Recent findings
Glucose deprivation can activate oncogenes and these can upregulate proteins
involved in aerobic glycolysis. In turn, proteins implicated in increased glycolysis can
render tumor cells more resistant to apoptosis. Aerobic glycolysis induces acidification
of the tumor environment, favoring the development of a more aggressive and invasive
phenotype. Altering the pH around tumors might represent a way to hamper tumor
development as suggested by a recent work demonstrating that bicarbonate, which
increases the pH of tumors, prevented spontaneous metastatization.
Summary
The acquisition of a glycolytic phenotype by transformed cells confers a selective
growth advantage to these cells. Interfering with aerobic glycolysis, therefore,
represents a potentially effective strategy to selectively target cancer cells.
Keywords
apoptosis, cancer, glucose, glycolysis, oncogene
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Carcinogenesis is a complex, multistep process that
requires the elimination of several cell-imposed barriers
such as antiproliferative responses, programmed cell
death-inducing mechanisms, and senescence. This
occurs mostly through mutations in oncogenes and tumor
suppressor genes [1,2]. The tumor microenvironment
plays a crucial role in the transition from precancerous
lesions to carcinogenesis by exerting an adaptive pressure
that selects cells for their clonal expansion [3–5]. Cellular
energy metabolism is one of the main processes that is
affected during the transition from normal to cancer cells.
In particular, glucose metabolism is very often altered in
tumor cells. Glycolysis is a catabolic process that converts
one molecule of glucose to two pyruvates with the
production of two ATP and two reduced nicotinamide
adenine dinucleotide (NADH) molecules. Pyruvate in
the presence of oxygen undergoes oxidation to CO2 and
H2O in the oxidative phosphorylation pathway, resulting
in the production of approximately 36 molecules of ATP.
Alternatively, in the absence of oxygen, pyruvate is
transformed into lactic acid in the anaerobic glycolysis
pathway. However, conversion of glucose to lactic acid
can occur in the presence of oxygen and this is known as
the Warburg effect or aerobic glycolysis [6]. Most canceropyright © Lippincott Williams & Wilkins. Unautho
1363-1950  2010 Wolters Kluwer Health | Lippincott Williams & Wilkins
44cells produce large amounts of lactate regardless of the
availability of oxygen [7]. This increased aerobic glycoly-
sis is considered by some to be the seventh hallmark of
cancer [8] (the others, initially proposed by Hanahan and
Weinberg [9], being limitless replicative potential, self-
sufficiency in growth signals, resistance to apoptosis,
insensitivity to antigrowth signals, sustained angiogenesis,
and tissue invasion and metastasis).
In this review, we will discuss the different mechanisms
responsible for the glycolysis switch in cancer and how
they contribute to apoptosis resistance and survival of
cancer cells. We will also present recent evidence indi-
cating that interfering with glucose metabolism is a
valuable anticancer approach.Glucose utilization in tumors: the Warburg
effect
Normal cell proliferation in tissues is controlled by the
availability of growth regulating factors and by the inter-
action with surrounding cells. The availability of nutri-
ents and oxygen, necessary for cell proliferation and
metabolism, largely depends on blood supply. Initial
tumor growth occurs in the absence of formation of
new blood vessels. In this phase, tumor cells ignorerized reproduction of this article is prohibited.
DOI:10.1097/MCO.0b013e32833a5577
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Figure 1 Glycolysis in cancer cells
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The metabolic switch towards aerobic glycolysis commonly observed in
cancer cells – the Warburg effect – is set after upregulation of some
enzymes (indicated in bold) that play an important role in glucose
metabolism. The increased glucose utilization through the glycolytic
pathway generates metabolic intermediates (indicated in italic) that
cancer cells need to sustain their rapid proliferation. One of these
intermediates, glucose 6-phosphate is used for the synthesis of nucleic
acid, through the pentose phosphate pathway, to allow rapid DNA
replication. The abundant production of pyruvate stimulates lipid syn-
thesis that is necessary for the formation of membranes in dividing tumor
cells. Finally, secretion of lactate by the tumor cells induces acidification
of the tumor microenvironment that creates a particular niche that favors
further tumor progression, as well as inhibiting the action of some
anticancer drugs. Aldo, aldolase; Eno, enolase; GAPDH, glyceraldehyde
3-phosphate dehydrogenase; GLUT1, glucose transporter 1; HK, hex-
okinase; LDH, lactate dehydrogenase; PFK-I, phosphofructokinase 1;
PGI, phosphoglucose isomerase; PGK, phosphoglycerate kinase; PGM,
phosphoglycerate mutase; PK, pyruvate kinase; TPI, triose phosphate
isomerase.environmental growth-controlling constraints. They can
do so by acquiring the ability to proliferate independently
of growth signals, through, for example, mutations in
receptor-associated signaling molecules, and by becom-
ing insensitive to antigrowth stimuli, such as those
mediated by cell-to-cell contacts [9,10].
In the early carcinogenesis phase, uncontrolled cell pro-
liferation moves tumor cells away from blood vessels and,
therefore, from oxygen and nutrient supply. The only way
oxygen and glucose can reach the inner cells of a non-
vascularized tumor is by diffusion across the basement
membrane and through the peripheral tumor-cell layers.
However, partial oxygen pressure drops to very low values
100mm away from blood vessels [11]. This implies that
hypoxia and glucose shortage are rapidly generated in the
inner mass of a growing tumor. Paradoxically, however, it is
known since the 1920s [12] that tumor cells have a much
higher rate of glucose consumption through a glycolysis
pathway that does not send pyruvate to the Krebs cycle (i.e.
the oxidative phosphorylation pathway) but that rather
converts pyruvate to lactate: the so called Warburg effect
[7] (Fig. 1). In fact, many tumors use this glucose to lactate
pathway even in the presence of oxygen, explaining why
the term aerobic glycolysis is often used as a substitute to
the Warburg effect. It is important to note that the glyco-
lytic switch occurring in cancer cells is not necessarily
accompanied by a reduction in oxidative phosphorylation
[13]. Nowadays, the augmented glycolytic activity of
tumors is clinically exploited by positron emission tom-
ography for the identification of metastatic lesions. This
technique takes advantage of the increased ability of tumor
cells to take up and metabolize glucose compared with
normal tissues [5].
It would seem logical to assume that hypoxia is what
drives tumor cells to fuel glucose in a nonoxidative
‘glucose to lactate’ pathway. However, it is currently
believed that the glycolytic switch is acquired very early
in carcinogenesis even before tumors experience hypoxia
[7]. For example, lung cancers and leukemic cells, which
are growing in the presence of oxygen, fuel glucose into
the aerobic glycolysis pathway [14,15]. Consequently, the
fact that, even in normoxic conditions, many tumors use
aerobic glycolysis for their metabolic requirements
indicates that the Warburg effect has functions that are
not solely limited to hypoxia adaptation. We will come
later to possible reasons why tumors turn on aerobic
glycolysis but let us first discuss other responses induced
by hypoxia in tumor cells.Hypoxia adaptation and apoptosis resistance
A crucial molecule involved in the adaptation to hypoxia
is the hypoxia-induced factor 1 (HIF-1). HIF-1 is a
pleiotropic transcription factor that regulates genesopyright © Lippincott Williams & Wilkins. Unauth
45involved in the hypoxia-induced metabolic switch, regu-
lation of tumor pH, and angiogenesis [16]. The high
glycolytic rate characteristic of hypoxic solid tumor is
due in part to the greatly increased expression of hex-
okinase II (HK II) [17], a known transcriptional target
of HIF-1. Hexokinase catalyses the first step in the
glycolytic pathway where glucose is phosphorylated toorized reproduction of this article is prohibited.
C468 Carbohydratesglucose-6-phosphate with conversion of one ATP to ADP
(Fig. 1). There are four isoforms encoded by the mam-
malian genomes (I to IV) that are usually expressed at low
levels in cells [18]. By increasing the expression level of
HK II, hypoxia via HIF-1, can therefore modulate
glucose metabolism.
HK II has additional features that are relevant in the
context of cancer-cell apoptosis. HK II is normally associ-
ated with voltage-dependent anion channel (VDAC) [19],
a 30 kDa pore protein inserted in the outer mitochondrial
membrane that regulates the transport of metabolites in
and out of the mitochondrial inter-membrane space [20].
Mitochondria are key components of the apoptotic cell-
death process. Upon exposure to cell-death stimuli,
mitochondria release cytochrome-c and other apopto-
genic factors such as SMAC/DIABLO into the cytoplasm
where they trigger caspase activation and apoptosis [21].
The release of cytochrome-c is orchestrated by members
of the Bcl-2 family of proteins [22,23]. Among these
proteins, only Bax and Bak are mandatory for the release
of cytochrome-c [24] although the exact mechanism by
which this happens is still debated. One model proposes
that Bax, once activated by death stimuli, cooperates with
VDAC to form a large cytochrome-c conducting channel
through the mitochondrial membrane [25,26].
It can be envisioned that a protein interacting with
VDAC, like HK II, has the potential to prevent the
interaction of proapoptotic proteins with mitochondria
and consequently interfere with apoptosis. Therefore in
hypoxic tumors, the initial overexpression of HK II as a
primary adaptation to hypoxia, may secondarily confer
resistance to apoptosis. Supporting this notion is the
observation that disruption of the binding of HK II
to mitochondria, through activation of GSK3b and
phosphorylation of VDAC, potentiates chemotherapy-
induced cytotoxicity in transformed cells [27]. Moreover,
methyl jasmonate, an anticancer agent that interacts
directly with mitochondria, is able to induce apoptosis
selectively in cancer cells apparently by detaching hexo-
kinases from mitochondria [28]. Recently, it has also
been shown that the release of HK II from mitochondria
potentiates cisplatin-induced cytotoxicity [29]. This was
shown using a peptide that competed with HK II for
VDAC binding and that enhanced cisplatin-induced
apoptosis through Bak oligomerization and mitochondrial
integrity loss.
The current evidence indicates, therefore, that hypoxia
response in cancer cells, in additon to modulating the way
they metabolize glucose, renders them more resistant to
death stimuli. Hypoxic tumors are often more invasive
and metastatic [30,31]. Whether this is linked to a higher
resistance to apoptosis or to the altered glucose metab-
olism is currently not known.opyright © Lippincott Williams & Wilkins. Unautho
46Oncogenic stress and alteration of glucose
metabolism
Hypoxia is not the only driving force that leads to
abnormal glycolytic flux in cancer cells. It has been
discovered in the last few years that oncogenes found
in a wide variety of human cancers can directly activate
HIF-1 and other components of glucose metabolism
independently of hypoxia. One of such oncogenes is
Akt. This serine/threonine kinase is involved in the
modulation of several cellular processes such as prolifer-
ation, autophagy and cell metabolism [32,33]. Akt
regulates factors involved in glucose metabolism, includ-
ing HK II, whose association with mitochondria and its
effect on apoptosis resistance was discussed in the
previous section, phosphofructokinase-1 (PFK-1) [34],
one of the rate-controlling enzymes of glycolysis, and
GLUT1, the most widely expressed glucose transporter
[35]. Recently, Akt was coined the ‘Warburg kinase’ able
to promote the metabolic changes that tumor cells experi-
ence en route to a more malignant state [36]. The fact
that Akt promotes a glycolytic switch under normoxia
conditions, without affecting the rate of oxidative phos-
phorylation, confirms that this occurs not only as an
adaptation to low-oxygen flux but also when tumoral
cells increase the production of metabolic intermediates
required for rapid proliferation, such as pentose phos-
phates necessary for nucleic acid synthesis (Fig. 1).
These Akt-mediated metabolic changes render cancer
cells dependent on aerobic glycolysis for their growth and
survival. This can be seen for example in tumor cells
bearing an activated form of Akt. These cells undergo
rapid cell death when shifted to low-glucose conditions
[37]. On the contrary, if tumor cells are given the chance
to activate another metabolic pathway to sustain their
high-energy demand, the addiction to aerobic glycolysis
is overcome. This is indeed seen when cells are switched
towards fatty acid metabolism by stimulating them with
the AMPK activator 5-aminoimidazole-4-carboxamide
ribonucleoside (AICAR) [38].
Another oncogene, K-Ras can alter glucose metabolism
so as to provide tumor cells with a selective advantage. It
has indeed recently been shown that expression of the
GLUT1 glucose transporter is increased in cells with
mutated K-Ras. Upregulation of this glucose receptor was
associated with an increased glucose uptake, increased
glycolysis and augmented lactate production, whereas
mitochondrial functions and oxidative phosphorylation
were not affected. When grown in low-glucose containing
media, K-Ras mutated cells showed increased survival.
Therefore, it was argued that agents able to inhibit
glucose metabolism could selectively kill K-Ras mutant
cells. Indeed the hexokinase inhibitor 3-bromopyruvate
(3-BrPA) was found to be highly toxic to different cancerrized reproduction of this article is prohibited.
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less toxic to cell lines lacking K-Ras mutation [39].
Interestingly, the K-Ras mutations that lead to low-glu-
cose adaptations can be induced by glucose deprivation
[39]. This suggests that a stress caused by nutrient
shortage might be a favorable ground for the activation
of oncogenes.Aerobic glycolysis as a generator of a tumor
friendly niche
There is evidence that an increased glycolysis rate con-
tributes to the acquisition of resistance to chemical drugs
by cancer cells, mainly through acidification of the tumor
microenvironment. The large amounts of lactate secreted
by tumor cells, as a direct consequence of the abnormal
production of pyruvate, leads to acidification of the tumor
surroundings [40]. Several anticancer drugs such as dox-
orubicin, mitoxantrone and vincristine are weak bases
that are protonated in slightly acid tumor microenviron-
ments. When protonated, these drugs cannot easily dif-
fuse across the plasma membrane and consequently their
cellular uptake is diminished. In this context it has
recently been shown that addition of sodium bicarbonate
in the drinking water raises the pH of the extracellular
milieu in mice, which translated into a greater efficacy of
doxorubicin to hamper the growth of xenotransplanted
tumors [41]. The reverse situation was shown in another
study where glucose administration to mice led to a
decrease in the extracellular pH and a lower efficacy of
doxorubicin on tumors [42]. In contrast to weak bases
such as doxorubicin, weak acid anticancer drugs like
chlorambucil are more efficacious when the pH of the
extracellular milieu decreases [42]. These studies have
important clinical implications because they suggest that
appropriate modulation of the extracellular pH in
patients with cancer based on the chemical properties
of the used antitumor drugs could optimize the che-
motherapy efficacy.
Additionally, pH lowering can influence more directly
tumor progression and expansion. The extracellular con-
ditions found within precancerous lesions (i.e. hypoxia,
low-nutrient availability) typically results in necrosis or
apoptosis of tumor cells through p53-dependent mech-
anisms and caspase-3-dependent mechanisms [43]. This
initial beneficial response may, however, later favor the
selection of cells that, in addition to upregulating gly-
colysis, acquire mutations allowing them to become
immune to apoptotic-inducing pathways and potentially
other antimalignant and anti-invasive checkpoints [5,9].
These cells are considered by some to be cancer stem-
like cells [44]. The identification of these cancer stem-
like cells and the mechanisms governing their anaerobic
metabolic pathways may potentially open new perspec-
tives in cancer treatment.opyright © Lippincott Williams & Wilkins. Unauth
47One peculiar feature of cancers is the ability to metas-
tasize. Spontaneous metastasis consists in two main
phases intravasation where transformed cells leave the
primary tumor to the bloodstream and extravasation
where tumor cells colonize new tissues. In-vitro studies
have shown that tumor cell invasion can be stimulated by
acidic conditions [45,46]. Moreover, acid pretreatment of
tumor cells increases their ability to metastatize after
injection in mice [47]. This effect could be attributed to
an augmented release of cathepsin B that is involved in
extracellular matrix remodeling. Recently, it has been
shown that bicarbonate therapy significantly reduces the
number and the size of metastases in a breast cancer
mouse model by increasing tumor pH [48]. Bicarbonate,
by modulating the pH of the tumor environment, nega-
tively affects the process of tumor cells extravasation
without significantly influencing intravasation and circu-
lation of tumor cells across the bloodstream [48]. This
finding is of high relevance if we consider that primary
tumors rarely kill affected patients, but that it is rather
formation of metastasis from primary tumors that is lethal.
Therefore, strategies that aim at limiting spreading of
primary tumors across the body could be highly beneficial
for cancer patients.Conclusion
Alteration of glucose metabolism can be the result of an
adaptive response to the lack of oxygen or following
activation of oncogenes. Aerobic glycolysis appears to
represent a selective advantage for tumor cells as they
become more resistant to apoptosis and acquire increased
growth and invasive properties. At present it is still
unclear if the molecular mechanisms controlling the
switch towards aerobic glycolysis are directly involved
in the acquisition of apoptosis resistance or whether this
resistance is a secondary adaptation to hypoxia of a
subpopulation of transformed cells in precancerous
lesions. Regardless of the mechanisms, glycolysis upre-
gulation represents a clear advantage for cancers cells and
at the same time a target for new anticancer therapies.
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OBJECTIVES 
Our laboratory developed a tumor-specific sensitizer, TAT-RasGAP317-326, able to potentiate the 
genotoxin-induced apoptosis in several cancer cell lines, but not in non tumoral cell lines. The 
active sequence of this peptide (amino acids 317-326 of RasGAP) was derived from the caspase-
3-generated fragment N2 of RasGAP, previously shown to selectively sensitize malignant cells to 
genotoxin, and was fused to a cell permeable sequence (amino acids 48-57 of HIV TAT protein). 
During my thesis I undertook the following research projects: 
 
I. Fragment N2, generated by the caspase-3 mediated proteolitic cleavage of RasGAP, 
specifically sensitizes tumor cells to genotoxin-induced apoptosis. This fragment exhibits 
a cytoplasmic localization in the cell and we wanted to ascertain whether changes in the 
sub-cellular location would impair fragment N2 ability to enhance genotoxin-induced 
apoptotic cell death.  
II. TAT-RasGAP317-326 is an efficient tumor sensitizer in vitro. We tested the sensitizing 
properties of TAT-RasGAP317-326 in in vivo settings using a tumor xenograft mouse 
model. 
III. G3BP1 (GAP SH3 Binding Protein 1) is a cytoplasmic protein described as binding to the 
SH3 of RasGAP on its sequence 317-326, which corresponds to the active sequence of 
our RasGAP-derived peptide. This observation, together with reports indicating G3BP1 as 
a protein involved in mRNA stability and adaptation to stress, made G3BP1 a potential 
effector of the TAT-RasGAP317-326-mediated sensitization. We therefore checked if TAT-
51
RasGAP317-326 modulated any of the G3BP1 functions or its cellular location and if the 
peptide needs G3BP1 to work. 
IV.  The molecular mechanisms underlying the TAT-RasGAP317-326-induced enhancement of 
apoptosis triggered by genotoxins is still poorly understood. Earlier reports showed that 
TAT-RasGAP317-326 need a functional p53/Puma axis to exert its sensitizing properties, 
but this could be solely explained by the fact that in the absence of either p53 or Puma, 
cells cannot properly undergo apoptosis induced by genotoxins. Genotoxins kill tumor 
cells by triggering the intrinsic apoptotic pathway, a cell death pathway tightly controlled 
by the Bcl-2 family members. Hence we studied the importance of several members of 
this family, as well as the implication of p53, in the sensitization mechanism. 
V. Radiotherapy is one of the most commonly used anti-cancer treatments. We evaluated the 
ability of TAT-RasGAP317-326 to sensitize several cancer cell lines and tumor xenografts, 
both p53 positive and negative, to γ-radiations.  
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Introduction 
 
 
RasGAP is a GAP (GTPase-activating protein) specific for Ras. The GAP activity resides 
within its C-terminus whereas the N-terminus is implicated in distinct signalling pathways. 
Our group has previously shown that RasGAP is also a caspase 3 substrate. In presence of 
mild stress conditions, RasGAP is cleaved by caspase 3 at position 455 to generate a C-
terminus fragment, named fragment C, and an N terminus fragment, called fragment N. 
Fragment N was reported to generate an anti-apoptotic response that depends on the activation 
of Ras/PI3K/Akt pathway. When stress conditions increase fragment N is further cleaved by 
caspase 3 at position 157 and this cleavage abrogates its anti-apoptotic function. The resulting 
fragments, called fragment N1 and fragment N2, do not play any role in the apoptotic 
response of normal cells. By contrast when over-expressed in cancer cells, fragment N2 
sensitizes them to genotoxin-induced death. 
We decided to look at fragment N2 localization in cancer cells to see if the sensitization event 
requires a specific sub-cellular location of this fragment. 
Our data show that fragment N2 has an almost exclusive cytoplasmic localization, that is 
required for its sensitizing properties. Indeed, when we localize fragment N2 to other cellular 
compartments (i.e. mitochondria or endoplasmic reticulum), it looses its ability to favour the 
genotoxin-induced apoptosis of cancer cells. Taken together our results show that fragment 
N2-mediated sensitization of cancer cells to genotoxins strictly depends on its sub-cellular 
location. 
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One hallmark of cancer cells is their ability to evade apoptosis.
Understanding the regulation of the apoptotic process can there-
fore lead to the development of new strategies to restore a normal
apoptotic response in tumors to facilitate their elimination during
anti-cancer therapies.
One of the mechanisms allowing cells to determine whether
they should survive or commit suicide involves the sequential
cleavage of RasGAP. This protein is a regulator of Ras- and Rho-ogy, Rue du Bugnon 7/9, 10
(C. Widmann).
rk.
r Inc. All rights reserved.
57signaling [1,2]. It bears two caspase cleavage sites at position 455
and 157 [3]. In stressed cells having mildly activated caspase-3,
RasGAP is only cleaved at position 455. This generates anN-terminal
fragment called fragment N that induces a potent anti-apoptotic
signal that depends on the activation of Ras, PI3K, and Akt [4] and
that is crucially required for the survival of stressed cells [5]. In
response to apoptotic stimuli, fragment N is further cleaved by
caspase-3 and this abrogates its anti-apoptotic properties [6]. The
resulting fragments (N1 and N2) do not appear to modulate
apoptosis in normal cells [6]. In contrast, tumor cells are strongly05 Lausanne, Switzerland. Fax: +41 21 692 5255.
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[3,6,7]. The tumor sensitizing ability of fragment N2 lies within a 10
amino acid stretch located at position 317–326 [7]. A cell permeable
synthetic peptide containing the 317–326 RasGAP sequence
peptide, called TAT-RasGAP317–326, is as potent as fragment N2 to
sensitize cancer cells to genotoxins [7]. The molecular mechanism
by which fragment N2 and TAT-RasGAP317–326 sensitize tumor cells
is however not well understood although it has been recently
demonstrated that a functional connection between p53 and PUMA
is required [8].
Here we show that fragment N2 is almost exclusively located in
the cytoplasm and that this location is required for its tumor
sensitization properties.Materials and methods
Cells and transfection
U2OS (LGC Promochem; ATCC no. HTB-96), HCT116 p53+/+, and
HCT116 p53−/− cells [9] weremaintained in DMEMcontaining 10%
fetal calf serum (GIBCO/BRL) at 37 °C and 5% CO2. They were
transfected using the calcium/phosphate precipitation procedure
[7] using 1 μg of the RasGAP-encoding plasmids and 0.5 μg of
pEGFP-C1. HeLa cellsweremaintained in RPMI 1640 containing 10%
newborn calf serum (NBCS) (catalog no. 26010-074; Invitrogen) at
37 °C and 5% CO2. They were transfected using lipofectamine
(GIBCO/BRL) [3]. The cells were submitted to the indicated
experimental conditions 24 h following their transfection (unless
indicated otherwise). Mouse embryonic fibroblasts (MEFs) were
maintained in DMEM containing 10% NBCS at 37 °C and 5% CO2.
Cell fractionation into nuclear and cytoplasmic fractions
U2OS cells were seeded at a density of 2×106 cells in 10 cm-plates
and transfected the next day with the indicated constructs.
Following an additional day in culture, the cells were solubilized
in 400 μl lysis buffer (0.5% Triton X-100, 500 mM Tris–HCl pH 7.5,
137mMNaCl, 10% glycerol, supplementedwith one tablet of EDTA-
free protease inhibitor [Roche] per 50 ml) and centrifuged at
16,000 g for 15 min at 4 °C. The supernatant, representing the
cytoplasmic fraction, was collected and quantitated for protein
content by Bradford assay. The pellet, containing nuclei, was rinsed
once with 400 μl lysis buffer and then resuspended in 200 μl lysis
buffer supplemented with 0.5% SDS. The nuclear lysate was
sonicated and centrifuged at 16,000 g for 10 min at 4 °C. Protein
content was then assessed by Bradford assay.
Sub-cellular fractionation into cytoplasmic,
mitochondrial/ER, and nuclear fractions
U2OS cells were seeded and cultured as above. They were then
washed with PBS and resuspended in 400 μl of hypotonic lysis
buffer (10 mM Hepes pH 7.4, 10 mM MgCl2, 42 mM KCl,
supplemented with one tablet of EDTA-free protease inhibitor
[Roche] per 50 ml) for 5 min on ice. Cells were scraped and then
were lysed using a Dounce homogenizer and centrifuged at 300 g
for 5min at 4 °C to collect crude nuclei that were further purified as
described below. The supernatant was further centrifuged at
10,000 g for 10 min at 4 °C to collect mitochondria and ER. The58supernatant represents the soluble cytoplasmic fraction.Mitochon-
dria/ER were resuspended in hypotonic lysis buffer supplemented
with 1% Triton X-100, sonicated and centrifuged at 16,000 g for
10 min. The supernatant represents the mitochondria/ER protein
fraction.
Nuclei were resuspended in hypotonic lysis buffer supplemented
with 1% Triton X-100, sonicated and centrifuged 10 min at 16,000 g.
Supernatant was discarded and nuclei were resuspended in lysis
buffer (0.5% TritonX-100, 0.5%SDS, 500mMTris–HCl pH7.5,137mM
NaCl, 10% glycerol, supplemented with one tablet of EDTA-free
protease inhibitor [Roche] per 50 ml), passed through a 26 gauge-
needle several times to break the DNA, sonicated, and centrifuged
10min at 16,000 g. The supernatantwas used as the nuclear fraction.
Antibodies
The polyclonal rabbit anti-RasGAP antibody directed at the Src
homology (SH) domains of RasGAP has been described before [10].
The polyclonal rabbit anti-RasGAP antibody directed at fragment
N2 is from Alexis (catalog no. ALX-210-860). The monoclonal
antibody specific for the hemagglutinin (HA) tag was purchased as
ascites from BabCo (catalog no. MMS-101R). This antibody was
adsorbed on HeLa cell lysates to decrease non-specific binding as
described previously [3]. Secondary antibodies were donkey anti-
mouse indocarbocyanine (Cy3)-conjugated antibody and donkey
anti-rabbit Cy3-conjugated antibody (Jackson ImmunoResearch,
catalog no. 715-165-151 and 711-165-152, respectively). The histone
H3antibody is fromMBL (catalog no. JM3623). The tubulin antibody
is from Serotec (catalog no. MCA77G). The calreticulin antibody is
from Cell Signaling (catalog no. 2891). The mouse monoclonal
antibody specific for the cytochrome c oxidase subunit 5A is from
Mitosciences (catalog no. MS409).
Plasmids
pEGFP-C1 and pEGFP-C3 encode the green fluorescent protein and
are fromClonetech. The extension .dn3 indicates that the backbone
plasmid is pcDNA3 (Invitrogen). HA-GAP.dn3 encodes the full-
length human RasGAP protein bearing an HA tag (MGYPYDVP-
DYAS) at the amino terminal end [3]. HA-GAP-N.dn3, HA-N1.dn3,
and HA-N2.dn3 encode the HA-tagged (at the N-terminus)
versions of fragments N, N1, and N2, respectively [3]. GFP-GAPC is
a fusion protein between GFP and RasGAP fragment C, bearing an
HA tag at the carboxy-terminal end (fragment C cannot be
expressed in cells unless fused to GFP [3]).
GFP-HA-GAP encodes a fusion protein between GFP and the HA-
tagged form of full-length RasGAP. It was constructed by subcloning
the3911 bpBamHI/EcoRI fragment fromHA-GAP.dn3 into pEGFP-C1
opened with BglII and EcoRI. GFP-HA-N encodes a fusion protein
between GFP and the HA-tagged form of fragment N. It was
constructed by subcloning the 1429 bp XhoI fragment from HA-
GAPN′.dn3 into pEGFP-C3openedwith the sameenzyme.HA-GAPN′.
dn3 is almost identical to HA-GAP-N but for the BamHI site replaced
with a XhoI site. It was constructed by annealing oligonucleotides
#187 (GATCTCTCGAGAAA) and #188 (GATCTTTCTCGAGA) and
subcloning them into HA-GAP-N opened with BamHI. GFP-HA-N2
encodes a fusion protein between GFP and the HA-tagged form of
fragment N2. It was constructed by subcloning the 967 bp ApaI
fragment from HA-N2.dn3 into pEGFP-C1 opened with the same
enzyme. Plasmid HA-N2-RKGQERFNR-Bcl-XL TMB.dn3 encodes the
Fig. 1 – The endogenous full-length RasGAP protein is
predominantly cytoplasmic. (A) MEFs derived from wild-type
mice were stained with a 1/300 dilution of a polyclonal
anti-RasGAP antibody recognizing the SH domains of the
protein and photographed using a confocal microscope. (B)
MEFs derived from RasGAP knock-out (RasGAP−/−) or
wild-type (RasGAP+/+) mice were stained as above together
with the Hoechst dye to label the nuclei. They were
photographed using a microscope equipped with normal
transmission optics.
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sequence of Bcl-XL. It was constructed as follows: GFP-C3 (corre-
sponding to plasmid EGFP-X-TMB[Bcl-x] in [11] was PCR-amplified
with the N2-Bcl-XL-sense oligo [AATAT GCGGCCGC (NotI)
AGCCGAGAGCCGAAAGGGCCAGGAAC (nucleotides 777–802 of the
human Bcl-XLmRNA; NM_001191)] andwith the C3 anti-sense oligo
[GTTTCAGGTTCAGGGGGAGGTG; sequence 1583-1562 of GFP-C3].
The 155 bp PCR fragment was cut with NotI and XbaI and subcloned
in plasmid HA-N2-no stop.dn3 opened with the same enzymes. The
latter plasmid is similar to plasmid HA-N2.dn3 but does not bear a
stop codon at the end of the coding sequence of fragment N2. It was
generated as follows: HA-N2.dn3was PCR-amplified using the sense
oligo 644 [GCGTGGATAGCGGTTTGACTC (nucleotides 644–664 of
pcDNA3)] and the anti-sense oligo ND157x [AAAAAAAA (trailer)
GCGGCCGC (NotI) GTC GAC TGT GTC ATT GAG TAC (human RasGAP
D455-V449; the 6 nucleotides preceding the NotI site creating a new
SalI site)]. The 1206 bp fragment was cut with Bsu36 and NotI. The
resulting784bp fragmentwas subcloned inHA-N2.dn3openedwith
the same enzymes. PlasmidHA-N2-Bcl-2.dn3 encodes theHA-tagged
fragment N2 fused to the intracellular membrane targeting domain
of Bcl-2. It was constructed as follows: GFP-C2 (corresponding to
plasmid EGFP-BH2X-TMB[Bcl-2] in [11])was pCR-amplifiedwith the
sense oligo N2-Bcl-2-sense [AATAT GCGGCCGC (NotI) G ATCCAGGA-
TAACGGAGGCTGGGATG (human Bcl-2 amino acids 189–239)] and
the anti-sense oligo N2-Bcl-2-AS [N2-Bcl-2-AS; #342; sequence
1780–1751 of GFP-C2): TGATCAGTTAT TCTAGA (XbaI) T G (mutation
to remove theDammethylation site)CGGTGGATCATC]. The resulting
374 bp fragment was digested with NotI and XbaI and subcloned in
HA-N2-no stop.dn3openedwith the sameenzymes. PlasmidHA-N2-
AAGQEAFNA-Bcl-XL TMB.dn3 is similar to HA-N2-RKGQERFNR-Bcl-XL
TMB.dn3 but bears mutations in the sequences upstream of the
trans-membrane domain that disrupt the mitochondrial targeting
(see Fig. 4). It was generated as follows: HA-N2-RKGQERFNR-Bcl-XL
TMB.dn3 was PCR-amplified with the sense primer Mutated Bcl-XL
TMB (CAGTCGAC [feeder] GCGGCCGC [NotI] AGCCGAGAGC gc A gc
TGGCCAGGAA gc CTTCAAC gc CTGGTTCCTGACGGGCATGAC [nucleo-
tides 777–833 of human Bcl-XLmRNA (NM_001191)withmutations
indicated by lower case letters; these mutations also introduce a
additional PvuII site) and the anti-sense primer Sp6 (CTAGCATT-
TAGGTGACACTATAG [pcDNA3 nucleotides 1021–999]). The 204 bp
PCR fragment was then cut with NotI and ApaI and the resulting
141 bp fragment subcloned into the template plasmid opened with
the same enzymes.
N(D157A).pgx encodes a fusion protein between GST and
fragment N. It was constructed by PCR amplification of plasmid N
(D157A).dn3 with the sense oligo [TTGGTT (feeder) GGATCC
(BamHI) ATG ATG GCG GCC GAG (amino acids 1–5 of RasGAP)]
and with the anti-sense oligo [TACCTAGCATGAACAGATTG (a
sequence that is not found in pcDNA3 and that has no use in the
present context) AGGGGCAAACAACAGATG (a pcDNA3 sequence
downstream of the multiple cloning sites). The resulting 1517
fragment was cut with BamHI and XhoI and subcloned in plasmid
pGEX-KG opened with the same enzymes. N(D157A).dn3 was
constructed by subcloning the SacII/BglII 1.2 kb fragment of h-
RasGAP (no 3′-UTR).dn3 into HA-N(D157A).dn3 opened with the
same enzyme. HA-N(D157A).dn3 encodes the HA-tagged caspase-
resistant version of fragment N [3].
h-RasGAP (no 3′-UTR).dn3 was constructed by PCR amplifica-
tion of h-RasGAP.dn3 (using the Pfu polymerase) using the sense
oligonucleotide (CTCATGCAAGGGAAGGGCAA: human RasGAP59mRNA nucleotides 2001–2020; accession no. M23379) and the
anti-sense oligonucleotide (CG [feeder]; GCGGCCGC [NotI];
CTACCTGACATCATTGGTTTTTGT [RasGAP cDNA sequence 3331–
3308 accession no. 34190380]). The PCR fragment (1.1 kb) was
then digested with NotI/EcoRV and subcloned in h-RasGAP.dn3
opened with the same enzyme. h-RasGAP.dn3 encodes the human
RasGAP mRNA (clone 101) [nucleotides 1–3987] [12].
The names of the plasmids used for the production of
lentiviruses end with .lti. Plasmids HA-N(D157A).lti (previously
called N-D157A.lti) was described earlier [5]; as were plasmids
HA-N2.lti and HA-RasGAP (no 3′-UTR).lti [6].
All the PCR-generated plasmids were sequenced to check that
no PCR-mediated errors were generated.
Immuno-cytochemistry
Cells were grown on glass coverslips and transfected. Two days
post-transfection, the cells were fixed as follows (all the stepswere
performed at room temperature). The cells on coverslips were
washedwith 4ml of PBS [116mMNaCl,10.4 mMNa2HPO4, 3.2 mM
KH2PO4 (pH 7.4)], fixed with 3 ml PBS, 3% formaldehyde, 3%
sucrose for 10 min, washed thrice with PBS, permeabilized with
2 ml of PBS, 0.2% Triton X-100 for 10 min, washed thrice with PBS,
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culture medium. After three additional PBS washes, the coverslips
were incubated for 1 h with the primary antibody diluted in
DMEM, 10% newborn calf serum. The coverslips were washed 3
times over 30 min in PBS and then incubated 1 h with a 1/100
dilution of labelled secondary antibodies in DMEM, 10% newborn
calf serum. The coverslips were washed 3 more times in PBS and
labelled when indicated with 10 μg/ml Hoechst 33342 (Molecular
Probe) before being mounted (Vectashield mounting medium,
Vector laboratories Inc). Confocal images were captured with a
Leica SP5 AOBS confocal microscope. Other images were taken
with a Zeiss Axioplan 2 imaging microscope.
Apoptosis measurements
Apoptosis was determined by scoring the number of cells
displaying pycnotic nuclei. Nuclei of live cells were labelled with
Hoechst 33342 (10 μg/ml final concentration) for about 5 min and
the cells were then analyzed (at least 200 cells per condition)
using an inverted Zeiss Axiovert 25 microscope equipped with
fluorescence and transmitted light optics. Assessment of apoptosis
was performed one day after treatment of the cells. The pEGFP-C1
plasmid was included in the transfection solution to label the
transfected cells with GFP. The extent of apoptosis was assessed in
transfected cells only.
Lentivirus
Recombinant lentiviruseswereproduced aspreviouslydescribed [13].
Statistical analysis
Statistical analyses were performed with Microsoft Excel (XP
edition) using the two-tailed unpaired student t-test. Significance
is indicated by an asterisk when p<0.05/n, where p is the
probability derived from the t-test analysis and n is the number of
comparisons performed (Bonferroni correction). In Fig. 4C,
statistical significance was assessed by ANOVA using the R
program (http://www.r-project.org/).Fig. 2 – Fragment N2 has a predominant nuclear location in fixed ce
indicated HA-tagged proteins and fragments. The location of the co
anti-HA antibody. The lower part of the panel graphically depicts t
distribution ratio (from exclusively cytoplasmic to exclusively nucl
were transfected with plasmids encoding the indicated HA-tagged c
cells were then visualized by fluorescence microscopy and the cellul
as described in panel A. (C) U2OS cells were either left untreated or t
fixed 24 h later and subjected to immuno-cytochemistry using an a
confocal microscope and the intensity of the RasGAP signal was qu
transfected cells, only the cells with a clear increase in RasGAP leve
cells). (D and E) U2OS cells were infected or not with a lentivirus en
were either fixed and subjected to immuno-cytochemistry analysis
trypsinization, or lysed. Different quantities of the lysates were loa
GST-fragment N recombinant protein. AWestern blot was then perf
(panel E, upper part). The quantity of RasGAP in the lysates was calcu
blot signals of the GST-fragment N recombinant proteins against the
of cells in the culture wells prior to lysis allowed for the conversion o
“number of RasGAP molecules per cell”.
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Sub-cellular location of RasGAP and its caspase-generated
fragments
The sub-cellular location of endogenous RasGAP was first assessed
in MEFs. Fig. 1A shows that the endogenous RasGAP protein is
mainly localized in the cytoplasm, as anticipated from earlier
studies demonstrating GAP activity in cytoplasmic extracts [14,15].
The specificity of the anti-RasGAP antibody was demonstrated by
the absence of staining in RasGAP−/−MEFs (Fig. 1B). There are no
currently available antibodies that can discriminate RasGAP from
its cleavage products by immuno-cytochemistry. To assess the sub-
cellular distribution of caspase-generated RasGAP fragments, HeLa
cells were therefore transfected with plasmids encoding HA-
tagged versions of RasGAP or its fragments. The location of the
various constructs was assessed by immuno-cytochemistry (Fig.
2A, upper part) and the proportions of cells displaying a given
cytoplasmic versus nuclear distribution ratio scored as shown in
the lower part of Fig. 2A. In comparison with the endogenous
protein, over-expressed full-length RasGAP had an increased
nuclear distribution but the nuclear staining was never more
intense than the cytoplasmic one. Fragments N and C had a similar
cellular location as the full-length protein. Fragment N1, in
contrast, had a nuclear staining that was as strong as or stronger
than the cytoplasmic staining. This was even more pronounced
when fragment N2 was over-expressed. About one third of
fragment N2-transfected cells expressed the protein exclusively
in the nucleus and for the remaining ones, the cytoplasmic staining
remained very low. None of the other constructs used here
displayed an exclusively nuclear location. The predominant
nuclear location of fragment N2 was confirmed in the U2OS
osteosarcoma cell line (Fig. 2B).
Two approaches were employed to evaluate the degree of over-
expression of full-length RasGAP that is achieved in U2OS cells.
First, U2OS cells were transfected or not with a plasmid encoding
the HA-tagged form of full-length RasGAP. The expression of
RasGAP was then evaluated by measuring the intensity of thells. (A) HeLa cells were transfected with plasmids encoding the
nstructs was assessed by immuno-cytochemistry using an
he number of cells having a given cytoplasmic versus nuclear
ear as schematized under the horizontal axis). (B) U2OS cells
onstructs together with a plasmid encoding the GFP protein. The
ar location of the transfected RasGAP-derived constructs scored
ransfectedwith a construct encoding HA-RasGAP. The cells were
nti-RasGAP fragment N2 antibody. Images were taken with a
antitated using the ImageJ software (1.34n version). In the
ls were recorded. Results correspond to the mean±SD (n=25
coding the HA-tagged form of RasGAP. Two days later, the cells
using an anti-HA antibody (panel D), counted after
ded on a SDS-PAGE gel along with known quantities of purified
ormed using an antibody recognizing the N2 portion of RasGAP
lated using the standard curve obtained by plotting theWestern
ir molar quantities (panel E, lower part). Recording the number
f “number of RasGAPmolecules in a given quantity of lysate” to
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(Fig. 2C). There was about a 7-fold increase in RasGAP expression
levels in the U2OS cells transfected with the RasGAP-encoding
plasmid. The second experiment was performed on U2OS cells
infected or not with a lentivirus encoding the HA-tagged form of
RasGAP. The amount of virus used led to virtually all of the cells to
over-express RasGAP (Fig. 2D). The quantity of RasGAP expressed
in the cells was determined byWestern blot analysis using an anti-
RasGAP antibody by comparing the signal obtained with known61amounts of purified GST-fragment N recombinant protein (that
bears the epitope recognized by the antibody used in the Western
blot) with the signals derived from cell lysates (Fig. 2E). This
analysis revealed that an U2OS cell expresses about 400,000
RasGAP molecules while an U2OS cell infected with a lentivirus
encoding RasGAP expresses on average about 2 million RasGAP
molecules. These two approaches indicate therefore that the level
of over-expression of RasGAP in U2OS cells, whether achieved by
transfection or following lentiviral infection, is ∼5–7 fold.
Fig. 2 (continued).
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fixed cells of fragment N2, but not of fragment N or RasGAP, is
artefactual. Live imaging of U2OS cells transfected with a plasmid
encoding a fusion protein between GFP and fragment N2
revealed cells with a strong green cytoplasmic labelling (Fig.
3A; compare with Fig. 2). Fragment N2 fused to GFP was still
functional as a genotoxin-sensitizer (Fig. 3B) indicating that the
GFP moiety did not interfere with its anti-cancerous function.62Sub-cellular fractionation of HA-fragment N2-transfected U2OS
cells into a nuclear histone H3-containing fraction, and a
cytoplasmic tubulin-containing fraction (Fig. 3C) confirmed the
predominant cytoplasmic location of fragment N2. In contrast to
what was observed with fragment N2, the locations of the
parental RasGAP protein and fragment N were similar in live and
fixed cells and more or less matched the distribution pattern
observed in sub-cellular fractions (Figs. 2 and 3): fragment N
Fig. 3 – Fragment N2 is mainly located in the cytoplasm of living cells. (A) U2OS cells were transfected with plasmids encoding the
indicated GFP-tagged constructs. Immediately following Hoechst staining, the cells were visualized while still alive, by fluorescence
confocal microscopy. (B) U2OS cells were transfected with the indicated constructs. They were then incubated with increasing
concentrations of cisplatin and one day later apoptosis was determined in the transfected cell population. The results correspond to
the mean±SD of three independent experiments. Statistical analysis was performed to assess the significance of the sensitization
induced by the N2-containing constructs (i.e. comparisons of control cells treated with cisplatin with the other cisplatin-treated
cells; 2 comparisons). (C) U2OS cells were transfected with plasmids encoding the HA-tagged forms of full-length RasGAP, fragment
N or fragment N2. Nuclear and cytoplasmic fractions (see Materials and methods) were then analyzed byWestern blotting using an
anti-HA antibody to detect RasGAP and its fragments. Tubulin and histone H3 were used as markers for the cytoplasm and nucleus,
respectively. (D) U2OS and MEFs were infected with the same amount of HA-RasGAP, HA-N and HA-N2-expressing lentiviruses and
48 h later they were lysed and the lysates were fractionated as described in (C).
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2088 E X P E R I M E N T A L C E L L R E S E A R C H 3 1 5 ( 2 0 0 9 ) 2 0 8 1 – 2 0 9 1was localized in the cytoplasm and in the nucleus and full-length
RasGAP was predominantly detected in the cytoplasm (see also
Fig. 1).Fig. 4 –Mitochondria and ER-targeted fragment N2 does not sensitiz
plasmids encoding the indicated HA-tagged constructs. The cells we
soluble cytoplasmic (C), mitochondria/ER-containing (M/ER), and n
presence of the indicated proteins was assessed byWestern blot. The
RasGAP. FL, full-length RasGAP; N2, the various forms of fragment
indicated HA-tagged constructs together with a plasmid encoding
visualized by fluorescence confocal microscopy. (C) U2OS cells tran
encoding the GFP protein were incubated with increasing concentr
determined 24 h later. The results correspond to the mean±SD of th
difference between cells expressing wild-type N2 and the other con
differences were detected within the conditions found in the brack
64As fragment N2 does not sensitize non-cancer cells (e.g. mouse
embryonic fibroblasts [MEFs]) to genotoxin-induced apoptosis [6],
it was of interest to determine whether the cytoplasmic location ofe tumor cells to genotoxins. (A) U2OS cells were transfectedwith
re then lysed to generate a total cell extract (T) or separated into
uclear (N) fractions as described in Materials andmethods. The
RasGAP-specific antibody used here recognizes the N2 region of
N2. (B) U2OS cells were transfected with plasmids encoding the
the GFP protein. Following Hoechst staining, fixed cells were
sfected with the indicated constructs together with a plasmid
ations of cisplatin. Apoptosis in the GFP-positive cells was
ree independent experiments. The asterisk denotes a statistical
ditions (for all the possible comparisons). No statistical
et.
Fig. 4 (continued).
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U2OS or HeLa cells) or whether fragment N2 was also mainly
found in the cytoplasm of normal cells. We therefore assessed the
sub-cellular location of fragment N2 in MEFs. Full-length RasGAP
and fragment N were also analyzed for comparison. As MEFs are
poorly transfectable, we used lentiviral infection to ectopically
express the proteins (the amount of viruses used led to 100% of the
cells being infected; not shown and Fig. 2D). As controls, U2OS
cells were similarly infected. Fig. 3D shows that fragment N2 was
mostly detected in the cytoplasmic fraction of both MEF and U2OS
infected cells. The cytoplasmic location of fragment N2 is therefore
not a specific feature of cancer cells.
In infected cells, low but clearly detectable amounts of
fragment N2 were found in the nuclear fraction. As fragment
N2 was not observed in the nuclear fraction of transfected U2OS
cells (see Fig. 3C), this suggests that lentiviruses somehow affect
the sub-cellular distribution of fragment N2 in cells. Lentiviruses
perturbed to seemingly a greater extent the sub-cellular
distribution of full-length RasGAP and fragment N since there
were obviously more of these proteins in the nuclear fraction of
infected U2OS cells in comparison to what was observed in
transfected U2OS cells. The main message of Fig. 3D however is
that the sub-cellular distribution pattern of fragment N2 does
not seem to be grossly different between cancer and non-cancer
cells.
The results described above indicate that fragment N2 is
found in the cytoplasm but they do not tell whether fragment
N2 is associated or not with a cytoplasmic organelle (e.g.
mitochondria). To assess this point, U2OS cells expressing the
HA-tagged form of the fragment were separated into nuclear,
organelle-free cytoplasmic, and mitochondria/ER-containing
fractions. The purity of these fractions were assessed using the
tubulin cytoplasmic marker, the cytochrome c oxidase subunit
5A (Cox) mitochondrial marker, the calreticulin ER marker, and
the histone H3 nuclear marker. Fig. 4A (left part) shows that the
majority of fragment N2 is found in the soluble fraction. A minor
portion of fragment N2 was distributed in the mitochondria/ER-
containing fraction. An even smaller portion was detected in the
nuclear fraction.65The cytoplasmic location of fragment N2 is required for its
tumor sensitization properties
The data presented above indicate that fragment N2 is mainly a
soluble protein present in the cytoplasm but they also show that a
small fraction of fragment N2 can be associated with organelles
(mitochondria and/or the ER). We reasoned that if the presence of
fragment N2 in the cytoplasm is important for its ability to
sensitize tumor cells to genotoxin-induced death, experimentally
relocating fragment N2 away from the cytoplasm onto given
organelles should negatively affect its sensitization properties.
Conversely, if the location of fragment N2 on a given organelle
favors or is required for its sensitization properties, such relocation
should positively affect its ability to sensitize tumor cells to
genotoxins. Specific sequences in Bcl-2 family members have been
shown to target proteins to various organelles. For example, amino
acids 136–170 of human Bcl-XL targets the protein to mitochondria
while amino acids 189–239 of human Bcl-2 targets it to
intracellular membranes including the endoplasmic reticulum
and perinuclear membranes [11].We therefore generated plasmids
encoding HA-tagged fragment N2 bearing these targeting
sequences at the carboxy-terminal end. The targeting capacity of
the Bcl-2 and Bcl-XL sequences was assessed by sub-cellular
fractionation and immuno-cytochemistry. Fig. 4A shows that both
the Bcl-2 and Bcl-XL sequences induce a relocation of fragment N2
from a soluble cytoplasmic fraction to mitochondrial/ER and
nuclear fractions. The presence of some N2-Bcl-2 fusion protein in
the nuclear fraction could be expected from the earlier demonstra-
tion that the Bcl-2 sequence used here (amino acids 189–239 of
human Bcl-2) targets protein to intracellular membranes including
perinuclear membranes [11]. In contrast, it is currently unclear
why the Bcl-XL mitochondrial targeting sequence (amino acids
136–170 of human Bcl-XL) [11] led some of the N2-Bcl-XL fusion
proteins ending up in the nuclear fraction. Despite the fact that
fragment N2 artefactually associates with the nucleus of fixed cells,
the Bcl-2 and Bcl-XL sequences were able to relocate fragment N2
to the mitochondria and ER/nuclear membranes in fixed cells
(Fig. 4B). Importantly, this change in sub-cellular location abro-
gated the ability of fragment N2 to sensitize tumor cells to
cisplatin-induced apoptosis (Fig. 4C).
It could be argued that it is the mere addition of sequences at
the carboxy-terminal end of fragment N2 that inhibits its
sensitization properties. To assess this issue, four point mutations
were introduced in the X domain preceding the trans-membrane
domain (TM) and the basic amino acids (B) in the mitochondrial
targeting sequence of Bcl-XL (Fig. 5A). These mutations have been
shown to abrogate mitochondria targeting [11]. Fig. 5B shows that
fragment N2 bearing such a mutated sequence at its COOH-
terminus was no longer retained in the cytoplasm but predomi-
nantly redistributed to the nucleus of fixed cells. This was
accompanied by a recovered ability to sensitize tumor cells to
cisplatin-induced apoptosis (Fig. 5C). This suggests that it is the
modification of the sub-cellular location of fragment N2 that
causes its inability to sensitize tumors to genotoxins rather than
the addition of sequences at its C-terminal end.
Fragment N2 and shorter peptides derived from it have been
shown to sensitize tumor cells, but not normal cells, to genotoxin-
induced death [6,7] and to photodynamic therapy [16]. It is
however not knownwhether this sensitization property could also
be seen in associationwith apoptotic stimuli that are not supposed
Fig. 5 – The presence of additional sequences at the
carboxy-terminal end of fragment N2 does not hamper its
ability to sensitize tumor cells to cisplatin. (A) The Bcl-XL
mitochondrial targeting sequence is shown. The mutations
known to abrogate mitochondrial targeting are indicated in
red. (B and C) U2OS cells were transfected with plasmids
encoding the indicated HA-tagged constructs together with a
plasmid encoding GFP. In panel B, the cells were treated as
in Fig. 2B. In panel C, the cells were processed as described
in Fig. 3B (only the cells expressing GFP were analyzed). In
panel C, statistical analysis was performed to assess the
significance of the sensitization induced by the N2-contain-
ing constructs (i.e. comparisons of control cells treated with
cisplatin with the other cisplatin-treated cells; 3
comparisons).
Fig. 6 – Fragment N2 does not sensitize cells to
starvation-induced apoptosis. U2OS cell were transfected with
the indicated plasmids together with a plasmid encoding the
GFP protein. Eight hours later, the cells were starved for 24 or
48 h (black bars). Apoptosis was then determined in the
GFP-expressing cells. Results correspond to the mean±SD
(n=3 determinations). Statistical analysis was performed to
assess the difference between cells transfected with pcDNA3
and the other transfected cells for a given condition (i.e. no
starvation or starvation for 24 h and 48 h). The triangles
indicate that the p value for the indicated comparison was
>0.05 (not significant). As a control to assess the functionality
of the plasmids, the cells were incubated with 15 μM cisplatin
for 22 h after which apoptosis was determined in the
GFP-expressing cells (grey bars). Results are expressed as the
mean of two determinations. As expected, HA-N2 sensitized
U2OS cells to cisplatin-induced apoptosis, while the
HA-N2-Bcl-XL construct did not.
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66to specifically target tumor cells (e.g. starvation). Moreover,
targeting fragment N2 on organelles that abrogates the capacity
of fragment N2 to sensitize tumor cells to genotoxin-induced death
might not affect the capacity of fragment N2 to promote apoptosis
of tumor cells to non-genotoxin-induced apoptosis. We assessed
these points by determining whether fragment N2, or fragment N2
coupled to the mitochondrial targeting Bcl-XL sequence, can
sensitize U2OS cells to starvation-induced apoptosis. As shown in
Fig. 6, U2OS cells expressing or not the two forms of fragment N2
underwent similar apoptosis in response to starvation. This
indicates that fragment N2 specifically sensitizes tumor cells to
certain (e.g. genotoxins), but not all, death stimuli and that
fragment N2 targeted to the mitochondria does not acquire
sensitization properties that would be absent in the cytoplasmic
form of fragment N2.Discussion
Fragment N2 generated upon the full processing of RasGAP by
caspases is able to sensitize tumor cells, but not normal cells, to
genotoxin-induced apoptosis [7]. Here we show that fragment N2
is almost strictly located in the cytoplasm of cells and is only
minimally associated with the nucleus or organelles such as the
mitochondria or the endoplasmic reticulum. Earlier work has
demonstrated that fragment N2 requires PUMA to exert its anti-
cancerous function [8]. PUMA, a transcriptional target of p53,
2091E X P E R I M E N T A L C E L L R E S E A R C H 3 1 5 ( 2 0 0 9 ) 2 0 8 1 – 2 0 9 1belongs to the BH3-only pro-apoptotic members of the Bcl-2
family of proteins [17,18]. It favors cell death by antagonizing pro-
survival Bcl-2 family members (e.g. Mcl-1, Bcl-2, Bcl-XL). The
ability of PUMA to promote cell death appears to be strictly
dependent on Bax, a BH1-2-3 Bcl-2 family member that is able,
upon activation, to induce the release of cytochrome c from
mitochondria, which in turn results in caspase activation [19]. Yet,
fragment N2 does neither alter PUMA levels nor the activity or
expression of p53 that controls PUMA expression [8]. It has
therefore been hypothesized that fragment N2 modulates the
concerted action of p53 and PUMA at the mitochondria level to
increase the sensitivity of tumor cells to the action of genotoxins
[8]. The data presented here however show that fragment N2
looses its anti-tumor property if located on mitochondria. Frag-
ment N2might thereforemodulate PUMA action before mitochon-
dria are targeted. One possibility would be that fragment N2 alters
the expression of other Bcl-2 family members so that the balance
between anti- and pro-apoptotic Bcl-2 proteins is tilted in favor of
the latter. In this context, it has to be mentioned that fragment N2
does not induce a decrease in the expression of the anti-apoptotic
Mcl-1 protein [8]. Additional work will be required to determine
the cytoplasmic mode of action of fragment N2 that sensitizes
tumor cells to genotoxin-induced death.
The present work also provides a striking example of a sub-
cellular location artefact induced by cell fixation. Fragment N2 is
virtuallyabsent fromthenucleus in living cells buthas apredominant
nuclear location in fixed cells. Permeabilization and fixation of cells
for immuno-fluorescence studies are known to potentially induce
improper nuclear targetingof proteins [20]. The example of fragment
N2 and others [21–23] clearly emphasize the need of additional
approaches (i.e. microscopy of live cells) to be used when the sub-
cellular location of proteins of interest is analyzed.Acknowledgments
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Introduction 
Cancer is a class of diseases that exhibit significant heterogeneity in term of genetic 
aberrations, cell proliferation rate and cell surface markers. Nevertheless one common feature 
of cancer cells is represented by apoptosis evasion. The design of strategies targeting the 
sensitivity of malignant cells to apoptosis could therefore help the improvement of the 
currently used anti-cancer regimens. In this sense one promising approach is represented by 
therapies relying on the utilization of genotoxins combined to compounds interfering with the 
apoptotic resistance of cancer cells. This might therefore enhance the genotoxin-induced 
death response, selectively in cancer cells. 
It was previously discovered that the RasGAP cleavage fragment N2 selectively sensitizes 
cancer cells to genotoxins in vitro while having no effect on non-cancer cell. The shortest 
sequence of fragment N2 still bearing this property, that corresponds to amino acids 317-326, 
was also determined. This sequence was fused to the TAT cell permeation sequence and the 
resulting peptide, called TAT-RasGAP317-326, was able to enter tumoral cells and sensitize 
them to genotoxins. 
In the present study we wanted to assess if the TAT-RasGAP317-326 sensitizes tumors in in vivo 
conditions. To answer this question we first synthesized the Retro-Inverso form of the 
peptide, called RI- TAT-RasGAP317-326, by converting its amino acids from the natural L-form 
to the protease-resistant D-form. We found that the RI-TAT-RasGAP317-326 is more stable in 
culture medium and biological fluids compared to the L-form; this property is most likely due 
to its resistance to protease-mediated degradation. 
Subsequently we evaluated the toxicity of the RI- TAT-RasGAP317-326. We determined the 
lethal dose and the causes of the RI- TAT-RasGAP317-326-induced mice death. 
71
Next we sub-cutaneously implanted nude mice with HCT1116 tumor cells and we look at the 
tumor development in presence of two different genotoxins (cisplatin and doxorubicin) alone 
or in combination with the RI- TAT-RasGAP317-326. 
Our data show that the RI- TAT-RasGAP317-326 significantly reduces tumor growth when 
administrated together with doses of genotoxins that by themselves only poorly reduce tumor 
growth. Importantly, the RI- TAT-RasGAP317-326 by itself has no effect on tumor growth. 
 
Contribution 
This work has been published in the Journal of the National Cancer Institute in 2009 and it is 
attached in the following section. I share the first authorship of this paper with Dr. David 
Michod. I performed all the experiments done for the revision of this paper. 
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osteosarcoma U2OS cells ( 12 ) to undergo 
apoptosis [assessed by scoring the percent-
age of cells displaying pycnotic nuclei ( 9 )] 
decreased as a function of increasing pep-
tide preincubation time in serum-contain-
ing medium, suggesting that this peptide is 
sensitive to degradation by serum proteases 
( Figure 1, A ). This sensitivity to degrada-
tion is likely to adversely affect the antitu-
mor activity of the peptide in vivo. One 
way to render a peptide more resistant to 
proteolytic degradation is to convert its 
amino acids from the natural  l -form to the 
protease-resistant  d -form. To best mimic 
the structure of the natural peptide, the 
sequence of the  d -peptide is generally 
inverted, generating the so-called retro-
inverso form ( 13 , 14 ). After preincubation 
in serum-containing medium for up to 2 
days, the retro-inverso form of TAT-
RasGAP 317 – 326 (RI·TAT-RasGAP 317 – 326 ) 
showed almost no decrease in its ability to 
sensitize U2OS cells to cisplatin-induced 
apoptosis ( Figure 1, A ). This ﬁ nding suggests 
that RI·TAT-RasGAP 317 – 326 is a more stable 
compound than L·TAT-RasGAP 317 – 326 . 
Dose – response analyses indicated that 
RI·TAT-RasGAP 317 – 326 was more effective 
than L·TAT-RasGAP 317 – 326 in sensitizing 
U2OS cells to the apoptosis-inducing 
action of cisplatin ( Figure 1, B and C ), a 
likely reﬂ ection of its higher stability com-
pared with L·TAT-RasGAP 317 – 326 . 
 Another parameter that can affect the 
efﬁ cacy of an anticancer compound in vivo 
is its rate of clearance from the circulation. 
We used liquid chromatography coupled 
with mass spectrometry to examine the 
persistence of RI·TAT-RasGAP 317 – 326 in 
blood samples taken at various times from 
 Chemotherapeutic drugs kill tumor cells by 
activating apoptosis. If this activation is com-
promised (eg, through additional gene muta-
tions), a tumor may develop resistance to the 
anticancer drugs ( 1 , 2 ). Consequently, strate-
gies to restore tumor sensitivity to apoptosis 
are promising approaches for treating can-
cer. Much is now known about the mode of 
action of proteins that regulate cell death in 
cancer cells. This knowledge has led to the 
design of peptides that, in vitro, can perturb 
the resistance of cancer cells to anticancer 
agents ( 3 , 4 ). However, few studies have 
examined the efﬁ cacy of those peptides as 
anticancer compounds in vivo ( 3 ). 
 We have previously reported that frag-
ment N2, a caspase-generated polypeptide 
from RasGAP, a regulator of Ras- and 
Rho-dependent pathways, strongly sensi-
tizes tumor cells, but not normal cells, to 
genotoxin-induced apoptosis ( 5 , 6 ). The 
tumor sensitization property of the N2 frag-
ment is contained within a 10 – amino acid 
sequence (amino acids 317 – 326) ( 7 ). A syn-
thetic peptide (called TAT-RasGAP 317 – 326 ) 
corresponding to this sequence fused to a 
cell-permeable peptide derived from the 
human immunodeﬁ ciency virus TAT pro-
tein was found to efﬁ ciently increase the 
extent of apoptosis induced by a variety of 
genotoxins ( 7 ) and other anticancer treat-
ments ( 8 ) in several tumor cell lines. Although 
it is now known that tumor cells must be 
able to activate the p53 and p53-upregulated 
modulator of apoptosis (PUMA) pathway 
for them to undergo TAT-RasGAP 317 – 326 peptide – 
mediated sensitization to genotoxin-
induced apoptosis ( 9 ), the molecular 
mechanisms underlying the apoptosis sen-
sitization property of TAT-RasGAP 317 – 326 
remain to be characterized in detail. Here, 
we assessed the ability of TAT-RasGAP 317 – 326 
to increase the efﬁ cacy of genotoxins in an 
in vivo context. 
 We ﬁ rst examined the functional stabil-
ity of the peptide in biological ﬂ uids because 
it has been shown that peptides that are 
susceptible to proteolytic degradation can 
rapidly lose their function ( 10 , 11 ). Indeed, 
the ability of the natural  l -form of TAT-
RasGAP 317 – 326 (L·TAT-RasGAP 317 – 326 ) to sen-
sitize cisplatin-treated human p53-positive 
 Effect of RasGAP N2 Fragment – Derived 
Peptide on Tumor Growth in Mice 
 David  Michod ,  Alessandro  Annibaldi ,  Stephan  Schaefer ,  Christine  Dapples , 
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 Peptides that interfere with the natural resistance of cancer cells to genotoxin-
induced apoptosis may improve the efficacy of anticancer regimens. We have previ-
ously reported that a cell-permeable RasGAP-derived peptide (TAT-RasGAP 
317 – 326
 ) 
specifically sensitizes tumor cells to genotoxin-induced apoptosis in vitro. Here, we 
examined the in vivo stability of a protease-resistant  d -form of the peptide, RI·TAT-
RasGAP 
317 – 326
 , and its effect on tumor growth in nude mice bearing subcutaneous 
human colon cancer HCT116 xenograft tumors. After intraperitoneal injection, 
RI·TAT-RasGAP 
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 persisted in the blood of nude mice for more than 1 hour and 
was detectable in various tissues and subcutaneous tumors. Tumor-bearing mice 
treated daily for 7 days with RI·TAT-RasGAP 
317 – 326
 (1.65 mg/kg body weight) and 
cisplatin (0.5 mg/kg body weight) or doxorubicin (0.25 mg/kg body weight) dis-
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 may be 
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a 7-week-old female NMRI Nu/Nu (nude) 
mouse (Janvier, Le Genest-St-Isle, France) 
that received a single intraperitoneal injec-
tion with the peptide at 3.3 mg/kg body 
weight. All experiments involving mice 
were approved by the State of Vaud 
Veterinary Ofﬁ ce (Lausanne, Switzerland). 
RI·TAT-RasGAP 317 – 326 was detectable in 
the circulation as early as 15 minutes after 
injection and for at least 90 minutes after 
injection; peak concentrations were 
observed 1 hour after the injection of the 
peptide (Supplementary Figure 1, A and B, 
available online). By contrast, we could not 
detect the peptide in blood samples 
obtained from two mice that were similarly 
injected with L·TAT-RasGAP 317 – 326 (data 
not shown), consistent with the notion that 
the  l -peptide is less stable, or more rapidly 
cleared, than the retro-inverso form. The 
observation that RI·TAT-RasGAP 317 – 326 
could be detected in the circulation for 
relatively long periods of time suggested 
that it might be able to reach distant tis-
sues, including tumors, after it is injected 
into mice. To test this possibility, a nude 
mouse bearing a visible tumor derived from 
subcutaneous injection of human colon 
cancer HCT116 cells was injected intrap-
eritoneally with RI·TAT-RasGAP 317 – 326 
(4.8 mg/kg body weight). The mouse was 
killed approximately 1 hour after peptide 
injection, and its liver, lungs, brain, and the 
tumor were removed and processed for 
peptide detection by mass spectrometry. 
RI·TAT-RasGAP 317 – 326 was detectable in 
the liver and lungs of this mouse but was 
not found in the brain (Supplemental 
Figure 1, C, available online), suggesting 
that it may not cross the blood – brain bar-
rier. Importantly, RI·TAT-RasGAP 317 – 326 
was also detected in the subcutaneous 
tumor. 
 We next evaluated the toxicity of 
RI·TAT-RasGAP 317 – 326 in nude mice that 
were injected intraperitoneally twice per week 
for 4 weeks with RI·TAT-RasGAP 317 – 326 
or RI·TAT (a control peptide consisting 
of the retro-inverso form of the TAT pep-
tide) (dose range  =  0.8 – 7.2 mg peptide/kg 
body weight; n  =  3 – 4 mice per group). 
Intraperitoneal injection of RI·TAT-
RasGAP 317 – 326 at a dose of 4.8 mg/kg of 
mouse body weight was lethal (three of the 
three injected mice died, all within 45 – 60 
minutes after the ﬁ rst injection), whereas a 
dose of 2.4 mg/kg body weight was not, 
even after repeated injections (three of the 
three injected mice were alive after the 
eighth injection) (Supplementary Table 1, 
available online). These results indicate 
that the dose of RI·TAT-RasGAP 317 – 326 that 
is lethal to 50% of mice (ie, the LD 50 ) is 
between  2.4  and 4.8 mg/kg body weight. 
The lethality induced by high doses of 
RI·TAT-RasGAP 317 – 326 did not seem to be 
due to the presence of the cell-permeable 
TAT peptide because none of the three 
mice injected intraperitoneally with 
RI·TAT at a dose of 4.8 mg/kg body weight 
died. Necropsy revealed that the cause of 
death in mice injected with lethal doses of 
RI·TAT-RasGAP 317 – 326 appeared to be mas-
sive hemorrhages in the lungs and kidneys 
(Supplementary Figure 1, D, available 
online). No damage to the liver, pancreas, 
or spleen was observed (data not shown). 
 We next conducted two types of in vivo 
experiments to examine the effect of 
RI·TAT-RasGAP 317 – 326 on the efﬁ cacy of 
cisplatin against tumors, in particular under 
conditions in which the doses of cisplatin 
had poor or marginal effects. In the 
ﬁ rst experiment, 7-week-old female nude 
mice were injected intraperitoneally with 
1.5 × 10 6 HCT116 cells. Beginning the 
next day, the mice were injected intraperi-
toneally twice per week for 4 weeks with 
phosphate-buffered saline (PBS), cisplatin 
(1 mg/kg body weight; catalog no. P4394, 
Sigma-Aldrich, St Louis, MO), RI·TAT-
RasGAP 317 – 326 (2.4 mg/kg body weight), or 
cisplatin plus RI·TAT-RasGAP 317 – 326 
(n  =  15 – 24 mice per group). At the end of 
the treatment period, the mice were killed 
by cervical dislocation, and their tumors 
were removed, weighed (when possible), 
and scored empirically as follows: tumors 
weighing more than 1 mg (score 5), tumors 
weighing more than 0.5 mg up to 1 mg 
(score 4), tumors weighing more than 0.1 
mg up to 0.5 mg (score 3), vascularized 
tumors grouped in clumps but too small to 
be weighed (score 2), or nonvascularized 
dispersed tumors too small to be weighed 
(score 1). Mice treated with RI·TAT-
RasGAP 317 – 326 plus cisplatin developed sta-
tistically signiﬁ cantly fewer tumors with 
higher scores than mice treated with cispla-
tin alone ( P  =  .032, two-sample location 
exact two-sided Wilcoxon test; all statistical 
analyses were performed using SAS/STAT 
software v9.1.3, SAS Institute, Inc. (Cary, 
NC) ( Figure 2, A ). This ﬁ nding indicates 
that cisplatin in combination with the pep-
tide hampers tumor growth better than 
cisplatin alone. 
 In the second type of experiment, 
HCT116 cells were injected subcutane-
ously into the left and right upper ﬂ anks of 
7-week-old female nude mice (2.5 × 10 5 
cells injected per ﬂ ank). One week later, 
when visible tumors had developed, the 
mice were injected intraperitoneally once 
per day for 1 week with PBS, RI·TAT-
RasGAP 317 – 326 (1.65 mg/kg body weight), or 
cisplatin (0.5 mg/kg body weight) or doxo-
rubicin (0.25 mg/kg body weight; catalog 
no. D1515, Sigma-Aldrich), alone or in 
combination with RI·TAT-RasGAP 317 – 326 
(n  =  4 – 7 mice per group). We tested doxo-
rubicin because it is structurally different 
from cisplatin and has a different mode of 
action ( 15 ). The orthogonal dimensions of 
 CONTEXT AND CAVEATS 
 Prior knowledge 
 Peptides that interfere with the natural 
resistance of cancer cells to genotoxin-
induced apoptosis in vitro, such as 
TAT-RasGAP 
317 – 326
 , a cell-permeable 
RasGAP-derived peptide, may improve the 
efficacy of anticancer regimens in vivo. 
 Study design 
 Examination of the in vitro and in vivo sta-
bility of a protease-resistant  d -form of the 
peptide, RI·TAT-RasGAP 
317 – 326
 , and its effect 
on tumor growth in nude mice bearing sub-
cutaneous human colon cancer HCT116 
xenograft tumors. 
 Contribution 
 RI·TAT-RasGAP 
317 – 326
 was stable in biologi-
cal fluids, and after injection into mice, it 
persisted in the bloodstream for more than 
1 hour, reached distant tissues and subcu-
taneous tumors, was effective at doses at 
least 150-fold below the dose lethal to 50% 
of mice, and improved the efficacy of 
genotoxins. 
 Implications 
 RI·TAT-RasGAP 
317 – 326
 may be useful for 
improving the efficacy of chemotherapy in 
patients. 
 Limitations 
 Tumors in nude (ie, immunocompromised) 
mice may not behave the same as synge-
neic tumors in immunocompetent mice. 
 From the Editors 
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 Figure 1 .  Effects of the L and the RI forms of TAT-
RasGAP 
317 – 326
 on cisplatin-induced apoptosis in 
U2OS cells. Sequences of the peptide used in 
the ﬁ gure: RI·TAT-RasGAP 
317 – 326
 , DTRLNTVWM-
WGGRRRQRRKKRG ( d -amino acid); L·TAT-
RasGAP 
317 – 326
 , GRKKRRQRRRGGWMWVTNLRTD 
( l -amino acid); RI·TAT, RRRQRRKKRG ( d -amino 
acid); and L·TAT, GRKKRRQRRR ( l -amino acid). 
Apoptosis was assessed by counting the cells that 
displayed a pycnotic nucleus. The results presented 
in each panel correspond to the mean percentage of 
apoptotic cells for three independent experiments; 
 error bars correspond to 95% conﬁ dence intervals. 
 A ) Peptide functional stability assay. U2OS cells 
were incubated for 20 hours with 15  µ M cisplatin 
plus the indicated peptides, which were previously 
preincubated for the indicated times in Dulbecco ’ s 
modiﬁ ed Eagle medium containing 10% newborn 
calf serum. Apoptosis was then assessed.  B ) Tumor 
cell sensitization in response to increasing peptide 
concentrations. U2OS cells were treated for 20 
hours with increasing concentrations of the indi-
cated peptides in the absence ( left panel ) or pres-
ence ( right panel ) of 15  µ M cisplatin. Apoptosis was 
then assessed.  C ) Tumor cell sensitization induced 
by the peptides in response to increasing cisplatin 
concentrations. U2OS cells were treated for 20 
hours without (Control) or with (20  µ M ﬁ nal concen-
tration) the indicated peptides in the presence of 
increasing concentrations of cisplatin. Apoptosis 
was then assessed. The values for L·TAT and RI·TAT 
are slightly offset for better visualization. L  =  natural; 
RI  =  retro-inverso. 
the tumors were measured daily with the 
use of a caliper on isoﬂ urane-anesthetized 
mice, beginning on the ﬁ rst day of treat-
ment injection (day 0, ie, when tumors 
were just visible), for up to 13 days. Tumor 
volume was calculated as [(largest orthogo-
nal dimension) 2 × (smallest orthogonal 
dimension) × (  /6)]. When a mouse devel-
oped tumors on both ﬂ anks, the volumes of 
the two tumors were averaged to get a sin-
gle value for that mouse to allow statistical 
comparisons with mice that developed only 
one tumor. All mice in a given experiment 
were killed by cervical dislocation while 
still anesthetized when the largest tumors 
exceeded a  speciﬁ c  threshold volume (500 –
 1000 mm 3 , depending on the experiment). 
Mice treated with RI·TAT-RasGAP 317 – 326 
plus either cisplatin or doxorubicin devel-
oped statistically signiﬁ cantly smaller 
tumors than mice treated with RI·TAT-
RasGAP 317 – 326 ( P  =  .005 and  P < .001, respec-
tively) or with the respective genotoxin 
alone ( P  =  .004 and  P  =  .005, respectively; 
repeated measures analysis of variance 
[ANOVA, two-sided]) ( Figure 2, B and C ). 
Compared with PBS, RI·TAT-RasGAP 317 –
 326 by itself had no effect on tumor growth 
( P  =  .89 and  P  =  .41 for the cisplatin and 
doxorubicin experiments, respectively; 
repeated measures ANOVA [two-sided]). 
These data demonstrate that RI·TAT-
RasGAP 317 – 326 can inhibit the growth of 
already formed and detectable tumors when 
used in combination with a genotoxin (cis-
platin or doxorubicin). 
 Given our ﬁ nding that one injection 
of a lethal dose of TAT-RasGAP 317 – 326 led 
to hemorrhages in lungs and kidneys 
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 Figure 2 .  In vivo chemosensitizing efﬁ cacy of RI·TAT-
RasGAP 
317 – 326
 .  A ) Effect of RI·TAT-RasGAP 
317 – 326
 on intraperi-
toneal tumors. Nude mice (7-week-old females) were 
injected with 1.5 million HCT116 cells intraperitoneally. 
The following day and thereafter twice a week, the mice 
were injected intraperitoneally with PBS, 2.4 mg/kg of 
RI·TAT-RasGAP 
317 – 326
 , 1 mg/kg cisplatin, or a combination 
of cisplatin and RI·TAT-RasGAP 
317 – 326
 . After 28 days, the 
mice were killed and the development of the tumors 
scored (score 5, tumors weighing more than 1 mg; score 
4, tumors weighing between 0.5 and 1 mg; score 3, 
tumors weighing between 0.1 and 0.5 mg; score 2, vascu-
larized tumors grouped in clumps but too small to be 
weighed; and score 1, nonvascularized dispersed tumors 
too small to be weighed); examples of tumors with scores 
1 and 2 are shown on the right in ( A ). Mice that did not 
show any presence of tumors (ie, mice in which the 
tumors did not “take”) were excluded from the analysis 
(PBS: four mice excluded of 15 injected; RI·TAT-
RasGAP 
317 – 326
 : three mice excluded of 15 injected; cisplatin: 
one mouse excluded of 21 injected; cisplatin + RI·TAT-
RasGAP 
317 – 326
 : four mice excluded of 24 injected); the pro-
portion of excluded mice did not differ statistically 
signiﬁ cantly among the groups (Fisher exact test,  P  =  .225). 
The  dots represent individual mice. Statistical analysis for 
the difference between the cisplatin and the cisplatin + 
RI·TAT-RasGAP 
317 – 326
 groups was performed with a two-
sample location exact two-sided Wilcoxon test.  B and C ) 
Cisplatin- and doxorubicin-sensitizing effect of RI·TAT-
RasGAP 
317 – 326
 on subcutaneous tumors. Nude mice 
(7-week-old females) were injected subcutaneously with 
250  000 HCT116 cells on the left and right upper ﬂ anks. 
Seven days later, the mice that developed visible tumors 
were injected each day for 7 consecutive days (in  red in 
the ﬁ gure) with PBS (300  µ L), RI·TAT-RasGAP 
317 – 326
 (1.65 
mg/kg in 300  µ L PBS), cisplatin (0.5 mg/kg in 300  µ L PBS), 
or RI·TAT-RasGAP 
317 – 326
 plus cisplatin ( B ). In the experi-
ment described in ( C ), cisplatin was replaced with 0.25 
mg/kg doxorubicin. Tumor volume was plotted as a func-
tion of time (for mice that developed tumors on both 
ﬂ anks, the two tumor volumes were averaged). The num-
ber of mice analyzed is indicated in the ﬁ gure. Mean val-
ues are plotted, and  error bars correspond to 95% 
conﬁ dence intervals.  D ) Dose – response analysis of the in 
vivo sensitizing effect of the peptide. Nude mice were 
treated and analyzed as in ( B ) but with the conditions 
indicated in the ﬁ gure.  E ) Peptide injection frequency. 
Nude mice were injected subcutaneously with 500  000 
HCT116 cells and treated as described in ( D ), except that 
0.16 mg/kg body weight RI·TAT-RasGAP 
317 – 326
 was injected 
on the indicated days [ open diamonds ,  triangles , and 
 squares ; cisplatin was injected every day as in ( D )]. The  P 
values in ( B – E ) are from repeated measures ANOVA (two-
sided). ANOVA  =  analysis of variance; PBS  =  phosphate-
buffered saline; RI  =  retro-inverso. 
(Supplementary  Figure 1, D, available 
online ), we assessed whether the nonlethal 
dose of RI·TAT-RasGAP 317 – 326 that 
enhanced the sensitivity of tumors to cis-
platin and doxorubicin in the previous 
experiment had any effect on these organs. 
Non – tumor-bearing mice were injected 
with PBS, RI·TAT-RasGAP 317 – 326 , cispla-
tin, or RI·TAT-RasGAP 317 – 326 plus cisplatin 
as described above (n  =  2 mice per group); 
the mice were killed by cervical dislocation 
after the last injection (ie, 8 days after the 
ﬁ rst injection), and histological sections of 
their lungs and kidneys were prepared. We 
observed no damage to these organs in any 
of the mice (Supplementary Figure 1, E, 
available online). Thus, a nonlethal dose of 
RI·TAT-RasGAP 317 – 326 (1.65 mg/kg body 
weight), which was only approximately 
two- to three fold lower than the lethal 
dose ( ~ 5 mg/kg body weight), did not 
appear to cause visible alterations in the 
lungs or kidneys, even when it was admin-
istered in the presence of cisplatin. 
 To examine if RI·TAT-RasGAP 317 – 326 
doses lower than 1.65 mg/kg body weight 
could exert a genotoxin-sensitizing effect on 
tumor growth in mice, we used the experi-
mental design described above but with 
decreasing doses of injected RI·TAT-
RasGAP 317 – 326 and with a dose of cisplatin 
that is at the threshold of inducing an inhibi-
tory effect on tumor growth by itself. This 
dose of cisplatin was determined by inject-
ing mice with various doses of cisplatin only 
(range  =  0.005 – 1 mg/kg body weight) using 
the injection protocol shown in  Figure 2, B . 
The highest dose of cisplatin tested that did 
not reduce tumor growth was found to be 
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0.1 mg/kg body weight (data not shown). 
HCT116 tumor – bearing mice were treated 
with PBS or RI·TAT-RasGAP 317 – 326 (at doses 
of 0, 0.16, 0.048, or 0.160 mg/kg body 
weight) combined with cisplatin at 0.1 mg/
kg body weight (n  =  4 – 8 mice per group). 
Cisplatin alone (0.1 mg/kg body weight) had 
no effect on the growth of HCT116 tumors 
compared with PBS ( P  =  .77; repeated mea-
sures ANOVA [two-sided]) ( Figure 2, D ). 
However, cisplatin plus RI·TAT-RasGAP 317 –
 326 at 0.16 mg/kg body weight efﬁ ciently 
inhibited tumor growth compared with cis-
platin alone ( P  =  .03; repeated measures 
ANOVA [two-sided]). Importantly, 
RI·TAT-RasGAP 317 – 326 at 0.016 mg/kg body 
weight, a dose more than 150-fold lower 
than the estimated LD 50 (ie, between  2.4 and 
4.8 mg/kg body weight), also improved the 
efﬁ cacy of cisplatin to inhibit the growth of 
HCT116 tumors compared with cisplatin 
alone ( P  =  .004; repeated measures ANOVA 
[two-sided]). 
 We also examined the effect of varying 
the frequency of RI·TAT-RasGAP 317 – 326 
peptide injection on tumor growth. HCT116 
tumor – bearing mice were injected for 1 
week with RI·TAT-RasGAP 317 – 326 (0.16 mg/
kg body weight), daily, every other day, or 
every 3.5 days, in combination with a daily 
injection of cisplatin (0.1 mg/kg body 
weight) (n  =  3 – 7 mice per group). Control 
mice were injected daily with PBS or cispla-
tin alone. Tumor volumes were measured 
every 3 – 4 days. Injection of the peptide 
every other day sensitized tumor cells to 
cisplatin (every-other-day peptide injection 
+ cisplatin vs cisplatin only:  P  =  .02; repeated 
measures ANOVA [two-sided]) as efﬁ ciently 
as daily injection of the peptide (every-oth-
er-day peptide injection + cisplatin vs daily 
peptide injection + cisplatin:  P  =  .94; repeated 
measures ANOVA [two-sided]). Injection of 
the peptide every 3.5 days also sensitized the 
tumors somewhat to cisplatin (every 3.5 
days peptide injection + cisplatin vs cisplatin 
only:  P  =  .15; repeated measures ANOVA 
[two-sided]) but with reduced efﬁ ciency 
compared with daily or every-other-day 
injections of the peptide. These results indi-
cate that RI·TAT-RasGAP 317 – 326 does not 
need to be injected every day along with 
cisplatin to exert its sensitization property, 
probably because of its increased resistance 
to degradation in biological ﬂ uids. 
 A limitation of this study is that tumors 
in immunocompromised mouse models 
(eg, nude mice) may not behave as synge-
neic tumors in immunocompetent mice. 
Indeed, there is now clear evidence that the 
immune system positively modulates some 
anticancer therapies ( 16 ). For example, 
doxorubicin-induced death of colon carci-
noma cells implanted in syngeneic mice 
elicits an immune response that favors the 
elimination of the tumor cells ( 17 ). The 
efﬁ cacy of RI·TAT-RasGAP 317 – 326 against 
human tumors implanted in nude mice 
might therefore be attenuated by the lack 
of an intact immune system in nude mice. 
 The properties of RI·TAT-RasGAP 317 – 326 
described here in mouse tumor models indi-
cate that this peptide has the potential to be 
used in humans to sensitize tumor cells to 
genotoxin treatments (ie, to enhance the 
antitumor effect of genotoxins): it is stable 
in biological ﬂ uids, it persists in the blood-
stream for more than 1 hour after intraperi-
toneal injection, it reaches distant tissues 
and organs (including subcutaneous tumors), 
its efﬁ cacious doses are at least 100-fold 
below the LD 50 , and it greatly improves the 
efﬁ cacy of genotoxins. To our knowledge, 
this peptide is the only compound that has 
been shown to improve the efﬁ cacy of geno-
toxins and that behaves strictly as a chemo-
sensitizer, that is, it has no effect on tumors 
by itself ( 4 ). This compound would there-
fore have the potential to improve the efﬁ -
cacy of chemotherapeutic agents that are 
currently used in the clinic, particularly in 
situations in which doses of genotoxin have 
to be lowered to reduce side effects. 
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Introduction 
 
Peptides enhancing the genotoxin-induced cell death in cancer cells could improve the efficacy of 
anti-cancer regimens and the survival of cancer patients. Our group discovered that fragment N2, 
generated by the caspase 3-mediated cleavage of RasGAP, favours the genotoxin-induced 
apoptosis of cancer cells. These sensitizing properties reside within a 10 amino acids stretch 
(317-326) that was fused to the TAT cell permeation sequence. The resulting peptide, called 
TAT-RasGAP317-326, still bears sensitizing properties in vitro and in vivo. The molecular 
mechanisms by which TAT-RasGAP317-326 fulfills its anti-cancer properties is not well 
understood.  
One potential candidate to explain how TAT-RasGAP317-326 delivers its pro-apoptotic effect in 
the presence of genotoxins was the RasGAP SH3 binding protein 1 (G3BP1). G3BP1 is an 
endoribonuclease known to associate to RasGAP in proliferating cells. Interestingly G3BP1 binds 
the SH3 domain of RasGAP in correspondence to the ten amino acids stretch (amino acids 317-
326) that composes the TAT-RasGAP317-326 peptide. This evidence, together with others showing 
that G3BP1 is involved in the regulation of mRNA stability, in the cell adaptation to several 
kinds of stresses and that it is over-expressed in various human tumors (e.g. breast cancer), 
prompted us to ascertain if G3BP1 was the TAT-RasGAP317-326 effector. 
In this report we show not only that G3BP1 is not involved at all in the TAT-RasGAP317-326-
mediated sensitization of malignant cells to apoptosis, but also that neither RasGAP nor fragment 
N2 (the caspase-3-generated RasGAP fragment from which the sensitizing sequence 317-326 was 
derived) are G3BP1 binding partners.   
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Abstract
RasGAP is a multifunctional protein that controls Ras activity and that is found in chromosomal passenger complexes. It also
negatively or positively regulates apoptosis depending on the extent of its cleavage by caspase-3. RasGAP has been
reported to bind to G3BP1 (RasGAP SH3-domain-binding protein 1), a protein regulating mRNA stability and stress granule
formation. The region of RasGAP (amino acids 317–326) thought to bind to G3BP1 corresponds exactly to the sequence
within fragment N2, a caspase-3-generated fragment of RasGAP, that mediates sensitization of tumor cells to genotoxins.
While assessing the contribution of G3BP1 in the anti-cancer function of a cell-permeable peptide containing the 317–326
sequence of RasGAP (TAT-RasGAP317–326), we found that, in conditions where G3BP1 and RasGAP bind to known partners,
no interaction between G3BP1 and RasGAP could be detected. TAT-RasGAP317–326 did not modulate binding of G3BP1 to
USP10, stress granule formation or c-myc mRNA levels. Finally, TAT-RasGAP317–326 was able to sensitize G3BP1 knock-out
cells to cisplatin-induced apoptosis. Collectively these results indicate that G3BP1 and its putative RasGAP binding region
have no functional influence on each other. Importantly, our data provide arguments against G3BP1 being a genuine
RasGAP-binding partner. Hence, G3BP1-mediated signaling may not involve RasGAP.
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Introduction
There is an ongoing need to improve current anti-tumor
regimens to reduce the rate of death due to cancer. In this
context, we discovered earlier that the caspase-3-generated
RasGAP N-terminal fragment (RasGAP158–455), called N2, was
able to selectively sensitize cancer cells, but not healthy cells, to
genotoxin-induced apoptosis [1]. RasGAP amino acids 317 to
326 within fragment N2 were found to carry this sensitizing
activity [2]. A cell-permeable peptide containing this sequence
(the so-called TAT-RasGAP317–326 peptide) was then generated
[2]. This peptide potently enhances the efficacy of genotoxins to
selectively kill cancer cells, both in in vivo [3] and in vitro [2]
settings. TAT-RasGAP317–326 does not induce apoptosis by itself
making it a pure sensitizer compound [2–4]. The understanding
of its mode of action is of particular relevance in the context
of the mechanisms allowing cancer cells to resist apoptosis. It is
known that TAT-RasGAP317–326 favors genotoxin-induced
mitochondrial outer membrane depolarization (MOMP) and
caspase-3 activation [5]. The RasGAP-derived peptide requires a
functional p53/PUMA axis to induce its genotoxin-sensitization
effect [5]. However, this might only reflect the fact that
genotoxins require the p53/PUMA axis to optimally kill
cancer cells [6,7]. At present, the direct molecular target(s) of
TAT-RasGAP317–326 are unknown and the cellular events
underlying its sensitizing properties are only minimally under-
stood.
GAP SH3 Binding Protein 1 (G3BP1) is one of the molecules
described to interact with RasGAP. This was first reported by
Parker et al. in 1996 [8] who identified and cloned a molecule able
to bind to the SH3 domain of RasGAP. Incidentally, this
interaction only took place in serum-stimulated cells. The binding
between RasGAP and G3BP1 could be prevented by a peptide
corresponding to sequence 317–326 found within the RasGAP
SH3 domain. These data were corroborated by two other reports
showing that G3BP1 binds to RasGAP in proliferating cells [9]
and that the G3BP1 domain responsible for these binding was the
nuclear transfer factor 2 (NTF2)-like domain, located at its N-
terminus [10]. This domain was also described to mediate the
binding of the yeast orthologue of G3BP1 (Bre5) to the Ubp3
deubiquitinating enzyme [11]. G3BP1 seems not to be a substrate
of USP10, the Ubp3 mammalian orthologue, but it appears to
inhibit the capacity of USP10 to cleave ubiquitin chains [12]. The
C-terminal portion of G3BP1 contains two canonical RNA
recognition motifs (RRMs) indicating that G3BP1 has RNA-
binding capacities. Indeed G3BP1 was reported to co-immuno-
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e29024
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precipitate with mRNAs and to bind to and cleave the 39
untranslated region (39UTR) of the c-myc mRNA in vitro [9].
Interestingly, the endoribonuclease activity of G3BP1 is governed
by its phosphorylation status. In proliferating cells, when G3BP1 is
hypo-phosphorylated, it loses its ability to cleave mRNA whereas
in quiescent cells, when it is hyper-phosphorylated, it does cleave
mRNAs [9]. This observation suggested a possible role of G3BP1
in coupling extra-cellular stimuli to mRNA stability. This
hypothesis is supported by the finding that G3BP1 is implicated
in stress granule (SG) assembly [13]. SGs correspond to
cytoplasmic loci where mRNAs are stored during stress conditions
and where the decision to degrade or convert them into
translationally active mRNA protein complexes (mRNPs) is taken
once the stress has subsided [14–16]. Formation of stress granules
in cells may inhibit apoptosis [17].
The observation that G3BP1 binds to RasGAP on the very
same sequence that mediates the tumor sensitizing activity of
fragment N2 and the fact that G3BP1 is over-expressed in some
cancer cells made G3BP1 a good candidate for the TAT-
RasGAP317–326 peptide ability to lower the resistance specifically
in cancer cells. We therefore investigated whether the known
functions attributed to G3BP1 could be modulated by TAT-
RasGAP317–326 and whether G3BP1 was required for the peptide
to sensitize tumor cells to genotoxin-induced apoptosis.
Materials and Methods
Cell lines and transfection
U2OS (LGC Promochem; ATCC nu HTB-96), HCT116 [18],
HEK293T [19], HeLa cells (LGC Promochem; ATCC nu CCL-
2), and CCL39 cells (LGC Promochem; ATCC nu CCL-39), as
well as wild-type and G3BP1 knock-out mouse embryonic
fibroblasts (MEFs) [20] were maintained in DMEM (Invitrogen
reference nu61965) containing 10% fetal calf serum (GIBCO/
BRL reference nu10270-106, lot nu41Q6001K) at 37uC and 5%
CO2. HEK293T and U2OS cells were transfected using the
calcium/phosphate precipitation procedure [2,21].
Buffers
The composition of phosphate buffered saline (PBS) is
116 mM NaCl, 10.4 mM Na2HPO4, 3.2 mM KH2PO4
(pH 7.4). The Stag lysis buffer is made of 50 mM Hepes
pH 7.4, 150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA pH 8.0,
10% glycerol, 1% Triton X-100, and is supplemented with one
tablet of EDTA-free inhibitor (Roche) per 50 ml. The
composition of sample buffer 2X is 25 mM 2-amino-2-(hydro-
xymethyl)-1,3-propanediol (Tris) HCl pH 6.5, 10% glycerol, 6%
SDS, 0.02% of bromophenol blue and 100 mM freshly added
dithiothreitol (DTT). The 1% Triton X-100 lysis buffer is made
of 20 mM Hepes pH 7.4, 150 mM NaCl, 1% Triton X-100,
1 mM MgCl2, 1 mM EGTA and 1 mM NaVO4 supplemented
with one tablet of EDTA-free inhibitor [Roche] per 50 ml. The
RIPA-like lysis buffer is made of 50 mM Tris-HCl pH 7.4,
150 mM NaCl, 1% NP-40, 0.25% deoxycholic acid, 1 mM
EGTA and 1 mM NaVO4 supplemented with one tablet of
EDTA-free inhibitor (Roche) per 50 ml. The composition of
sample buffer 5X is 250 mM Tris-HCl pH 7, 10% SDS, 30%
glycerol, 5% b-mercaptoethanol. Tris buffer saline (TBS) is
made of 20 mM Tris base, 130 mM NaCl, pH 7.6.
Antibodies
The monoclonal antibody specific for the hemagglutinin (HA)
tag was purchased as ascites from BabCo (reference nuMMS-
101R). This antibody was adsorbed on HeLa cell lysates to
decrease non-specific binding as described previously [22]. Mouse
anti-human G3BP1 was from BD Transduction Laboratories
(reference nu611127). The rabbit polyclonal anti human TIA-1
antibody was from Santa Cruz (reference nusc-28237) The anti S-
Protein HRP-conjugated antibody was from Novagen (reference
nu69047). The anti-GST antibody was from Upstate (reference
nu06-332). The polyclonal rabbit anti-c-Myc antibody was from
Cell Signaling (reference nu9402). The polyclonal rabbit anti-
RasGAP antibody directed at the Src homology (SH) domains of
RasGAP was from Enzo Life Sciences (reference nuALX-210-860-
R100). The monoclonal mouse anti-SV40 large T antigen was
from BD Pharmingen (reference nu554149). The rabbit anti-
USP10 antibody was provided by Dr. Olivier Staub (University of
Lausanne, Switzerland). The monoclonal mouse anti-V5 antibody
was from Invitrogen (reference nu46-0705). Secondary antibodies
were donkey anti-mouse fluorescein-conjugated antibody and
donkey anti-rabbit Cy3-conjugated antibody (Jackson ImmunoR-
esearch, reference nu715-095-1507 and 711-165-152, respective-
ly).
Plasmids
The extension .dn3 indicates that the backbone plasmid is
pcDNA3 (#1) (Invitrogen). S?tag corresponds to the first 15 amino
acids of the S-peptide of RNase A (amino acids 1–15 of RNAse A).
The S?tag is able to bind with high affinity to the S protein (amino
acid 21–124 of RNAse A) [23,24]. TRIP-PGK-IRESNEO-
WHV (#350) is a lentiviral vector bearing the neomycine
resistance. The pEGFP-C1 plasmid (#6) encodes the green
fluorescent protein and is from Clonetech. The hG3BP1.dn3
plasmid (#322) encodes human G3BP1 [8]. HA-rRhoGAP.prc
(#196) encodes the HA-tagged form of rat p190RhoGAP. The
6xHis-Stag-mUSP10.dn3 plasmid (#646) encoding the poly-
histidine- and S-tagged form of mouse USP10 was described
earlier [25]. HA-hRasGAP.dn3 (#118), previously called HA-
GAP.dn3 [22], encodes the HA-tagged form of human RasGAP.
HA-hRasGAP[158–455].dn3 (#145), previously called HA-
N2.dn3 [22], encodes the HA-tagged form of fragment N2. HA-
hRasGAP[1–455](D157A).dn3 (#352), previously called N-
D157A.dn3 [22], encodes the HA-tagged caspase-3-resistant form
of fragment N. V5-hRasGAP[3–455](D157A).dn3 (#585)
encodes a V5-tagged version of the caspase-3-resistant form of
fragment N that lacks its first two methionine residues (to prevent
potential internal translation events). It was constructed by PCR
amplifying HA-hRasGAP[1–455](D157A).dn3 with oligonucleo-
tide #559 [AA (feeder sequences) GGTACC (KpnI site)
GCCACC (Kozak sequence) ATG GGA AAA CCA ATA CCA
AAT CCA CTA CTA GGC CTA GAC AGT ACA (V5 tag)
GCG GCC GAG GCC GGC AGTG (sequences complementary
to RasGAP from third amino acid on; nucleotides 124–133 of the
human RasGAP mRNA; entry M23379)] and oligonucleotide
#560 [GCA ACG AAG TGG GCA GTT TG (sequences lying
within the human RasGAP mRNA downstream of the SacII site;
nucleotides 489–469 of human RasGAP mRNA; entry M23379)].
The resulting 427 bp PCR fragment was cut with KpnI and SacII
and subcloned in HA-hRasGAP[1–455](D157A).dn3 opened with
the same enzymes. V5-hRasGAP[3-1931].dn3 (#686) encodes
a V5-tagged version of human RasGAP that lacks its first two
methionine residues (to prevent potential internal translation
events). It was made by subcloning the SpeI/SacII fragment of
V5-hRasGAP[3–455](D157A).dn3 into HA-hRasGAP.dn3
opened with the same enzymes. HA-hG3BP1.dn3 (#541)
encodes an HA-tagged version of human G3BP1. It was produced
by PCR amplifying the hG3BP1.dn3 plasmid with oligonucleotide
#501 [AAAA (feeder sequences), GGATCC (BamHI site),
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GGATCC (Kozak sequence), ATG GGC TAC CCG TAC GAC
GTG CCG GAC TAC GCT TCT (HA tag), ATG GTG ATG
GAG AAG CCT AG (nucleotides 172–191 of the human G3BP1
mRNA; NCBI entry NM_005754) and oligonucleotide #502
[TTTTT (feeder sequences), GTCGAC (SalI site) TTC ACT
GCC GTG GCG CAA GCC CCC TTC (nucleotides 1573–1547
of the human G3BP1 mRNA; NCBI entry NM_005754). The
resulting 1465 bp fragment was blunted with T4 DNA polymerase
(Promega reference nuM421A), digested with BamHI and
subcloned into pcDNA3 opened with BamHI and EcoRV.
Stag-GFP.dn3 (#647) encodes an S-tagged form of the green
fluorescent protein (GFP). It was generated by PCR amplifying
plasmid pEGFP-C1 with oligonucleotide #686 [AAAAAA
(feeder), GGATCC (BamHI site), GCCACC (Kozak sequence),
ATG AAA GAA ACC GCT GCT GCT AAA TTC GAA CGC
CAG CAC ATG GAC AGC (S?tag), ATG GTG AGC AAG
GGC GAG GA (first 20 coding nucleotides of GFP)] and with
oligonucleotide#687 [AAA (feeder), CCG TCG ACT GCA GAA
TTC GAA GC (nucleotides of pEGFP-C1 surrounding the EcoRI
site; underlined)]. The amplified PCR fragment was then digested
with BamHI and EcoRI and subcloned into pcDNA3 opened with
the same enzymes. Stag-hRasGAP[158–455].dn3 (#754)
encodes the S-tagged form of fragment N2 and was constructed
by PCR amplifying plasmid HA-hRasGAP[158–455].dn3 with
oligonucleotide #796 [TAAGCAG (feeder sequence), AAGCTT
(HindIII), CTCGAG (XhoI), CCACC (Kozak sequence; the last
nucleotide of the XhoI recognition site provides the G at the 26
Kozak position), ATG GCG (start codon and alanine codon),
AAA GAA ACC GCT GCT GCT AAA TTC GAA CGC CAG
CAC ATG GAC AGC (S?tag) TCT CTG GAT GGA CCA GAA
TA (first 21 base pairs of fragment N2) and oligonucleotide #679
[GCA TTT AGG TGA CAC TAT AG (nucleotides 1018–999 of
pcDNA3)]. The resulting 1027-base pairs PCR fragment was then
digested with HindIII and subcloned in HA-hRasGAP[158–
455].dn3 opened with the same enzyme. SV40LargeTantigen.
pBABE-puro (#731) encodes the SV40 large T antigen
(Addgene; plasmid 13970). SV40LargeTantigen.lti-neo
(#738) similarly encodes the large T antigen but in a lentiviral
expression vector. It was constructed by subcloning the BamHI
2187 base pairs fragment of SV40LargeTantigen.pBABE-puro
into TRIP-PGK-IRESNEO-WHV opened with the same enzyme.
Non-target.pLKO-puro (#584) corresponds to a pLKO.1-puro
lentiviral expression vector containing a shRNA insert that does
not target human and mouse genes (Sigma Aldrich, reference
nuSHC002). shRNA-hG3BP1.pLKO-puro (#641) encodes a
shRNA targeting a sequence within the 39UTR of the human
G3BP1 mRNA (nucleotides 1976–1997 of entry NM_005754). It
was purchased from Sigma Aldrich. 6xHis-hRasGAP[279–
343].pET28 (#544) encodes a histidine-tagged form of the
SH3 domain of RasGAP. It was constructed as follows. HA-
hRasGAP(no 39UTR).dn3 (#424) [1] was amplified by PCR using
oligonucleotide #505 [AT (feeder) CATATG (NdeI site) AGA
AGG CGT GTA CGA GCT AT (human RasGAP; nucleotides
959-978 of NCBI entry M23379)] and oligonucleotide #506 [AT
(feeder) GCGGCCGC (NotI site) CTA (stop codon) CCG GCC
CAC CTC CTC TAC TA (human RasGAP; nucleotides 1143–
1122 of NCBI entry M23379)]. The amplified fragment was cut
with the NdeI and NotI restriction enzymes and the resulting 192
base pair fragment was subcloned into vector pET-28a(+) (#543)
opened with the same enzymes. A PCR-generated A to G silent
mutation was found at position 1129 (numbering based on NCBI
entry M23379) in 6xHis-hRasGAP[279–343].dn3. His-TAT-
GFP (#130) encodes a fusion protein made of a stretch of 6
histidine residues, the TAT sequence, and GFP.
SNTAG pull down
Two millions U2OS cells were seeded in a six-well plate and the
next day transfected using the calcium/phosphate precipitation
procedure. After an additional 24-hour period, cells were lysed in
Stag lysis buffer and 1 mg of the lysates were incubated with 1 ml
of biotinylated S-protein (Novagen; reference nu69218) for 3 hours
at 4uC. Thirty ml of streptavidin beads (GE Healthcare Bio-
Sciences; reference nu17-5113-01) were then added to the samples
and the incubation resumed for an additional 1-hour period. Pull
down complexes were then washed 3 times with PBS, 1% NP40
and solubilized in 30 ml of sample buffer 2X.
Immunoprecipitation
One million cells (either CCL39 or U2OS) were seeded in 10-
cm plates and 24 hours later the cells were lysed in 1% Triton X-
100 lysis buffer. Alternatively, one million HEK 293T cells were
seeded in 10-cm plates and 24 hours later they were transfected
using the calcium/phosphate precipitation procedure. After an
additional 24-hour period they were lysed in RIPA-like lysis buffer.
Protein content was measured by Bradford. Seven hundreds mg of
total protein were immunoprecipitated with 1 mg of the anti-
RasGAP antibody overnight at 4uC with rotation at 9 rpm.
Twenty ml of G protein sepharose beads (GE Healthcare;
reference nu17-0618-01) were then added for an additional 2 hour
period. Immunocomplexes were then washed three times with
washing buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1%
NP-40) and solubilized in 30 ml of sample buffer 2X. Samples were
heated 10 minutes at 95uC before loading.
Quantitative PCR
RNA was isolated with the ‘‘High Pure RNA isolation kit’’
(Roche; reference nu 11828665001) according to the manufactur-
er’s instruction. The RNA was then reverse-transcribed with the
‘‘Transcriptor high fidelity cDNA kit’’ (Roche; reference nu05 091
284 001) as per the manufacturer’s instruction. Quantitative PCR
assays were carried out on a real-time PCR detection system (iQ5;
Bio-Rad) using iQ SYBR Green Supermix (Bio-Rad; reference nu
170–8862) using primers at a 500 nM concentration. The
sequences of the c-myc specific primers were GGA CGA CGA
GAC CTT CAT CAA (oligonucleotide#728, nucleotide 926–946
of c-myc mRNA, NCBI entry: NM_002467.3) and CCA GCT
TCT CTG AGA CGA GCT T (oligonucleotide #729, nucleotide
996–1017 of c-myc mRNA, NCBI entry: NM_002467.3). The 18S
ribosomal RNA was used for normalization. The primers used to
amplify this RNA were GCA ATT ATT CCC CAT GAA CG
(oligonucleotide #774, nucleotide 1617–1636, NCBI entry:
NR_003278.1) and GGC CTC ACT AAA CCA TCC AA
(oligonucleotide #775, nucleotide 1720–1739, NCBI entry:
NR_003278.1).
Western blotting
Two hundred thousand cells were seeded in six-well plates and
24 hours later they were subjected to the treatments indicated in
the figures after which they were lysed in sample buffer 5X.
Proteins were quantitated using the Bradford method. Equal
amounts of proteins were subjected to SDS-PAGE and then
transferred onto a nitrocellulose membrane (Biorad; reference
nu162 0115). The membranes were blocked with TBS containing
0.1% Tween-20 and 5% non-fat milk and incubated overnight at
4uC with the indicated primary antibodies used at 1:1000 dilution.
Blots were then washed with TBS-Tween 0.1%, incubated with
the appropriate secondary antibody (1:5000 dilution) 1 hour at
room temperature and subsequently visualized with the Odyssey
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infrared imaging system (LICOR Biosciences, Bad Homburg,
Germany).
Lentivirus
Recombinant lentiviruses were produced as described [26].
Briefly, HEK293T cells were co-transfected using the calcium
phosphate DNA precipitation method [21] with 50 mg of the
lentiviral vector (TRIP-PGKATGm-MCS-WHV) containing the
cDNA of interest (i.e. G3BP1 shRNA), 2.5 mg of the envelope
protein–coding plasmid (pMD.G), and 7.5 mg of the packaging
construct (pCMVDR8.91). Two days after transfection, the virus-
containing medium was harvested. Infection of the cells was
performed as follows. Hexadimethrine bromide (Polybrene;
Sigma; reference nu52495) was added to cells cultured in six-well
plates at a final concentration of 5 mg/ml followed by the addition
of the lentivirus. The plates were then centrifuged 45 minutes at
800 g and placed 24 hours at 37uC in a 5% CO2 humidified
atmosphere. The medium was then replaced with fresh medium,
and the cells were further cultured for an additional 48 hour
period before being used in specific experiments.
Immunocytochemistry
Two hundred thousand cells were seeded in six-well plates
containing glass coverslips and 24 hours later they were transfect-
ed with the calcium/phosphate precipitation procedure. One day
post-transfection, the cells were fixed as follows (all steps were
performed at room temperature). The cells on coverslips were
washed with 4 ml of PBS, fixed with 3 ml PBS, 3% formaldehyde,
3% sucrose for 10 minutes, washed thrice with PBS, permeabi-
lized with 2 ml of PBS, 0.2% Triton X-100 for 10 min, washed
thrice with PBS, and incubated 30 minutes with 3 ml of filtered
serum-containing culture medium. After three additional PBS
washes, the coverslips were incubated for 1 hour with the primary
antibody diluted in DMEM, 10% newborn calf serum. The
coverslips were washed 3 times over 30 minutes in PBS and then
incubated 1 hour with a 1/100 dilution of labeled secondary
antibodies in DMEM, 10% newborn calf serum. The coverslips
were washed 3 more times in PBS and labeled when indicated
with 10 mg/ml Hoechst 33342 (Molecular Probe) before being
mounted (Vectashield mounting medium, Vector laboratories
Inc). Confocal images were captured with a Leica SP5 AOBS
confocal microscope.
Determination of G3BP1 nuclear content
Confocal images were converted to tif format and opened with
the Adobe Photoshop Elements 5.0 software. Pictures of Hoechst-
stained cells were used to create masks of the nuclei that were then
overlaid on the pictures of G3BP1-stained cells in order to delimitate
the nuclear area. The nuclear G3BP1 signal image was then opened
using the ImageJ software (1.34n version) and the nuclear signal was
quantitated. Similarly, the total G3BP1 staining was quantitated for
each picture with the ImageJ software (in this case the cell contours
were manually drawn). The nuclear G3BP1 signal was calculated as
the percentage of the total G3BP1 cell staining.
Peptides
TAT and TAT-RasGAP317–326 are retro-inverso peptides (i.e.
synthesized with D-amino acids in the opposite direction
compared to the natural sequence). The TAT moiety corresponds
to amino acids 48–57 of the HIV TAT protein
(RRRQRRKKRG) and the RasGAP317–326 moiety corresponds
to amino acids 317–326 of the human RasGAP protein
(DTRLNTVWMW). These two moieties are separated by two
glycine linker residues in the TAT-RasGAP317–326 peptide. The
peptides were synthesized at the Department of Biochemistry,
University of Lausanne, Switzerland, using FMOC technology,
purified by HPLC and tested by mass spectrometry.
Protein production and purification
Plasmids coding for recombinant proteins were expressed in
BL21 E. coli. Bacteria were grown overnight in lysogeny broth (LB)
medium (casein enzymic hydrolysate 10 g/l, yeast extract 5 g/l,
NaCl 170 mM, pH 7.5). The induction of the recombinant proteins
was performed by the addition of 0.1 mM isopropyl-beta-thio-
galactoside (IPTG) to the culture medium when it reached on
optical density at 600 nm of 0.6. After 4 hours of induction, the cells
were harvested and resuspended in 5 ml Buffer A [HEPES 50 mM,
magnesium acetate 200 mM, NaCl 500 mM, Triton X-100 0.1%,
lysozyme 2 mg/ml, 0.5% b-mercaptoethanol and 10 mg/ml
DNaseI, supplemented with one tablet of EDTA-free inhibitor
(Roche) per 50 ml]. In order to fully lyse the cells, the suspension
was sonicated (Heischer DmBH sonicator, 0.9 cycles per second,
80% amplitude) 4 times 30 seconds on ice and then centrifuged
20 minutes at 9’000 g at 4uC. A sample of the lysate was kept to
verify the induction of the protein. GST-tagged proteins were then
purified. The glutathione-sepharose beads (Amersham Pharmacia
Biotech; reference nu17-0756-01) were washed 3 times with PBS
and then incubated with the lysate at 4uC with rotation (Labinco
rotary mixer, 12 rpm). The beads were washed thrice with PBS. To
elute the recombinant protein, the beads were incubated with
500 ml of glutathione elution buffer (50 mM Tris pH 8, 10 mM
reduced glutathione [Sigma reference nuG-4251]) for 15 minutes at
4uC with rotation. The beads were then pulled down at 4’000 g and
the supernatant was collected. Histidine-N2 recombinant proteins
were produced as described above, except that nickel beads were
used (Ni-NTA agarose, Qiagen; reference nu1000632) instead of
glutathione-Sepharose beads. The elution step was then performed
with buffer A (see above) supplemented with 25 mM imidazole
(Sigma reference nuI2399).
Statistics
All the statistical analyses were done with Microsoft Excel (XP
edition) using the unpaired Student’s t test. Significance is
indicated by an asterisk when P,0.05/n, where P is the
probability derived from the t test analysis and n is the number
of comparisons done (Bonferroni correction).
In silico protein docking assays
The G3BP1 NTF2 domain structure (PDB entry #2Q90) was
first refined using Maestro v90211 in order to complete and refine
the loops. Molecular dynamics simulations were conducted using
the AMBER 11.0 force field from the NAMD 2.7 package. Using
AmberTools 11.0, the resulting system was solvated in a
rectangular box extending 12 A˚ around the molecule using TIP3P
water molecules. Sodium and chloride ions were added to
neutralize the system. Five thousand steps of energy minimization
were applied on the entire system. Following minimization, the
system was equilibrated with 5’000 steps of water-only molecular
dynamics at 150uK, the system was heated from 0 to 300uK for
100 picoseconds. After heating, a 5 nanosecond production
simulation was conducted with a 1 picosecond time step at a
pressure of 1 bar and a temperature of 300uK. The RasGAP SH3
domain (PDB entry #2JO5) was optimized using the same
method. The docking was performed using Hex 5.1 standard
parameters. The 150 best poses out of 10’000 were collected and
analyzed. The resulting complexes were ranked according to their
free interactions energy. The same docking method was applied to
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the SH3 domain of RasGAP and sequence 190–233 of UBP3, the
USP10 yeast orthologue (PDB entry #2QIY).
Results
No evidence for a RasGAP-G3BP1 interaction
Previous data indicated that G3BP1 binds to a discrete sequence
of RasGAP within its SH3 domain that corresponds to amino
acids 317–326 of the protein [8]. As fragment N2 bears this SH3
domain, we postulated that it should allow fragment N2 to bind to
G3BP1. However, Figure 1 shows that in HEK 293T cells
fragment N2 failed to pull down G3BP1 in conditions where
USP10, a deubiquitinating enzyme known to interact with G3BP1
[12], did. It could be argued that the 317–326 sequence is not
accessible on fragment N2 while it would be exposed on the
parental full-length protein. We therefore assessed if an interaction
between RasGAP and G3BP1 could be demonstrated. Figure 2
indicates that RasGAP could not co-immunoprecipitate with
G3BP1, while it did with p190 RhoGAP, a known RasGAP
binding partner [27,28]. G3BP1 binding to RasGAP has been
reported in the CCL39 (Chinese hamsters lung fibroblast) cell line
[9]. Conceivably, this interaction could be cell-type specific.
Therefore, we immunoprecipitated RasGAP from both CCL39
cells and U2OS cells. Figure 3 shows that endogenous RasGAP
protein interacted with p190 RhoGAP in both cell lines. In these
conditions, no interaction could be detected between RasGAP and
G3BP1.
TAT-RasGAP317–326 does not affect the binding of G3BP1
to USP10
It might be argued that the G3BP1-RasGAP interaction is
transient and difficult to detect by the techniques we have used
here. This interaction might nevertheless occur and one could
hypothesize that TAT-RasGAP317–326 sensitizes tumor cells by
modulating G3BP1 functions by either inhibiting the binding of
RasGAP to G3BP1 or by mimicking the binding of RasGAP to
G3BP1. One of the reported functions of G3BP1 is to bind to and
inhibit USP10 [12]. We therefore assessed if TAT-RasGAP317–326
could prevent the binding of G3BP1 to this protein. Figure 4
shows that the interaction of G3BP1 to USP10 was unaffected by
TAT-RasGAP317–326, indicating that the peptide does not affect
the inhibitory function of G3BP1 on USP10.
TAT-RasGAP317–326 does not impair stress granule
formation
In response to environmental stress (i.e. heat and oxidative
conditions) eukaryotic cells stop the translation of constitutive
Figure 1. G3BP1 does not bind to RasGAP-derived fragment N2. Lysates (1 mg) from HEK293T cells that had been transfected with the
indicated plasmids were subjected to SNTAG pull-down. Pulled-down complexes were then analyzed by Western blotting using an HA-specific
antibody. In parallel, 50 mg of total cell lysates were subjected to Western blot analysis using antibodies recognizing HA or the SNTAG.
doi:10.1371/journal.pone.0029024.g001
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expressed mRNAs that are then routed to phase-dense cytoplas-
mic granules called stress granules (SGs). Many RNA-binding
proteins participate in SG assembly including G3BP1, which
together with TIA-1, is a SG marker [16]. An attractive hypothesis
was that TAT-RasGAP317–326 mediates its sensitization effect by
inhibiting the capacity of G3BP1 to participate in SG formation
when cells are subjected to cytotoxic stresses. Therefore we tested
if cisplatin was able to induce SG formation in U2OS cells and if
TAT-RasGAP317–326 could impair this stress-induced response. As
shown in Figure 5A, formation of SGs after treatment with
arsenite was observed, but cisplatin did not induce SG assembly.
Consequently, it is unlikely that the ability of TAT-RasGAP317–326
to sensitize U2OS cells to genotoxin-induced apoptosis relies on an
effect on SGs. Nevertheless, to assess whether TAT-RasGAP317–326,
in conditions where SGs are efficiently induced, modulates their
assembly, U2OS cells were pre-incubated with TAT-RasGAP317–
326 and then incubated with arsenite. Figure 5B–C shows that the
peptide did not affect the number of SG per cell or the number of
cells exhibiting SGs. To directly evaluate whether TAT-Ras-
GAP317–326 affects SG formation induced by G3BP1, U2OS cells
Figure 2. Ectopically-expressed RasGAP and G3BP1 fail to
interact in conditions where RasGAP binds to RhoGAP. Lysates
(1 mg) from HEK293T cells that had been transfected with the indicated
plasmids were immunoprecipitated with an anti-V5 antibody. Immu-
noprecipitated complexes and cell lysates (50 mg) were analyzed by
Western blotting using HA- and V5-specific antibodies. Asterisks: non-
specific bands; #: immunoglobulin heavy chains; white arrowhead:
expected migration of HA-G3BP1.
doi:10.1371/journal.pone.0029024.g002
Figure 3. Endogenous RasGAP binds to RhoGAP but does not
associate with G3BP1. Non-confluent, exponentially growing CCL39
cells (panel A) or U2OS cells (panel B) were lysed in 1% Triton X-100 lysis
buffer and 1 mg of total protein extracts were immunoprecipitated
with an anti-RasGAP antibody. Immunoprecipitated complexes and cell
lysates (50 mg) were analyzed by Western blotting using G3BP1- and
p190 RhoGAP-specific antibodies. T.L.: total lysate; asterisks: non-
specific bands; #: immunoglobulin heavy chains.
doi:10.1371/journal.pone.0029024.g003
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were transfected with a GFP-tagged form of G3BP1 and incubated
or not with the RasGAP-derived peptide. In this case again, the
presence of TAT-RasGAP317–326 did not alter the formation of SGs
(Figure 5D–E). Altogether, these results show, not only that
genotoxins do not induce SG formation, but also that TAT-
RasGAP317–326 does not affect the ability of G3BP1 to mediate the
formation of SGs.
TAT-RasGAP317–326 does not sensitize cancer cells
through the modulation of c-myc mRNA levels
The endoribonuclease activity of G3BP1 was first reported by
its ability to cleave the 39 untranslated region (UTR) of the c-myc
transcript [9,29]. This transcription factor regulates the expres-
sion of hundreds of gene controlling many cellular functions
including cell survival and cell death [30]. It is an oncogene (one
of the first to have been characterized actually) that is deregulated
in many cancer types [31]. It plays a role in apoptosis by
modulating proteins belonging to the Bcl-2 family, such as the
pro-apoptotic BH3 only protein Bim [32,33]. The 39 UTR of the
c-myc mRNA regulates its stability but how it does so is unclear.
There are reports indicating that the 39 UTR favors c-myc mRNA
decay [34,35], while another one provides indirect evidence that
the 39 UTR contributes to c-myc mRNA stabilization [29]. If
TAT-RasGAP317–326 modulates the ability of G3BP1 to cleave
the c-myc mRNA it could affect the sensitivity of cells to apoptosis,
in particular if c-Myc protein levels are increased because this can
lead to cancer cell apoptosis, potentially via induction of Bim
expression [36,37]. We therefore checked if TAT-RasGAP317–326
modulated c-myc mRNA levels and whether it affected c-Myc and
Bim protein expression. Figure 6 shows that TAT-RasGAP317–326
did not modulate c-myc mRNA or c-Myc protein levels. Similarly,
Bim expression was not affected by the peptide (Figure 6B). The
levels of c-Myc and Bim were efficiently decreased by
Actinomycin D, a transcription inhibitor, indicating that the
experimental conditions used in the figure allow detecting down-
modulation of c-Myc and Bim. Finally, G3BP1 protein levels did
not appear to be affected by TAT-RasGAP317–326 but an effect of
the peptide on the transcription or translation of G3BP1 cannot
be ruled out as the half-life of G3BP1 is considerably longer than
c-Myc or Bim (Figure 6B). Collectively these results do not
support the possibility that TAT-RasGAP317–326 modulates the
endoribonuclease activity of G3BP1 to mediate its tumor
sensitization property.
TAT-RasGAP317–326 does not affect G3BP1 subcellular
location
Another possibility we wanted to explore concerned G3BP1
localization. It was reported that in quiescent MEFs, G3BP1
relocalizes to the nucleus and that this relocalization modulates its
phosphorylation status and endoribonuclease activity [29]. Spe-
cifically, when G3BP1 translocates to the nucleus, it becomes
phosphorylated on serine 149 and it functions as an active
endoribonuclease whereas in proliferating cells, possibly in
association with RasGAP, it is dephosphorylated and loses its
ability to cleave RNAs [29]. Therefore we assessed whether TAT-
RasGAP317–326 could alter the sub-cellular location of G3BP1. In
HeLa cells, three-dimensional reconstructions of confocal sections
indicated that G3BP1 was mainly located on a flat section of the
cytoplasm and was absent in areas directly above or below the
nucleus (egg-on-a-plate configuration) (Figure 7A). This permitted
quantitation of the nuclear G3BP1-specific signal to be performed
on conventional epifluorescence images (Figure 7B), which
revealed that 15–20% of G3BP1 was localized in the nucleus
(Figure 7C). This nuclear location was not affected by the
RasGAP-derived peptide however, indicating that the mechanism
by which TAT-RasGAP317–326 sensitizes tumor cells to genotoxin-
induced apoptosis does not rely on modulation of the nuclear
G3BP1 content.
Figure 4. TAT-RasGAP317–326 does not affect the binding of G3BP1 to USP10. HEK293T cells were transfected with the indicated plasmids.
Eight hours later, they were treated with the indicated concentrations of TAT-RasGAP317–326 for an additional 20 hour period at which time they were
lysed. Lysates (1 mg) were subjected to SNTAG pull-down. Pulled-down complexes were analyzed by Western blotting using HA- and SNTAG specific
antibodies. In parallel 50 mg of total cell lysates were subjected to Western blotting analysis using the same antibodies.
doi:10.1371/journal.pone.0029024.g004
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Figure 5. TAT-RasGAP317–326 does not affect G3BP1-induced SG formation. A. U2OS cells were left untreated or incubated with 15 mM
cisplatin, 20 mM TAT-RasGAP317–326, or a combination of the two compounds for 22 hours. Alternatively, the cells were treated with 200 mM arsenite
for 2 hours. The cells were then processed for immunofluorescence analysis using TIA-1- and G3BP1-specific antibodies. Nuclei were stained with
Hoechst 33342. Images were taken with a fluorescent microscope (Nikon Eclipse 90i). Scale bar: 20 mm for the first 4 columns, 5 mm for the last
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G3BP1 ablation does not abolish TAT-RasGAP317–326-
mediated sensitization of cancer cells to cisplatin
The evidence provided so far indicates that G3BP1 is not a
(strong) RasGAP or fragment N2 binding partner and that TAT-
RasGAP317–326 does not modulate any of the known G3BP1
functions. To unequivocally determine whether G3BP1 is needed
for TAT-RasGAP317–326-mediated tumor sensitization, we used
tumor cells in which G3BP1 was silenced and transformed MEFs
from G3BP1 knock-out mice. Silencing G3BP1 using shRNA
directed at the 39 UTR of its mRNA resulted in 90% reduction in
G3BP1 levels in U2OS cells (Figure 8A–B). This however did not
prevent TAT-RasGAP317–326 from sensitizing the cells to cisplatin-
induced death (Figure 8C). Earlier work has demonstrated that
TAT-RasGAP317–326 does not sensitize non-cancer cells to
cisplatin-induced apoptosis [2]. MEFs, which are non-cancer cells,
were indeed not experiencing more cisplatin-induced death in
presence of the peptide (Figure 8F). It is however possible to
transform MEFs with the SV40 large T antigen [38]. We therefore
expressed the large T antigen in MEFs via lentiviral infection
(Figure 8D) and, as expected, this rendered them sensitive to the
genotoxin-sensitizing effect of TAT-RasGAP317–326 (Figure 8F).
However, the peptide displayed identical sensitizing efficacy in
large T-transformed MEFs lacking or not G3BP1 (Figure 8G).
G3BP1 is therefore dispensable for TAT-RasGAP317–326 to
mediate its genotoxin-sensitizing effect on cancer cells.
Discussion
The tumor-sensitizing activity of fragment N2 towards geno-
toxin-induced apoptosis resides in a 10 amino acid stretch
corresponding to amino acids 317–326 of RasGAP [2]. This
peptidic sequence fused to a cell-permeable peptide (the so-called
TAT-RasGAP317–326 peptide) is indeed capable of favoring the
death of several tumor cell lines to various genotoxins [2]. Amino
acids 317–326 of RasGAP correspond exactly to the sequence
reported to mediate the binding of RasGAP to G3BP1 [8]. G3BP1
is a protein regulating mRNA stability, stress granule formation,
and other cellular functions (reviewed in [39]). Formation of stress
granules in cells has been reported to inhibit apoptosis [17].
Additionally, G3BP1 is over-expressed in certain tumors such as
breast cancers [40]. As G3BP1 binds to amino acid 317–326 of
RasGAP, an attractive hypothesis to explain how TAT-Ras-
GAP317–326 sensitizes specifically tumor cells to genotoxin-induced
death was that the peptide inhibits the ability of G3BP1 to form
stress granule and consequently, as stress granules may exert anti-
apoptotic properties [16], decreases the resistance of cancer cells
towards apoptosis. This hypothesis would predict that cells lacking
G3BP1 would not be sensitized by TAT-RasGAP317–326. The
evidence reported in the present study demonstrates that this
hypothesis is incorrect. First, genotoxins did not induce the
formation of stress granules in cancer cells. Formation of stress
granules cannot therefore represent a protective mechanism
against genotoxins in these cells. Secondly, TAT-RasGAP317–326
did not modulate stress granules in conditions known to induce
their formation (e.g. in the presence of arsenite). Third, the peptide
efficiently sensitizes tumor cells lacking G3BP1 to genotoxin-
induced death. It can therefore be unequivocally concluded that
G3BP1 plays no role in the anti-tumor activity of TAT-
RasGAP317–326.
The non-implication of G3BP1 in the function of TAT-
RasGAP317–326 led us to reassess the reported interactions of
G3BP1 with RasGAP. The RasGAP-G3BP1 interaction was first
column. B–C. U2OS cells were pre-incubated or not with 20 mM TAT-RasGAP317–326 for 18 hours and then treated with arsenite (200 mM, 2 hours).
The cells were then processed as in panel A. Scale bar: 20 mm. Quantitation of the number of SGs per cells and the percentage of cells with SGs is
shown in panel C. D–E. U2OS cells were transfected with a plasmid encoding GFP-HA-G3BP1 and 6 hours later were incubated or not with 20 mM
TAT-RasGAP317–326 for an additional 22 hour period. Cells were then fixed and their nuclei stained with Hoechst 33342. Scale bar: 20 mm. Panel E
shows the quantitation of the number of SGs per cells as well as the percentage of cells with SGs.
doi:10.1371/journal.pone.0029024.g005
Figure 6. TAT-RasGAP317–326 does not affect c-mycmRNA and protein levels or expression of the c-Myc target Bim. A. HeLa cells were
treated or not for 24 hours with 20 mM TAT, 20 or 40 mM TAT-RasGAP317–326 (P), or 1 mg/ml actinomycin D (actD). Quantitative RT-PCR was then used
to measure c-myc mRNA levels. B. Alternatively, the cells were lysed and 50 mg of protein extracts were analyzed by Western blotting using the
indicated antibodies. Note that the Bim gene encodes three different forms of the protein, the expected migrations of which are indicated. Asterisks
indicate non-specific bands.
doi:10.1371/journal.pone.0029024.g006
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reported in 1996 [8]. In this report, it was shown by Far Western
blotting that a fusion protein between GST and the SH3 domain
of RasGAP bound to G3BP1 from ER22 cell lysates and that this
binding could be prevented by the addition of a peptide
corresponding to the 317–326 RasGAP amino acid sequence.
We were not able to reproduce these data using U2OS cell
lysates and a recombinant histidine-tagged SH3 domain of
RasGAP as a probe in the Far Western blotting procedure (data
not shown). Moreover, in conditions where RasGAP and G3BP1
bound to known partners (i.e. p190 RhoGAP and USP10,
respectively), no interaction between G3BP1 and RasGAP was
detected (Figures 1, 2, 3). We used exponentially growing cells for
these experiments as it was reported that G3BP1 does not
interact with RasGAP in quiescent cells [9]. The results
presented in Figures 1, 2, and 3 contrast with reports showing
binding of RasGAP to G3BP1 by co-immunoprecipitation
methods [8,9] and by using GST pull-down assays [10]. It has
to be noted however that these studies did not provide controls
excluding a non-specific binding to beads for example. The
interaction between RasGAP and G3BP1 might be occurring in
very specific situations. It has been reported that G3BP1 only
binds to serum-stimulated cells [8,9] and only after specific
cyclical periods of time following the stimulation: association
detected 1 hour, 8 hours and 16 hours after serum addition but
no association seen 10 minutes, 20 minutes, 2 hours, 4 hours
following serum addition [9]. Whether such pattern of G3BP1-
RasGAP association correlates with a known physiological cell
cycle has not been defined.
Figure 7. TAT-RasGAP317–326 does not affect G3BP1 nuclear localization. A. HeLa cells were left untreated or treated for 18 hours with TAT
(20 mM), TAT-RasGAP317–326 (20 or 40 mM). Immunocytochemistry against G3BP1 was then performed (the nuclei were stained in blue with the
Hoechst 33342 dye) and confocal z-stacks were acquired. Three-dimensional images were then built with the Imaris software. Representative
examples of untreated and TAT-RasGAP317–326-treated cells are shown (scale bar: 5 mm). Alternatively, images were taken using conventional
epifluorescence microscopy (scale bar: 10 mm). Panel B depicts representative examples and panel C shows the corresponding quantifications
performed on 80 cells as described in the methods.
doi:10.1371/journal.pone.0029024.g007
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We also tried to crosslink RasGAP to G3BP1 in U2OS cell lysates
to visualize a 180 kDa RasGAP-G3BP1 complex, as previously
shown [9], but our analysis failed to reveal such a complex (data not
shown). We were therefore unable to reveal a binding between
G3BP1 and either RasGAP or the SH3 domain-containing
fragment N2 of RasGAP, even when we used techniques, conditions
(e.g. cells incubated with serum) and cell lines (e.g. CCL39) used by
others to report this interaction. A similar lack of interaction
between RasGAP and G3BP1 has been reported earlier by another
laboratory [12]. It is pertinent to mention here that RasGAP was
not found in the proteins identified by mass spectrometry in the
cellular material pulled down with an anti-G3BP1 antibody (Sophie
Martin and Jamal Tazi, unpublished results). The reverse was also
true, i.e. G3BP1 was not identified by mass spectrometry in the
cellular material pulled down with an anti-RasGAP antibody (Hadi
Khalil and Christian Widmann, unpublished results). Last, we took
advantage of the recently crystallized structure of the NTF2 domain
of human G3BP1 (PDB; http://www.pdb.org; #3QN) and the
previously published structure of the RasGAP SH3 domain [41] to
conduct molecular dynamics and docking simulations. This analysis
failed to reveal a preferred binding site between the NTF2 domain
of G3BP1 and the SH3 domain of RasGAP (Figure 9A). As a
control, the ability of USP10 to dock to G3BP1 was also tested.
Figure 9B shows that there was a preferred interaction conforma-
tion between these two proteins at sites demonstrated to interact in
the crystal structure made of these two proteins [42]. In light of all
our results, the possibility that RasGAP is not a genuine G3BP1
partner has to be considered.
Figure 8. G3BP1 silencing does not affect TAT-RasGAP317–326-mediated sensitization of cancer cells to cisplatin-induced apoptosis.
A, B. U2OS were infected with a non-target shRNA control vector or a G3BP1 shRNA-expressing lentivirus. After 72 hours, cells were analyzed by
immunocytochemistry (panel A) and Western blotting (panel B) for the presence of G3BP1. C. Infected cells were incubated with 20 mM cisplatin and
20 mM TAT-RasGAP317–326 for 22 hours as indicated on the figure. Apoptosis was then scored. D. MEFs were infected or not with a large T antigen-
expressing lentivirus and 3 days later the expression of the large T antigen was assessed by immunocytochemistry. E. G3BP1 expression in wild-type
(WT) and G3BP1 knock-out (KO) SV40 large T antigen-transformed MEFs was assessed by Western blotting. F. Alternatively, these cells were
incubated with increasing concentrations of cisplatin in the presence or in the absence of TAT-RasGAP317–326 for 22 hours. Apoptosis was then
measured by scoring the number of cells with pycnotic nuclei. G. Wild-type (WT) and G3BP1 knock-out (KO) SV40 large T-transformed MEFs were
treated as in panel C. Asterisks indicate statistically significant differences; NS: not significant.
doi:10.1371/journal.pone.0029024.g008
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 Introduction 
This section contains unpublished data obtained in the context of understanding the molecular 
mechanisms that underlie the TAT-RasGAP317-326-mediated sensitization of cancer cells to 
genotoxin-induced apoptosis. Deciphering the mode of action of TAT-RasGAP317-326 might be 
critically important to unravel how cancer cells resist genotoxic stress and to design new more 
targeted and efficient anti-cancer strategies. 
The manuscript presented in this part shows that TAT-RasGAP317-326 potentiates the 
genotoxin-mediated activation of Bax, a member of the Bcl-2 family that acts as effector of 
the mitochondrial apoptotic pathway.   
 
Contribution 
This work has been entirely carried out by me; it is presented below as manuscript. 
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 Introduction 
The modulation of tumor cell sensitivity to genotoxic agents is one major issue in anticancer 
research. The development of small molecules able to selectively increase the susceptibility of 
cancer cells to genotoxin-induced cell death would ameliorate the efficacy of chemotherapy 
and offer incalculable benefits to cancer suffering patients. Our laboratory earlier developed a 
cell permeable peptide whose active sequence was derived from the SH3 domain of the 
RasGAP protein [1]. This peptide, TAT-RasGAP317-326, was shown to selectively sensitize 
several cancer cell lines, but non non-cancer cell lines, to genotoxin-induced apoptosis , while 
having no effect by itself [1]. TAT-RasGAP317-326 was also demonstrated to be a 
chemosensitizer in vivo in a tumor xenograft mouse model [2]. Understanding how TAT-
RasGAP317-326 delivers its pro-apoptotic effect would potentially give new insights into the 
mechanism allowing cancer cells to resist apoptosis. This would therefore allow the 
development of more target-specific anti-cancer strategies.  
Genotoxins are DNA-damaging substances that prevalently exert their anti-tumor activity by 
causing apoptosis in cancer cells through the mitochondrial pathway [3-5]. The genotoxin-
induced DNA-damage response is orchestrated by a series of kinases (e.g. the ataxia-
telangiectasia mutated, ATM) [6;7] that sense the extent of the damage and activate 
downstream effectors. One of the key DNA damage response effector is p53, a transcription 
factors that regulates the expression of genes mainly involved in cell cycle arrest (e.g. p21) 
and apoptosis (e.g. Puma and Bax) [8]. Puma and Bax are two Bcl-2 family members, a 
family of proteins that tightly controls the mitochondrial membrane integrity [9]. When the 
balance between pro and anti-apoptotic members of this family tips in favor of the anti-
apoptotic players, mitochondrial membrane integrity is lost with consequent release of 
cytochrome c that leads to caspase activation and apoptosis [10]. 
100
 We earlier showed that TAT-RasGAP317-326 does not modulate the MAPK signaling pathways 
(p38, ERK and JNK), the NF-kB transcriptional activity and it does not influence the AKT 
protein levels and phosphorylation status [1;11]. We also provided evidence suggesting that a 
functional p53/Puma apoptotic axis is needed by the peptide to potentiate the genotoxin-
induced cell death, even though their protein levels are not altered by TAT-RasGAP317-326 
[11].  
The aim of this study is to gain a deeper insight into the molecular events allowing TAT-
RasGAP317-326 to potentiate the genotoxin-activated mitochondrial cell death pathway. 
 
Materials and methods 
Chemicals 
Cisplatin (Sigma, ref. n°P4394) was diluted in water at a final concentration of 1 mg/ml and 
stored at -80°C. TNFa (Pierce, ref. n°RTNFA10) was diluted in water at a concentration of 10 
µg/ml. Cycloheximide (Sigma, ref. n°C7698) was diluted in methanol and stored at -20 °C. 
Paraformaldehyde (PFA) and HCl were from Acros (ref. n°30525-89-4 and 7647-01-0, 
respectively). Hoechst 33342 (Molecular Probe, Invitrogen, ref. n°H21492) was diluted in 
water at a concentration of 10 mg/ml and used at a final concentration of 10 µg/ml. The pan-
caspase inhibitor MX1013 was a kind gift from Maxim Pharmaceuticals (San Diego, CA). 
Tris, sodium dodecyl sulfate (SDS), mannitol and sucrose were from Sigma (ref. n°T1503, 
L4390, M4125 and S0389 respectively). HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) was from Applichem (ref. n°A3724).  NaCl, EGTA 
(ethylenebis[oxyethylenenitrilo]tetraacetic acid) and bromophenol blue were from Acros (ref. 
n°7647-14-5, 67-42-5, and 115-39-9, respectively). CHAPS (3-[(3-
Cholamidopropyl)dimethylammonio]-1-propanesulfonate), EDTA 
(ethylenediaminetetraacetic acid), dithiothreitol (DTT), KCl and glycerol were from Fluka 
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 (ref. n°26680, 03620, 43817, 60130  and 49780, respectively). G-Sepharose beads were from 
GE Healthcare (ref. n°17-0618-01). Nitrocellulose membranes were from Biorad (ref. n°162 
0115). MgCl2 was from Eurobio (ref. n°018023). EDTA-free Protease Inhibitor Cocktail 
Tablets were from Roche Applied Science (ref. n°1873580). Polyoxyethylene (20) sorbitan 
monolaurate (Tween 20) was from AppliChem (ref. n° 90005-64-5). 
 
Buffers  
The composition of phosphate buffered saline (PBS) is 116 mM NaCl, 10.4 mM Na2HPO4, 
3.2 mM KH2PO4 (pH 7.4). The composition of the isotonic mitochondrial buffer (MB) is 10 
mM HEPES (pH 7.4), 210 mM mannitol, 70 mM sucrose, 1 mM EDTA supplemented with 
one tablet of EDTA-free inhibitor (Roche) per 50 ml. The KCl buffer is made of 10 mM 
HEPES (pH 7.4), 125 mM KCl, 0.5 mM EGTA, 4 mM MgCl2 and 5mM KHPO4. 1% 
CHAPS lysis buffer is made of 5 mM MgCl2, 137 mM NaCl, 1 mM EDTA, 1 mM EGTA, 
1% Chaps, 20 mM Tris-HCl, supplemented with one tablet of EDTA-free Protease Inhibitor 
Cocktail (Roche) per 50 ml. MonoQ-c buffer is made of 70 mM β-glycerophosphate, 0.5% 
Triton X-100, 2 mM MgCl2, 1 mM EGTA, 100 µM Na3VO4, 1 mM dithiothreitol, 20 µg/ml 
aprotinin supplemented with one tablet of complete EDTA-free Protease Inhibitor Cocktail 
per 50 ml. 
 
Peptides 
TAT and TAT-RasGAP317-326 are retro-inverso peptides (i.e. synthesized with D-amino 
acids in the opposite direction compared to the natural sequence).  The TAT moiety 
corresponds to amino acids 48-57 of the HIV TAT protein (RRRQRRKKRG) and the 
RasGAP317-326 moiety corresponds to amino acids 317-326 of the human RasGAP protein 
(DTRLNTVWMW). These two moieties are separated by two glycine linker residues in the 
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 TAT-RasGAP317-326 peptide.  The peptides were synthesized at the Institute of 
Biochemistry, University of Lausanne, Switzerland, using FMOC technology, purified by 
HPLC and tested by mass spectrometry. 
 
Cell lines 
U2OS, HCT116 were cultured in DMEM (Invitrogen, ref. n°61965) supplemented with 10% 
heat-inactivated fetal bovine serum (FBS; Invitrogen, ref. n°10270-106) in 5% CO2 at 37°C. 
HeLa cells were cultured in RPMI (Invitrogen, ref. n°61870) supplemented with 10% heat-
inactivated FBS in 5% CO2 at 37°C. Culturing of the cells prior to performing the 
experiments described in this article was performed in six-well plates by seeding 100'000 
cells (Figure 1; Figure 2, right graph), 150'000 (Figure 5, U2OS and HeLa cells), 200'000 
(Figure 5, HCT116 cells), or 250'000 cells (Figure 2, left graph; Figure 3) in the wells 24 
hours before being treated as indicated in the figures. B Mouse embryonic fibroblast (MEFs) 
knock-out (KO) for Bcl-XL, Bcl-2, Mcl-1, Bim, Bmf and Bid were generously provided by 
Dr David Huang. MEFs KO for Bax, Bak, Bax/Bak and Bad were generously provided by Dr 
Stansley Korsmeyer. Culturing of the KO MEFs prior to performing the experiments 
described in this article was performed in six-well plates by seeding 150'000 cells (Figure 8). 
 
Starvation  
Cells were washed three times with PBS and incubated for 24 hours with medium lacking 
FBS. 
 
UV illumination  
Cells in culture dishes with the lid removed were illuminated with UV-C using the UV lamp 
of a cell culture hood (Fortuna from Scanlaf 1200) delivering an intensity of 0.25 J/m2 per 
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 second. The cells were then incubated in their culture medium for the indicated periods of 
time in 5% CO2 at 37°C. 
 
Apoptosis quantitation 
Cells were fixed in 2% PFA and nuclei labeled with Hoechst 33342. Apoptotic cells (i.e. cells 
displaying a pycnotic nucleus) were counted under a Nikon Eclipse TS100 microscope. When 
apoptosis was assessed on a population of transfected cells, only green cells (i.e. cells having 
incorporated the transfected plasmids) were counted.  
 
Statistics 
Statistical analyses were performed with the SAS/STAT software (version 9.1.3; SAS 
Institute, Cary, NC) using one-way ANOVA procedures followed by post-hoc Bonferroni 
(Dunn) t tests. 
 
Mitochondria purification and cytochrome c release assay 
HeLa cells were harvested in PBS and centrifuged 10 minutes at 1000 x g. Cells were then 
risuspended in isotonic mitochondrial buffer (MB),  broken by twenty passages through a 
25G1 0.5- by 25-mm needle fitted on a 2 ml syringe and centrifuged at 1500 x g 5 minutes.  
This procedure was repeated twice and supernatants from each step were pooled and 
centrifuged 5 minutes at 1500 x g. Supernatant was collected, centrifuged 5 minutes at 2000 x 
g and further centrifuged 10 minutes at 90000 x g. Pellet was then resuspended in MB and 
centrifuged 10 minutes at 7000 x g and the pellet, representing the mitochondrial fraction, was 
finally resuspended in MB. Mitochondrial content was quantitated by Bradford. 30 µg of 
mitochondria were incubated in KCl buffer with or without the recombinant protein tBid in a 
total volume of 100 µl for 30 minutes at room temperature. Samples were then centrifuged at 
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 12000 x g 5 minutes, supernatants and pellets were then used to determine the cytochrome c 
release.  
 
Transfection 
Cells were transfected using Lipofectamine 2000 (GibcoBRL, ref. n°18324-012) according to 
the manufacturer's instructions. Briefly, the indicated plasmids, together with 0.5 mg of GFP-
encoding plasmid, were diluted in 250 ml DMEM without FBS. The amount of DNA used in 
the transfection was kept constant to 4 mg by adding the appropriate quantities of pcDNA3 
plasmid. In parallel, 8 ml of lipofectamine were added to 250 ml of DMEM without FBS and 
kept at room temperature for 5 minutes. Finally, the DNA-containing medium was added drop 
by drop to the lipofectamin-containing medium and the resulting 500 ml mix was added to 
cells. Five hours later, cells were washed once with fresh medium (DMEM supplemented 
with FBS) and cultured for an additional 20 hour period in the presence of the treatments 
indicated in the figures. 
 
Coimmunoprecipitation and immunoblotting 
7.5x105 U2OS and HeLa cells and 106 HCT116 cells were seeded in 10 cm plates and the 
next day treated as shown in the figures. Sixteen hours later, the cells were lysed in 300 µl of 
1% CHAPS lysis buffer and 700 µg of the lysate proteins were immunoprecipitated overnight 
with 1.5 µg of the 6A7 anti-Bax antibody (Figure 4) or 1.5 µg of the anti-Bcl-XL antibody 
(Figure 6). Immunoprecipitates were captured on 30 µl of protein G-Sepharose at 4 °C for 2 
hours. Immunocomplexes were then washed three times in CHAPS lysis buffer and eluted in 
30 µl of 2X sample buffer [25 mM Tris-HCl pH 7.5, 10% glycerol, 6% SDS,  0.02% of 
bromophenol blue and 100 mM freshly added DTT]. The immunoprecipitates and 50 µg of 
total cell lysates were separated by SDS-PAGE and then transferred onto nitrocellulose 
105
 membrane. The membranes were blocked with TBS (20 mM Tris, 130 mM NaCl, pH 7.6) 
containing 0.1% Tween 20 and 5% non-fat milk (TBS-TM) and incubated overnight at 4°C 
with a 1/1000 dilution of the N-20 anti-Bax antibody (Figure 4) or 1/1000 dilutions of the 
antibodies directed at the proteins indicated in the other figures. Blots were then washed with 
TBS containing 0.1% Tween 20 (TBS-T), incubated 1 hour at room temperature with the 
appropriate fluorophore-conjugated secondary antibody (1:5'000 dilution) and subsequently 
visualized with the Odyssey infrared imaging system (LICOR Biosciences, Bad Homburg, 
Germany). 
 
Western blotting 
Cells were lysed in 100 µl of monoQ-c buffer. Visualization and quantitations of the bands 
were performed using the Odyssey infrared imaging device and software (Licor, Homburg, 
Germany). 
 
Antibodies 
The anti-PUMA rabbit polyclonal IgG, the anti-Bid rabbit polyclonal antibody and the anti-
Bcl-XL rabbit polyclonal IgG and the anti-Caspase-3 rabbit polyclonyl IgG were from Cell 
Signaling (ref. n°4976, 2002, 2764 and 9665, respectively). The 6A7 anti-Bax mouse 
monoclonal IgG1 and the N-20 anti-Bax rabbit polyclonal IgG were from SantaCruz (ref. 
n°sc-23959 and n°sc-493, respectively). The anti-Bcl-2 mouse monoclonal IgG1 was from 
Upstate (ref. n°05-341), the Y37 anti-Mcl-1 rabbit monoclonal IgG was from Abcam (ref. 
n°ab32087), the 3C5 anti-Bim rat monoclonal IgG2a and the 1E1-1-10 anti-cIAP1 rat 
monoclonal IgG2a were from Enzo Life Sciences (ref. n°ALX-804-527-C100 and n°ALX-
803-335-C100, respectively), the 48/hILP/XIAP anti-XIAP mouse monoclonal IgG1 was 
from BD Biosciences (ref. n°610762). The anti-cytochrome c rabbit polyclonal antibody was 
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 a gift from Dr, Jean-Claude Martinou. Secondary antibodies were goat anti-mouse IRDye800-
conjugated antibody (Rockland, ref. n°610-132-121), goat anti-rabbit Alexa Fluor 680-
conjugated antibody (Molecular Probes, ref. n°A21109) and donkey anti-rabbit HRP-
conjugated antibody (Jackson immunoresearch ref n ° 711-035-152).    
 
Plasmids 
The pcDNA3 expression vector is from Invitrogen. pEGFP-C1 (Clontech) encodes the green 
fluorescent protein. Puma.cmv (Origene) encodes human Puma. hTPP53.dn3 encodes the 
human p53. It was generated by subcloning the 1900 bp EcoRI/BamHI fragment from 
hTP53.lti (gift from Richard Iggo) into pcDNA3 opened with the same two enzymes. TRIP-
PGK-IRESNEO-WHV (#350) is a lentiviral vector bearing the neomycine resistance 
SV40LargeTantigen.pBABE-puro (#731) encodes the SV40 large T antigen (Addgene; 
plasmid 13970). SV40LargeTantigen.lti-neo (#738) similarly encodes the large T antigen 
but in a lentiviral expression vector. It was constructed by subcloning the BamHI 2187 base 
pairs fragment of SV40LargeTantigen.pBABE-puro into TRIP-PGK-IRESNEO-WHV 
opened with the same enzyme. The extension .lti indicates that the backbone is a lentiviral 
vector. The extension .cmv indicates that the backbone is the pCMV-AC vector. The 
extension .dn3 indicates that the backbone plasmid is pcDNA3. 
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 Results 
 
TAT-RasGAP317-326 sensitizes diverse cancer cells to genotoxin-induced apoptosis but not 
to TNFα-induced apoptosis and variably to starvation- and UV-induced apoptosis 
We demonstrated earlier that TAT-RasGAP317-326 sensitizes various cancer cell lines to 
apoptosis induced by genotoxins such as cisplatin [1]. These compounds induce apoptosis via 
the intrinsic apoptosis pathway [3;4]. To gain further insight about the manner by which 
TAT-RasGAP317-326 exerts its tumor sensitization effect, HeLa, U2OS, and HCT116 cancer 
cells were treated with additional pro-apoptotic compounds, including TNFα that induces cell 
death via the extrinsic apoptotic pathway. Figure 1 shows that TAT-RasGAP317-326 favors 
apoptosis induced by cisplatin in the three different cancer cell lines, confirming earlier 
results [1;11]. However, TAT-RasGAP317-326 does not sensitize all tumor cell lines to UV- or 
growth factor deprivation-induced apoptosis, despite that these treatments activate the 
intrinsic apoptotic pathway [12;13]. None of the tumors is sensitized by the peptide to the 
extrinsic pathway stimulator TNFα [14;15] in presence of cycloheximide, a protein synthesis 
inhibitor that prevents the expression of anti-apoptotic proteins that would otherwise 
counteract the pro-apoptotic abilities of TNFα [16;17]. These results indicate that TAT-
RasGAP317-326 exerts a pro-apoptotic role only in conditions where the intrinsic cell death 
pathway is engaged. However since the cancer cell lines used here are type II cells [18;19], 
i.e. they need the mitochondrial pathway to fully activate caspase-3 in response to extrinsic 
death stimuli [20], it is unclear why TAT-RasGAP317-326 does not have any sensitizing effect 
on these cell lines when incubated with TNFα. One possibility could be that the peptide 
requires protein translation (blocked by cycloheximide) to mediate its effect. Possibly 
therefore, the activation of the mitochondrial pathway upon TNFα treatment is not 
pronounced enough for TAT-RasGAP317-326 to operate. 
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Figure 1. Ability of TAT-RasGAP317-326 to sensitize tumor cell to various cell death stimuli. U20S, HeLa and 
HCT116 were subjected to UV-C illumination or treated during 24 hours with various apoptotic stimuli as 
indicated in the figure. Cells were then fixed and apoptosis was counted by scoring pycnotic nuclei. C: cisplatin 
30 µM, P: TAT-RasGAP317-326 20 µM, TAT: 20 µM, UV-C: 20 J/m2 (U20S), 25 J/m2 (HeLa and HCT116), S: 
starvation, CHX: cyclohexmide 10 µg/ml, TNFα: 1 ng/ml (U20S and HeLa), 0,5 ng/ml (HCT116). The results 
correspond to the mean +/- 95% CI of at least three independent experiments. The asterisks indicate a 
statistically significant difference (as assessed by impaired t-test between cells treated or not with TAT-
RasGAP317-326 in the presence of the apoptogenic stimulus.   
 
TAT-RasGAP317-326 does not sensitize cells to PUMA over-expression 
We previously reported that TAT-RasGAP317-326 requires an intact p53/Puma axis to deliver 
its genotoxin-sensitizing effect in cancer cells [11]. To determine if the peptide potentiates the 
pro-apoptotic activity of PUMA, Puma was ectopically expressed in U2OS cells to levels 
comparable to those induced by cisplatin (Figure 2A). This does not lead to apoptosis whether 
109
 the cells were incubated with TAT-RasGAP317-326 or not (Figure 2B, squares). In contrast, the 
peptide efficiently sensitizes tumor cells to cisplatin-induced apoptosis (Figure 2B, circles). 
PUMA is a p53 transcription target that may, once synthesized, need p53 to exert its full pro-
apoptotic actions [21]. Figure 3 shows that ectopic expression of p53 in U2OS cells induces 
apoptosis. However this is neither modulated by PUMA nor by TAT-RasGAP317-326. Taken 
together these data suggest that TAT-RasGAP317-326 does not directly amplify the DNA-
damage-induced p53/PUMA arm. Hence, even though cisplatin requires p53 and PUMA to 
induce apoptosis [11], this genotoxin may modulate other pro-apoptotic signals that are 
targeted by TAT-RasGAP317-326 to induce cell death in cancer cells. Additionally, the results 
presented in Figure 3 do not support the model proposed by Chipuk and collaborators where 
PUMA and p53 collaborate to induce apoptosis [21]. 
 
 
 
Figure 2. Increase in Puma expression levels does not make tumor cells sensitive to TAT-RasGAP317-326. 
U20S were treated with increasing concentrations of cisplatin or transfected with the indicated amount of a 
Puma-encoding plasmid in the presence or not of TAT-RasGAP317-326 (20 µM) for 22 hours. Apoptotic cell 
percentage (B) and Puma protein levels (A) where then quantitated. Results correspond to the mean +/- 95% CI 
of three independent experiments.      
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Figure 3. p53, in combination or not with Puma, does not sensitize cancer cells to TAT-RasGAP317-326. 
U20S were transfected with the indicated plasmids and treated or not with 20 µM of TAT-RasGAP317-326 for 22 
hours. Apoptosis was then determined. Results correspond to the mean +/- 95% CI of four independent 
experiments. NS, no statistically significant difference 
 
TAT-RasGAP317-326 affects long term survival of cancer cells independently of p53 
The observation that the RasGAP-derived peptide does not amplify the p53/Puma axis led us 
to reconsider the implication of p53 in the TAT-RasGAP317-326-mediated sensitization of 
cancer cells. Cells lacking an intact p53/Puma axis show a drastically reduced apoptotic rate 
when exposed to genotoxin treatment [1], but their overall resistance to genotoxins might not 
be affected. Figure 4B shows that the overall survival of HCT116 p53-/- tumor cells, tested by 
colony formation assay, is reduced by cisplatin treatment and, more importantly, TAT-
RasGAP317-326 significantly augments the cisplatin-mediated impairment in cell survival 
(Figure 4). The same TAT-RasGAP317-326-mediated effect is observed, as expected, in 
HCT116 p53 WT cells treated with cisplatin (Figure 4A). Moreover TAT-RasGAP317-326 by 
itself has no effect on the clonogenic survival as well as the cell permeable sequence TAT, 
alone or in combination with cisplatin. These data led us to the conclusion that, contrary to 
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 what previously hypothesized, p53 is dispensable for the TAT-RasGAP317-326-mediated 
sensitization of malignant cells. 
 
 
 
 
Figure 4. TAT-RasGAP317-326 sensitizes cancer cells to cisplatin-induced cell death irrespective of the p53 
status. HCT116 and HCT116 p53 -/- were treated with 1 µM cisplatin in the presence or not of  20 µM TAT-
RasGAP317-326 (P) or 20 µM TAT for 3 days. Culture medium was then replaced with fresh medium and and after 
an additional 10-day period the number of colonies was recorded. N/T:untreated.  The results correspond to the 
mean +/- 95%CI of at least three independent experiments. The asterisks indicate a statistically significant 
difference (as assessed by ANOVA between cells treated or not with TAT-RasGAP317-326 in the presence of 
cisplatin). 
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 TAT-RasGAP317-326 increases cisplatin-induced Bax activation. 
Tumor cells sensitized by TAT-RasGAP317-326 to genotoxin-induced apoptosis show increased 
caspase-3 activation and more pronounced mitochondrial membrane depolarization [11]. This 
suggests that the RasGAP-derived peptide acts upstream of cytochrome c release from 
mitochondria. Consequently, Bax, which is required for outer mitochondrial membrane 
permeabilization, cytochrome c release, and caspase activation [10], should be more activated 
by genotoxins in the presence of TAT-RasGAP317-326. Figure 5A shows indeed that, while the 
peptide alone does not affect Bax activity, it increases cisplatin-induced Bax stimulation. 
There is evidence that caspase activation induces a positive feedback loop to increase Bax 
activation and cytochrome c release from the mitochondria [22]. To determine if TAT-
RasGAP317-326 modulates this feedback loop, the experiment shown in Figure 5A was 
performed in the presence of the pan-caspase inhibitor MX1013 [23;24] that efficiently blocks 
executioner caspase activity (Figure 5B). This experiment shows that caspase inhibition does 
not prevent TAT-RasGAP317-326 from enhancing cisplatin-mediated Bax activation (Figure 
5C). Altogether, these experiments indicate that the mechanisms underlying TAT-RasGAP317-
326-mediated apoptosis sensitization occur upstream or at the level of mitochondria. 
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Figure 5. TAT-RasGAP317-326 favors, in a caspase-independent manner, the ability of cisplatin to activate 
Bax. 
A.U2OS, HeLa and HCT116  were treated for 16 hours with 20 µM TAT-RasGAP317-326 and/or with 30 µM of 
cisplatin as indicated in the figure. The cells were then lysed and the activated form of Bax detected after 
immuno-precipitation (see methods). IP, immunoprecipitate; TL, total lysate; *, non-specific band. 
B. HCT116 were either left untreated or treated with the indicated concentration of cispatin for 20 hours, in the 
presence or not of the pan-caspase inhibitor MX1013. The cells were then lysed and the cleavage of Caspase-3 
was assessed by Western blot. 
C. U2OS cells were processed as in panel A in the presence or not of 10 µM of the pan-caspase inhibitor 
MX1013. 
 
TAT-RasGAP317-326 does not modulate any of the Bcl-2 and IAP family members 
Bax activation is controlled by pro- and anti-apoptotic members of the Bcl-2 family of 
proteins [9;10]. Conceivably, TAT-RasGAP317-326 could favor genotoxin-induced apoptosis 
by increasing the levels of pro-apoptotic Bcl-2 family members and/or decreasing the levels 
of the anti-apoptotic members. However, the peptide does neither modulate the pro-apoptotic 
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 Bim, Puma and Bid proteins nor the anti-apoptotic Bcl-XL, Bcl-2 and Mcl-1 proteins (Figure 
6). Another possibility that could explain how TAT-RasGAP317-326 favors apoptosis is 
inhibition of inhibitor of apoptosis (IAP) family proteins. However, the peptide does not alter 
cellular levels of cIAP1, cIAP2 and XIAP (Figure 6). Therefore, modulation of the expression 
of IAPs and Bcl-2 family members is not the mechanism used by TAT-RasGAP317-326 to favor 
Bax activation and apoptosis. However, this does not exclude the possibility that the peptide 
affects the activity of these proteins. 
 
 
Figure 6. TAT-RasGAP317-326 does not modulate Bcl-2 family protein levels.  U2OS, HCT116 and HeLa 
were treated as shown in the figure for 22 hours (TAT-RasGAP317-326, 20 µM; cisplatin, 30 µM). Cells were then 
lysed and total protein extracts were immunoblotted with antibodies specific for the indicated proteins (*: non-
specific band). cIAP2 is not detected in HCT116. 
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 The ability of Bcl-XL to bind p53 and Puma is not impaired by TAT-RasGAP317-326 
Bcl-XL is one of the main anti-apoptotic proteins that bind to and neutralize pro-apoptotic 
proteins such as PUMA [25]. Additionally, the p53 tumor suppressor binds to Bcl-XL, 
antagonizing the latter’s anti-apoptotic activity [26]. TAT-RasGAP317-326 may promote 
apoptosis by displacing Bcl-XL from its pro-apoptotic binding partners. However, cisplatin-
induced increased binding of Bcl-XL to p53 or to PUMA is unaffected by the peptide (Figure 
7). Therefore, TAT-RasGAP317-326 does not appear to modulate Bcl-XL functionality. 
 
Figure 7. TAT-RasGAP317-326 does not affect the ability of Bcl-XL to bind to p53 or Puma. Cells were 
treated as shown in the figure (C: 30 µM cisplatin; P: 20 µM TAT-RasGAP317-326). Bcl-XL was 
immunoprecipitated from cell lysates and its association with p53 and Puma was analysed by Western blot. In 
parallel, proteins expression was assessed on total protein extracts. *, immunoglobulin light chains; #, non-
specific bands. The immunoglobulin heavy chains of the MEKK1 antibody (§) are shifted up compared to the 
corresponding chains of the Bcl-XL-specific antibody. 
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 Targeted disruption of individual Bcl-2 family members does not prevent TAT-
RasGAP317-326-mediated tumor cell sensitizing 
Large T antigen-transformed MEFs lacking specific Bcl-2 family member were used to 
investigate the role of this protein family in the capacity of TAT-RasGAP317-326 to sensitize 
tumor cells to genotoxin-induced apoptosis. MEFs are not cancer cells and hence are not 
susceptible to TAT-RasGAP317-326-mediated genotoxin sensitization. However, transforming 
MEFs with the SV40 large T antigen renders them sensitive to the peptide (Annibaldi, A.,, 
Plos One, 2011). Figure 8 shows that transformed MEFs lacking the pro-apoptotic Bim, Bmf, 
Bad, Bax, or Bak proteins, or the anti-apoptotic Bcl-XL, Bcl-2, or Mcl-1 proteins are 
efficiently sensitized by TAT-RasGAP317-326 to cisplatin-induced apoptosis. As expected, 
transformed MEFs lacking both Bax and Bak are totally resistant to cisplatin-induced death 
[27]. Similarly, transformed MEFs lacking Bid are totally resistant to cisplatin-induced 
apoptosis, consistent with the notion that Bid is a main cell death effector in DNA-damage 
response [28;29]. These results indicate that taken individually Bim, Bmf, Bad, Bax, Bak, 
Bcl-XL, Bcl-2, or Mcl-1 and dispensable for TAT-RasGAP317-326 to mediate its tumor 
sensitization activity. 
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Figure 8. Role of single Bcl-2 family proteins in the TAT-RasGAP317-326-mediated sensitization to cisplatin-
induced apoptosis. 
SV40-transformed MEFs KO for the indicated Bcl-2 family proteins were treated as indicated in the figure for 
22 hours. Cells were then fixed and apoptosis was counted by scoring picnotic nuclei.TAT-RasGAP317-326: 20 
µM. The results correspond to the mean +/- 95%CI of at least three independent experiments. The asterisks 
indicate a statistically significant difference (as assessed by unpaired t-test  between cells treated or not with 
TAT-RasGAP317-326 in the presence cisplatin). 
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 TAT-RasGAP317-326 enhances cisplatin-induced Bax activation via tBid 
The absence of apoptosis observed in Bid KO MEFs does not allow us to conclude if TAT-
RasGAP requires Bid to sensitize tumors. To address this point we used HeLa-purified 
mitochondria, taking advantage of the fact that Bax is weakly associated with the 
mitochondrial membrane in an inactive configuration [30;31]. The addition of recombinant 
tBid to the isolated mitochondria was shown to trigger Bax oligomerization, insertion into the 
outer mitochondrial membrane and citochrome c release [30;32]. If TAT-RasGAP317-326 needs 
tBid to fulfill its sensitizing functions, we predict that the peptide should favor the tBid-
induced cytochrome c release. Consistently with our prediction, figure 9 shows that tBid 
induces cytochrome c release in a dose dependent manner and that TAT-RasGAP317-326 
enhances the tBid-mediated cytochrome c release, while having no effect by itself. These data 
support a role for tBid in the above-mentioned TAT-RasGAP317-326-induced activation of Bax 
that results then in mitochondrial membrane depolarization and cytochrome c release. 
 
 
 
 
 
Figure 9. TAT-RasGAP317-326 enhances the tBid-induced cytochrome c release. 
30 µg of HeLa-isolated mitochondria were left untreated or incubated with the indicated concentrations of 
recombinant tBid in the presence or not of 1 µM TAT-RasGAP317-326 (TP) or  1 µM RasGAP317-326 (P) as 
indicated in the figure for 30 minutes at room temperature. Supernatants were analysed for cytochrome c release 
and mitochondrial pellets for Cox as gel-loading control. These blots are representative of 4 different 
experiments.   
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 Discussion 
This study provides advances in the understanding on the mode of action of TAT-RasGAP317-
326. Firstly, it clarifies the role played by p53 (and Puma) in TAT-RasGAP317-326-mediated 
sensitization of tumor cells to genotoxin-induced apoptosis. Secondly, it shows that this 
peptide enhances Bax activation, providing a mechanistic basis for its sensitizing capacity. 
Earlier work has indicated that TAT-RasGAP317-326 required a functional p53-PUMA axis to 
favor apoptosis of cisplatin-stimulated tumor cells [11]. We therefore hypothesized that 
increased expression of p53 and Puma in cancer cells, which occurs when cells are treated 
with cisplatin, would render them sensitive to TAT-RasGAP317-326. However, this proved not 
to be the case. Moreover, tumor cells lacking p53, even though highly resistant to cisplatin-
induced apoptosis in short-term experiments [11], were nevertheless less able to survive long-
term cisplatin treatment when co-treated with TAT-RasGAP317-326. This indicates that the 
RasGAP-derived peptide does not require p53 to exert its tumor sensitization activity.  Hence, 
p53 and Puma are not targets of TAT-RasGAP317-326. The apparent requirement of p53 and 
Puma for the genotoxin-sensitizing function of the peptide in short-term apoptosis assays 
most likely results from the fact that genotoxins inefficiently induce apoptosis of tumor cells 
lacking a functional p53-Puma axis [33]. In other words, the absence of TAT-RasGAP317-326-
mediated sensitization observed in p53- or Puma-negative cells merely reflects the fact these 
cells cannot properly undergo genotoxin-induced apoptosis. Measuring cell death in short-
term assays (e.g. within the first 24 hours of treatment) might lead to an underestimation of 
the killing potential of genotoxins, as long-term cell survival is not taken into account. This 
may particularly be the case in cells bearing mutations in apoptosis-controlling proteins. 
Tumor cells lacking p53 can bypass the primary apoptotic decision, which takes place shortly 
after the administration of an apoptotic stimulus, and undergo several cell divisions before 
dying. This can occur either by p53-independent apoptosis or as a result of mitotic catastrophe 
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 or necrotic cell death [34]. The observation that TAT-RasGAP317-326, in combination with 
cisplatin, reduces the viability of p53-negative tumor cells demonstrates that this peptide can 
also positively reinforces p53-independent cell death mechanism(s) that occur in a more 
delayed manner compared to short-term apoptosis. 
Bid is a BH3-only Bcl-2 family member bearing a caspase-8 recognition site. Caspase 8-
mediated cleavage of Bid at asp59 generates a C-terminal fragment, called truncated Bid 
(tBid), which translocates to mitochondria to induce the release of cytochrome c through the 
oligomerization of Bax [30]. Consistently with previous reports, we found that Bid-deficient 
cells are fully resistant to cisplatin [28] (Figure 8). Thus, similarly to p53 and Puma, Bid is 
also required for genotoxin-induced apoptosis of at least some cancer cells. Consequently, the 
use of Bid knockout cells did not allow us to assess the involvement of Bid in TAT-
RasGAP317-326-mediated tumor cell sensitization to genotoxins. To circumvent this limitation, 
we used a cell free assay in which the release of cytochrome c is induced by recombinant 
tBid. This approach showed that TAT-RasGAP317-326 is able to increase the capacity of tBid to 
activate Bax as assessed by augmented cytochrome-c release. This is consistent with our 
observation that the peptide increases cisplatin-induced Bax activation in cells (Figure 5). 
Two possibilities can be proposed to explain this observation: i) the peptide pre-sensitizes 
Bax (and/or Bak) so that they can be better activated by direct stimulators such as tBid, Puma, 
or Bim; ii) the peptide makes truncated forms of Bid more potent in activating Bax. At 
present, we cannot discriminate between these two possibilities but the following arguments 
need to be taken into consideration. First, Bax activation does not result from a peptide-
induced balance shift between the expression levels of pro- and anti-apoptotic Bcl-2 family 
members. Indeed, the protein levels of Bcl-2, Bcl-XL, Mcl-1, Bim, Puma, and Bid were not 
modulated by TAT-RasGAP317-326 (Figure 6). Moreover, many Bcl-2 family proteins (Bcl-2, 
Bcl-XL, Mcl-1, Bim, Bmf and Bad) were shown to be dispensable individually for the 
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 sensitizing activity of the peptide. Second, the ability of TAT-RasGAP317-326 to increase 
genotoxin-induced Bax activation did not require caspase activation (Figure 5C). Therefore, 
the peptide does not amplify a positive feedback loop on Bax activation induced by the 
activation of caspases following cytochrome c release [22]. The fact that caspase inhibition 
does not prevent TAT-RasGAP317-326 from increasing genotoxin-induced Bax activation 
would rule out the implication of tBid generation in this process. Additionally, stimuli 
activating the extrinsic apoptotic pathway, hence caspase-8 and potentially the formation of 
tBid were not killing tumor cells better in the presence of the peptide (Figure 1). However, 
Bid can be cleaved by other cellular protease such as calpains and cathepsins [35] and there 
are indications that calpain-induced Bid cleavage plays an important role in cisplatin-induced 
apoptosis [36]. Taken together our data led us to the elaboration of the model proposed in 
Figure 10. Future studies will determine whether TAT-RasGAP317-326 targets Bax directly or 
indirectly. 
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Figure 10. Proposed model for the TAT-RasGAP317-326 mode of action. 
Genotoxin-induced DNA damage triggers an apoptotic cell death response that requires the p53/Puma axis as 
well as the generation of tBid for the full activation of Bax. Activation of Bax mediates mitochondrial membrane 
permeabilization and cytochrome c release with the consequent activation of caspase 3 and induction of 
apoptosis. TAT-RasGAP317-326 enhances the genotoxin-mediated activation of Bax in a tBid-dependent manner. 
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Introduction 
Radiotherapy is one of the most commonly used anti-cancer therapies. Its toxicity towards tissues 
surrounding the tumoral mass still remains a major concern in radio-oncology. In this work we 
wanted to ascertain if TAT-RasGAP317-326 sensitizes cancer cells to radiation-induced cell death, 
augmenting the killing efficacy of γ-irradiations. We provided evidence showing that TAT-
RasGAP317-326 efficiently potentiates the cytotoxicity of γ-irradiations in several cancer cell lines, 
but not in non-cancer cell lines, and, in combination with radiotherapy, it delays the tumoral 
growth in a xenograft mouse model. This suggests that TAT-RasGAP317-326 might be a good 
therapeutical tool to augment the efficiency of radiotherapy, allowing a reduction of the curative 
doses with consequent reduction or elimination of side effects in cancer suffering patients. 
 
Contribution 
I carried out this study in collaboration with Dr. David Viertl, we equally contributed to the data 
presented below in form of manuscript.  
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Introduction 
Radiotherapy is the treatment of choice in numerous tumor treatments and has offered 
incalculable benefits for cancer patients [1]. Radio-therapy induces DNA strand breaks that are 
lethal for the cell when extensive enough [4]. Despite technical improvements, radiation toxicity 
remains the major obstacle to effective therapy. Indeed, the toxic effects of radiotherapy on 
healthy tissues often limit the dose of γ-radiation that can be administered to tumors [2]. 
Therapeutic gain is defined by an increase in tumor control probability without a parallel increase 
in the severity of side effects. In an ideal setting, the probability of normal tissue damage should 
be minimal at a dose level that induces maximal probability of tumor control. Several strategies 
of combined modality treatments have been developed in order to improve the therapeutic index. 
The concept of using a radio-sensitizer was established in Heidelberger’s studies in 1958 by 
giving a drug in conjunction with radiotherapy to strengthen the effect of radiation [6]. Most of 
the clinical research published has reported successful use of traditional cytotoxic agents, 
nucleoside analogues or platinum compounds to improve radiotherapy. More recently non-DNA 
targeting compound such as growth factor inhibitors or inhibitors of tumor vasculature are being 
studied. However, most of these compounds show limitations in clinical use because of their 
intrinsic toxicity or limited radio-sensitizing effect [7]. Ideally, an optimal radio-sensitizer should 
exert no side effects by itself while being able to improve the potency of ionizing radiation. 
Our laboratory developed a chemosensitizer, TAT-RasGAP317-326, able to sensitize tumor cell 
lines and human tumor xenografts to chemotherapy [9]. In this study we explore the 
radiosensitizing properties of the TAT-RasGAP317-326. In particular, we show that TAT-
RasGAP317-326 sensitizes tumor cell lines and human tumor xenografts to radiotherapy 
irrespective of the p53 status. 
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Materials and methods 
Cell lines 
HCT116, HCT116 p53 -/- and HaCaT were cultured in DMEM (Invitrogen, ref. n°61965) 
supplemented with 10% heat-inactivated fetal bovine serum (FBS; Invitrogen, ref. n°10270-106) 
in 5% CO2 at 37°C. HeLa cells were cultured in RPMI (Invitrogen, ref. n°61870) supplemented 
with 10% heat-inactivated FBS in 5% CO2 at 37°C 
 
Peptide synthesis 
The HIV-TAT48-57 (GRKKRRQRRR) and TAT-RasGAP317–326 
(GRKKRRQRRRGGWMWVTNLRTD) peptides were synthesized at the Institute of 
Biochemistry, University of Lausanne, Switzerland using FMOC technology, purified by HPLC 
and tested by mass spectrometry. Peptides were diluted at a concentration of 1 mM in H2O and 
stored at -20°C 
 
Colony Formation Assay (CFA) 
Five hundred cells were seeded on 100 x 20 mm tissue culture dishes in 8 ml fresh culture 
medium. The following day they were irradiated (0, 1, 2, 4 Gy) using a Philips RT 250 gamma-
irradiator and treated. In experiments combining TAT-RasGAP317-326 and irradiation, cells were 
irradiated immediately after the addition of TAT or TAT-RasGAP317-326. After two weeks from 
the irradiation cells were fixed and stained with 0.5 % crystal violet in methanol/acetic acid (3:1, 
v/v). Colonies containing  50 cells were counted. Each experiment was repeated at least three 
times and the average of experiments was plotted with interval of confidence (95%). 
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Xenograft mouse model 
All experiments were performed according to the principles of laboratory animal care and Swiss 
legislation. The protocol was specifically approved by the cantonal veterinary service (VD 2243). 
Female homozygous athymic Foxn1nu/nu nude mice (Harlan) of 6 to 8 weeks of age were 
subcutaneously injected on the left and right lower flanks with 0.7 x 106 cells. After 5 days mice 
displaying tumor volume of 10 mm3 were randomly assigned to the different groups of treatment. 
Treated mice received every day, for 10 consecutive days, 3 Gy of -radiations on the lower back, 
with or without intraperitoneal injection of either TAT-RasGAP317-326 (1.65 mg/kg in 200 μl of 
PBS) or PBS (200 μl). Mice not exposed to irradiation were intraperitoneally injected either with 
PBS (200 μl) or with TAT-RasGAP317-326 (1.65 mg/kg in 200 μl of PBS). Tumors were measured 
3 times a week and tumor volume was calculated as length × width × height × π/6. When tumors 
reached 800 mm3 mice were sacrificed. 
 
Statistical analysis 
The R statistic software was used (http://www.r-project.org/). For CFAs, statistical differences 
between groups were determined by ANOVA followed by the post-hoc Tukey HSD test for 
multiple comparisons. For the in vivo experiments statistical differences between groups were 
determine by repeated measures ANOVA. Significant difference (p< 0.05) is indicated by *. 
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Results 
TAT-RasGAP317-326 sensitizes cancer cells, but not normal cells, to -radiations 
The radiosensitizing capacities of TAT-RasGAP317-326 were assessed by colony formation assay. 
Two different cancer cell lines WT for p53 (HCT116 and HeLa) and one lacking p53 (HCT116 
p53 -/-) showed reduced clonogenicity when exposed to increasing doses of -radiations. 
Interestingly, TAT-RasGAP317-326, while having no effect alone, in combination with -radiations 
significantly reduces the clonogenic potential of the analyzed tumoral cell lines, irrespective of 
the p53 status (Figure 1). It has also to be noticed that the cell permeable sequence TAT, alone or 
in combination with -radiations, has no influence on the number of colonies. On the contrary, 
the clonogenicity of a non tumoral cell line, HaCaT, exposed to irradiations, is not affected by the 
RasGAP-derived peptide (figure 1). These results are consistent with the previously reported 
specificity of TAT-RasGAP317-326 for cancer cells [8] and prove that the RasGAP-derived peptide 
sensitizes cancer cells to -radiations, independently of the p53 status. 
 
Tumor sensitizing activity of TAT-RasGAP317-326 
In order to evaluate the ability of TAT-RasGAP317-326 to sensitize tumors in in vivo settings nude 
mice were subcutaneously injected with HCT116 tumoral cells and the tumoral growth was 
recorded over time in the presence of the indicated treatment (Figure 2A). Mice treated with 
radiotherapy plus TAT-RasGAP317-326 developed statistically significant smaller tumor than mice 
treated with radiotherapy or with TAT-RasGAP317-326 alone.  
P53 is deleted or mutated in about 50% of human tumor [10] and this has been correlated with 
tumor resistance to radiotherapy [3;5]. Therefore we wondered whether our RasGAP-derived 
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peptides would keep its tumor sensitizing properties in p53-deficient tumors. Figures 2B shows 
that radiotherapy delays the tumoral growth of the p53 KO HCT116 xenografts, but it is evident 
that p53 deficient tumors are much more resistant to -radiations than p53 proficient tumors 
(compare 2A with 2B, open squares). Interestingly, when TAT-RasGAP317-326 was co-
administrated with radiotherapy, the p53 negative tumor growth was dramatically reduced, to 
more or less the same extent as the p53 positive tumors (compare 2A with 2B, filled triangles).  
Taken together these results show that, consistently with what was observed in vitro, TAT-
RasGAP317-326 sensitizes tumors to radiotherapy irrespective of the p53 status.   
 
 
Fugure 1.  TAT-RasGAP317-326 selectively sensitizes cancer cells to irradiation. HCT116, HCT116 p53 -/-, 
HeLa and non-tumoral HaCaT cells were subjected to the indicated doses of γ-radiation in the presence or not of 20 
μM TAT-RasGAP317-326 (P) and 20 μM TAT. Two weeks later, the number of colonies was recorded. The results 
correspond to the mean +/- 95%CI of at least independent experiments. The asterisks indicate a statistically 
significant difference (as assessed by ANOVA  between cells treated or not with TAT-RasGAP317-326 in the 
presence of the indicated doses of γ-radiations). 
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Figure 2. TAT-RasGAP317-326 greatly impairs radiotherapy-treated tumor development. 
Mice bearing wild-type (A) and p53 knock-out (B) HCT116 xenografts were subjected to one of the following 
treatements: 
1) Intraperitoneal PBS injections and no irradiation. 
2) Intraperitoneal TAT-RasGAP317-326 injections (every day, 1.65 mg peptide per kg of mouse in 300 
microliter of PBS) and no irradiation. 
3) Intraperitoneal PBS injection and gamma-irradiation (3 Gy; gamma-irradiation was performed 1 hour after 
the peptide injection). 
4) Intraperitoneal TAT-RasGAP317-326 injections and gamma-irradiation. 
The treatments (i.e. peptide injections followed by irradiation) were performed every day for 10 days without 
interruption. The size of the tumors was monitored 3 times a week. # : mice were sacrificed when the tumors reached 
a volume of about 800 mm3. Asterisks indicate a statically significant difference (as assessed by ANOVA repeted 
measures between groups subjected to irradiation and irradiation plus TAT-RasGAP317-326) 
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Discussion 
This study started the characterization of a new TAT-RasGAP317-326 facet. In fact, we 
demonstrate that the RasGAP-derived peptide is able to synergize with -radiations for the 
elimination of malignant cells. In particular, consistently with the results obtained combining 
TAT-RasGAP317-326to genotoxins, the RasGAP-derived peptide sensitizes different cancer cell 
lines and human tumor xenografts to irradiation. Moreover, as previously reported, TAT-
RasGAP317-326 does not have any pro-apoptotic function in non-cancer cells and no side effects on 
mice.  
Importantly, the TAT-RasGAP317-326-mediated sensitization to -radiations occurs independently 
of p53. P53 deletion or mutation are found in around half of human malignancies and are 
associated with tumor insensitivity to irradiation. In this work we showed that p53 deficient 
HCT116-generated tumors are effectively more radio-resistant than their p53 positive 
counterparts. Nevertheless,TAT-RasGAP317-326 is somehow able to convert p53 negative tumors 
into p53 proficient-like tumors, restoring their normal sensitivity to -radiations. The provided 
data are of high clinical and therapeutical importance because they show not only that TAT-
RasGAP317-326 is able to enhance the tumor killing potential of -radiations but also that it might 
be used to overcome the tumor resistance to radiotherapy due to p53 deletion/mutations.  
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DISCUSSION AND PERSPECTIVES 
The most used anti-cancer regimens rely on the utilization of DNA-damaging agents: genotoxins 
for the chemotherapy and ionizing radiations for radiotherapy. Unfortunately, these two kinds of 
therapies, besides targeting cancer cells, also damage healthy cells leading to the generation of 
side effects. Signaling circuits regulating apoptosis are often altered in cancer [1]. Strategies 
aimed to fix or to amplify the apoptotic circuitry in cancer cells would improve the killing 
potential of anti-cancer treatments. This approach would allow a reduction of the therapeutical 
doses, without affecting the toxicity of the treatments towards malignant cells, with consequent 
prevention of harmful effect on healthy tissues. In this sense cancer research devotes a lot of 
efforts to the design and development of therapeutic peptides targeting the apoptotic signaling 
pathway [2]   
Our laboratory early demonstrated that a cell permeable RasGAP-derived peptide, TAT-
RasGAP317-326, is able to selectively sensitize several cancer cell lines, but not non-cancer cell 
lines, to genotoxin-induced apoptosis [3]. This finding represented a very attractive starting point 
for a translational study where the potential of TAT-RasGAP317-326 as sensitizer could be tested in 
pre-clinical and clinical models.  
In the present work I first wanted to check if the ability of TAT-RasGAP317-326 to sensitize human 
cancer-derived cell lines to genotoxins could be extended to human tumors implanted in mice. In 
part I we showed that human tumors xenografted in nude mice treated with TAT-RasGAP317-326 
plus cisplatin or doxorubicin grow significantly slower than tumors implanted in mice treated 
with the peptide or the genotoxin alone [4]. Importantly, the doses of cisplatin and doxorubicin 
we used have almost no effect on the tumoral growth by themselves and do not induce any 
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detectable toxic effects in treated mice. Similarly, TAT-RasGAP317-326 alone has no effect on the 
tumoral growth, demonstrating that the RasGAP-derived peptide strongly potentiates the 
genotoxin capacity to shrink tumors. These findings are of particular interest from a clinical and 
therapeutical point of view because they represent the proof of principle that TAT-RasGAP317-326 
may be used to augment the efficacy of chemotherapy in cancer suffering patients, especially 
when the therapeutical doses have to be lowered to avoid harmful side effects. 
As mentioned above, radiotherapy is a widely used anti-tumor therapy and, in spite of the 
excellent advances made in term of delivery to the tumoral mass, its toxicity towards tumor 
surrounding tissues still remains a limitation. In part V we showed that TAT-RasGAP317-326 
sensitizes both human tumor cell lines and human tumor xenografts to radiotherapy. Importantly, 
this tumor sensitization occurs irrespective of the p53 status. Indeed, p53-deficient human colon 
cancer HCT116 cells, as well as HCT1116 p53-positive cells, were sensitized to radiotherapy and 
the expected resistance of p53-negative tumor xenografts to γ-radiations was overridden by TAT-
RasGAP317-326. These findings are relevant for two reasons: i) they show that TAT-RasGAP317-326 
is a good radio-sensitizer in vivo and its application may be envisaged in cancer suffering patients 
to increase the efficacy of radiotherapy and limit side effects; ii) p53-deleted/mutated cancers 
represent around half of the human malignancies [5] and the fact that TAT-RasGAP317-326 
overcomes their resistance to irradiation greatly extends the potential field of use of our peptide.  
Although the presented data highlight the in vivo therapeutical potential of TAT-RasGAP317-326, 
further pre-clinical study will have to be performed in order to be able to start a phase I of clinical 
trials. In particular two points will be object of future studies: bio-distribution and anti-tumoral 
effect on immune-competent mice. Bio-distribution studies will be performed using a 125I-
radiolabeled peptide in mice; they will give us a clear view of the incorporation, accumulation 
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and elimination of TAT-RasGAP317-326 in various organs as well as in tumors. The immune 
system was described to significantly contribute to the elimination of tumors subjected to specific 
chemotherapeutic agents (e.g. oxaliplatin) or radiotherapy. Hence we will evaluate the ability of 
TAT-RasGAP317-326 to potentiate the effect of γ-radiations in a syngeneic mouse model using 
B16F10 melanoma cell line that can grow subcutaneously in immune-competent C57BL/6 mice.  
Understanding the mode of action allowing TAT-RasGAP317-326 to sensitize cancer cells to 
genotoxin-induced apoptosis would be of great relevance for anti-cancer therapy. Indeed it might 
help to identify a (new) mechanism of cancer resistance to apoptosis induced by genotoxins and 
to design more targeted and efficient anti-tumor strategies. Our first candidate that could 
potentially act as TAT-RasGAP317-326 effector was G3BP1 (RasGAP SH3 Binding Protein 1). 
Indeed G3BP1 was reported to bind to RasGAP on the very same sequence that forms the active 
peptide sequence (amino acids 317-326) [6]. Evidence we provided in part III shows that G3BP1 
is not involved at all in the TAT-RasGAP317-326-mediated sensitization to genotoxin-induced 
apoptosis, as shown by G3BP1 KO MEFs that are still sensitive to the peptide [7]. Moreover the 
lack of interaction reported between G3BP1 and RasGAP or the RasGAP-derived fragment N2 
(the fragment from which the peptide active sequence 317-326 was identified) pushed us to 
reconsider G3BP1 as a RasGAP binding protein.  
Earlier study conducted in our laboratory showed that TAT-RasGAP317-326 potentiates the 
genotoxin-induced mitochondrial apoptotic pathway by an enhancement of the mitochondrial 
membrane depolarization and an increased processing of caspase 3 [8]. It was also shown that 
p53 and Puma are required by the sensitization event to occur but their protein levels are not 
modulated by TAT-RasGAP317-326 [8]. We now know that the p53/Puma axis is only required for 
the TAT-RasGAP317-326-mediated sensitization to short term apoptosis, whose induction needs the 
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presence of p53, but it is dispensable for the peptide-mediated impairment of cell survival 
observed long term after the administration of genotoxins. This last observation suggests that 
TAT-RasGAP317-326 might also potentiate p53-independent mechanisms of cell death occurring 
with a slower kinetic than short-term apoptosis (e.g mitotic catastrophe).  
In order to explain the increased mitochondrial membrane depolarization observed when TAT-
RasGAP317-326 is combined to genotoxins, we assessed the activation status of Bax. Bax is a 
member of the Bcl-2 family, a group of protein that tightly regulates mitochondrial integrity 
[9;10]. Particularly, Bax is directly able to trigger the mitochondrial membrane permeabilization 
and the release of cytochrome c [11;12]. Our data demonstrate that TAT-RasGAP317-326 
potentiates the genotoxin-mediated activation of Bax. We also show that this peptide-mediated 
enhancement of Bax activation is most likely Bid-dependent. Bid is a member of the Bcl-2 family 
belonging to the BH3-only sub-group.  In cell-free system truncated Bid (from now on referred to 
as tBid) was shown to directly activate Bax, leading to mitochondrial cytochrome c release 
[11;12]. In this study, using HeLa-isolated mitochondria, known to contain inactive Bax, we 
show that the addition of tBid triggers cytochrome c release. Interestingly, the t-Bid-mediated 
cytochrome c release was potentiated by TAT-RasGAP317-326. This suggests that the peptide most 
probably needs tBid to enhance the activation of Bax, which is then translated into an increase of 
cytochrome c release and, in a cellular system, into more apoptosis.  
However it remains to be determined if TAT-RasGAP317-326 directly favors the tBid-mediated 
activation of Bax or if it needs a mitochondrial or cytoplasmic protein (HeLa-isolated 
mitochondria still contain cytoplasmic material). To answer this question a much purer system 
will be employed: rat liver-isolated mitochondria that do not contain at all cytoplasmic material, 
including Bax [13], which has to be provided as recombinant protein. Using this system it would 
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be possible to ascertain if TAT-RasGAP317-326 needs the presence of a cytoplasmic protein. 
However if TAT-RasGAP317-326 would still favor cytochrome c release in rat liver mitochondria, 
the possibility that this effect is mediated by a mitochondrial protein cannot be ruled out. This 
issue will be addressed by using liposomes (synthetic vesicles made of lipid bilayer, containing a 
fluorescent compound) [14] incubated with Bax and tBid in the presence or not of TAT-
RasGAP317-326 and the release of the fluorescent compound will be used as read-out for membrane 
permeabilization. 
The understanding of how TAT-RasGAP317-326 favors the activation of Bax could allow the 
design and development of more specific strategies to potentiate the genotoxin-mediated cell 
death process in cancer cells and therefore to improve chemo and radiotherapy with high 
beneficial effects for cancer patients. 
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Standard protocols from the Widmann’s laboratory
used during this thesis work
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Reagents 
 
1. HEPES buffer  (2X) pH 7.05 (23°C): 
 
1.1. Important note: always calibrate the pH meter before starting preparing the Hepes buffer. 
1.2. Composition. 
Chemicals Final concentration Source/Company Code/quantities 
    
NaCl 280 mM Fluka 71380 (1 kg) 
KCl 10 mM Fluka 60130 (1 kg) 
Na2HPO4 1.5 mM Merck 1.06586.0500 (500 g) 
D-glucose•H2O 12 mM Merck 1.08342.1000 (1 kg) 
HEPES 50 mM Fluka 54461 (250 g) 
    
 
1.3. Recipe. 
Chemicals For 500 ml 
  
NaCl 8 g 
KCl 0.38 g 
Na2HPO4 0.1 g 
D-glucose•H2O 1.1 g 
HEPES 5 g 
Adjust pH with NaOH (1 N, then 0.1 N) to 
7.05 (23°C) 
See 1.4 
  
 
1.4. Add ddH2O to about 450 ml, then adjust to pH 6.8-6.9 with 1 N NaOH, and finally to pH 
7.05 with 0.1 N NaOH. Complete to 500 ml with ddH2O. Control that the pH is still at 7.05. 
1.5. Sterilize through a 0.22 µm 500 ml Stericups (Millipore #SCGPU05RE). Under a sterile 
hood, aliquot in 50 ml tubes (40 ml per tube). Write the lot number and the date on the tubes 
(the lot number should be indicated in your laboratory book). Store at –20°C.  
 
2. Others 
Chemicals Source/Company Code/quantities Solvent [stock] Storage Sterile 
       
NaOH Fluka #71690 (500 g) ddH2O 10 N Room temp. no 
Chloroquine Sigma C6628 (25g) PBS 25 mM -20°C yes 
CaCl2•2H2O (MW 
147.02) 
Acros 207780010 (1 kg) ddH2O 2.5 M 4°C yes 
Gelatin Fluka 48722 (500 g) PBS 0.1% 4°C yes 
DMEM, glutamax I, 
4.5 g/l glucose, sans 
sodium pyruvate 
Gibco 61965026 (500 ml)     
Newborn calf serum 
(NBCS), heat 
inactivated 
Gibco 26010041 (500 ml)     
       
 
2.1. Preparation of NaOH solutions. 
NaOH can cause irreversible damage to the eyes. It is thus mandatory to wear glasses when 
preparing or using NaOH solutions. The preparation of 10 N NaOH involves a highly 
exothermic reaction, which can cause breakage of glass container. Prepare this solution with 
extreme care in plastic beakers. To 80 ml of H2O, slowly add 40 g of NaOH pellets, stirring 
continuously. As an added precaution, place the beaker on ice. When the pellets have 
dissolved completely, adjust the volume to 100 ml with H2O. Store the solution in a plastic 
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container at room temperature (plastic containers are to be used because NaOH slowly 
dissolves glassware). Sterilization is not necessary. 
 
2.2. Preparation of a 25 mM chloroquine solution. 
In a 50 ml Falcon tube, add 0,645 gr of chloroquine and complete to 50 ml with ddH2O. 
Transfer to a 50 ml syringe and sterilize through a 0.22 µm filter (Millex – GV filters 
[Millipore #SLGV025LS]). Under a sterile hood, aliquote in 15 ml tubes (10 per tube). Write 
the lot number and the date on the tubes (the lot number should be indicated in your 
laboratory book). 
 
2.3. Preparation of a 2.5 M CaCl2 solution. 
In a 50 ml Falcon tube, add 18.4 g of CaCl2•2H2O and complete to 50 ml with ddH2O. 
Transfer to a 50 ml syringe and sterilize through a 0.22 µm filter (Millex – GV filters 
[Millipore #SLGV025LS]). Under a sterile hood, aliquote in 15 ml tubes (10 per tube). Write 
the lot number and the date on the tubes (the lot number should be indicated in your 
laboratory book). 
 
2.4. Preparation of a PBS/0.1% gelatin solution (500 ml). 
Add 0.5 g gelatin and 50 ml PBS 10X to 450 ml ddH2O in a glass bottle. Autoclave and store 
at 4°C. 
 
___________________________________________________________________________________ 
 
 
Procedure 
 
Day 0. 
1. Plate cells in appropriate medium (use gelatinized dishes if required). 
Cells Number per 10 
cm dish 
Number per well (6 
well-plates) 
medium Gelatinized 
dish 
     
HEK 293 and 
derived cell lines 2
.106 350’000 DMEM; 10% NBCS yes 
COS cells   DMEM; 10% NBCS no 
     
 
1.1. Gelatinization of the dishes. 
Place the indicated volume of PBS/0.1% gelatin in the dish (tilt the plate to cover the entire 
surface with the solution). Wait at least 10 min. Just before adding the cells to the plates, 
aspirate the PBS/0.1% gelatin (do not allow the plates to dry). 
Dish size Volume of PBS/01% gelatin 
  
10 cm 2-5 ml 
6 well plates 0.5 ml 
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Day 1. 
2. Prewarm the HEPES 2X buffer in a 37°C water bath (at least 20 min). In case the buffer is thawed, 
mix very well before using. 
 
3. Add the DNA in the indicated volume of H2O. Add the corresponding volume of 2.5 M calcium 
solution. Mix 10 times by pipetting the solution up and down. Allow 20-30 min the solution to 
equilibrate. 
Cells Dish size Volume of 
medium in the 
dish 
DNA 
amount 
Volume of water in 
which the DNA is 
added 
Volume of 2.5 M 
calcium to be added 
      
HEK293 10 cm 10 ml 5-20 µg 450 µl 50 µl 
 6 well plate 2 ml 2 µg 90 µl 10 µl 
 
4. Add 25 µM chloroquine to the cell culture medium (not necessary to change the medium). 
Note: if the cells are grown in RPMI medium (e.g. HeLa cells), you have to replace it with DMEM 
because RPMI medium is not compatible with the present transfection technique. 
Dish size Volume of medium Volume of stock 
   
10 cm 10 ml 10 µl 
6 well plates 2 ml 2 µl 
 
5. Place the plates back in the incubator for at least 10 min. 
 
6. Add the indicated volume of prewarmed (37°C) 2X HEPES buffer to the DNA/calcium solution, 
mix 5 times by pipetting the solution up and down. Incubate for 1 minute exactly (starting from the 
moment the HEPES has been added to the DNA; not from the time when the mixing is finished). 
Put the DNA-HEPES mix in the culture medium (rock the plate left to right and up and down 2 
times). 
 
Dish size Volume of HEPES 2X to be added 
  
10 cm 500 µl 
6 well plate 100 µl 
  
 
 
7. Incubate the cells at 37°C for 8-16 hours (always mention this time of incubation in your 
laboratory book). Replace the transfection medium with normal culture medium containing 
penicillin and streptomycin [use a 1:100 dilution of a Penicillin-Streptomycin Glutamine 100X 
solution (10’000 units/ml penicillin G; 10 mg/ml streptomycin sulfate; 29,2 mg/ml L-glutamine; 
10 mM sodium citrate; 0.14% NaCl {GibcoBRL #10378-016})] to avoid contamination (the DNA 
used for the transfection is generally not sterile!). 
 
8. Expected transfection efficiencies (count at least 500 cells). 
Cells Transfection efficiency 
  
HEK293 30-80% 
COS 30-40% 
  
 
9. In your laboratory book, always mention how long after step 7 were the cells analyzed. 
___________________________________________________________________________________ 
 
References 
 
153
1. Jordan et al. - Nucl. Acid Res. (1996) 24:596 (#3461) 
 
154
Reagents 
 
Chemicals Source/Company Code/quantities 
   
Lipofectamine 2000 (1 mg/ml) Gibco/Invitrogen 11668-019 (1.5 ml) 
RPMI1640 Medium SIGMA R8758 (500 ml) 
DMEM SIGMA D5796 (500 ml) 
Newborn calf serum, heat inactivated SIGMA N4637 (500 ml) 
15 ml polystyrene round-bottom tube Becton Dickinson 352057 
   
 
___________________________________________________________________________________ 
 
Procedure 
 
Day 0. 
1. Plate cells in appropriate medium according to Table I. 
 
Table I 
Cells Number per 10 cm dish Number per well of 6 
well-plates 
medium 
    
HeLa cells 0.5-2.106 
(use 0.5.106 cells for P-Akt assay) 
4 105 RPMI, 10% 
NBCS 
    
 
Day 1. 
a. Add the required DNA amounts at the bottom of sterile Eppendorf tubes (see column 3 of 
Table II). Using a 2 ml plastic pipette, add the serum-free medium (for the volume of medium 
to be used, please refer to column 3 of Table II). Using the same plastic pipette, transfer the 
required volume of serum-free medium to the 15 ml polystyrene round-bottom tubes (for the 
volume of medium to be used, please refer to column 4 of Table II). 
b. Mix the Lipofectamine 2000 stock solution gently before use, centrifuge quickly to pellet the 
drops to the bottom of the tube, and then add the Lipofectamine 2000 to the serum-free 
medium that has been placed in the 15 ml tubes (for the volume of Lipofectamine 2000 to be 
used, please refer to the column 4 of table II). Mix gently and incubate 5 minutes at room 
temperature. 
c. Using 1 ml tips, add the diluted DNA drop by drop to the diluted lipofectamine2000. Mix 
gently and incubate 20 min at room temperature. 
d. Just before the next step, wash the plates twice with serum-free culture medium (see column 5 
of Table II for the volumes to be used). 
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e. Add serum-free culture medium to the DNA + lipofectamine mix with a 5 ml plastic pipette 
and, using the same plastic pipette, add this mixture to the cells (refer to column 6 of Table II 
for the volumes to be used). 
f. Incubate 5 hours at 37°C in a CO2 incubator 
g. After 5 hours replace the medium with serum-containing medium (use twice as much as the 
volumes indicated in column 5 of Table II). The cells can then be processed according to the 
experimental design. 
 
 
Table II 
1 2 3 4 5 6 
Cells Dish size Total DNA 
amount (µg) and 
Dilution 
Volume (µl) 
Lipofectamine 
2000 (µl) and 
Dilution Volume 
(µl) 
Washing 
steps 
(volume to 
be used) 
Volumes of 
serum-free 
medium to be 
added to the 
Lipofectamine-
DNA mix 
      
HeLa 10 cm dish 7 µg in 600 µl 8-10 µl in 600µl 5 ml 3.8 ml 
HeLa 6 well-plate 4 µg in 250 µl 4 µl in 250 µl 2 ml 1.5 ml 
      
 
_________________________________________________________________________________ 
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Apparatus 
Transfer tank located in the drawers next to Christian’s office door. It is the transparent tank containing 
red-black electrode module inside. Gel cassetes and sponges are either in the drawer above the one containing 
the tanks or above the sink  in the middle of the lab.  
 
 
 
 
 
 
Materials and reagents 
1. Plastic sheets, commercial Enhanced chemiluminescence (ECL) solution and other reagents. 
1.1. Materials and reagents. 
Materials and reagents Source/Company Code/quantities 
   
Plastic sheets 
Kapak Tubular Roll Stock 
[9.5’’x250’ #5 Scotchpak (2 
Mil)]. 
Kapak Parkdale Drivewe, 
Minneapolis, Minnesota 55416 • 
1681 
 
Tris Sigma T1503 5Kg 
Tween Acros p7949 100ml 
Milk   
ECL reagent 
Supersignal West Femto 
Substrate 
Pierce #34095 
Ponceau S Acros 161470250 (25 g) 
   
   
 
 
1.2. Ponceau S Staining Solution [0.1%(w/v) Ponceau S in 5% (v/v) acetic acid] 
• 1g Ponceau S  
• 50ml acetic acid  
• Make up to 1 liter with ddH2O  
Store at 4oC. Do not freeze. 
 
Alternative recipe:0.2% (w/v) Ponceau S in 3% (v/v) acetic acid. 
 
1.3. Tris-buffer saline (TBS; 18 mM HCl, 130 mM NaCl, 20 mM Tris pH 7.2) 
• 30ml HCl 
• 152g NaCl 
• 48g Tris base 
• Up to 1L dH2O 
 
 
1.4. TBS/tween 
• 19L dH2O 
• 1L 20X TBS 
• 0.1% Tween (final concentration) 
 
 
1.5. TBS/milk 
• 5% powdered milk (25g for 500ml of TBS/tween) 
• TBS/tween 
• Alternatively some primary antibodies work better if they are diluted in 5% BSA (5%BSA in 
TBS/tween) 
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2. Home-made ECL solution. 
 
2.1. Composition of the stocks. 
Chemicals Stock 
concentration 
Final concentration Source/Company Code/quantities 
     
Luminol (3-
aminophthalydrazid
e) 
250 mM (1 g in 
22.7 ml DMSO). 
Make 1.5 ml 
aliquotes 
1.25 mM Sigma A-8511 (1 g) 
P-coumaric acid 90 mM (0.5 g in 
33.3 ml DMSO). 
Make 660 µl 
aliquotes. 
0.2 mM Acros 12109-0250 (25 g) 
Tris 1 M pH 8.5 100 mM Boehringer 
Mannheim 
708976 (1 kg); IBCM 
stock 
H2O2 30% 30% 0.01% Merck 1.07210.0250 (250 ml) 
     
Solution 1: 2.5 mM luminol and 0.4 mM coumaric acid in 100 mM Tris pH 8.5. 
Solution 2: 0.02% H2O2 in 100 mM Tris pH 8.5. 
 
 
3. Home-made enhanced ECL solution Note: for the moment this is not working (use the above recipe 
instead). 
 
3.1. Composition of the stocks. 
Chemicals Stock 
concentration 
Final concentration Source/Company Code/quantities 
     
Luminol (3-
aminophthalydrazid
e) 
250 mM 1.25 mM Sigma A-8511 (1 g) 
p-iodophenol (in DMSO) 50 µM   
Tris 1 M pH 8.5 100 mM Boehringer 
Mannheim 
708976 (1 kg); IBCM 
stock 
H2O2 30% (8.82 M) 30% 2 mM Merck 1.07210.0250 (250 ml) 
     
 
 
___________________________________________________________________________________ 
Procedure 
 
1. General remarks. 
1.1. The conditions of incubation of the blots have to be adapted for each antigen and each antibody used. 
Therefore, the procedures presented in the following sections have to be considered as general 
guidelines and should not be assumed to work in all cases. Indications of possible improvements when 
the conditions are not found optimal will be mentioned. 
1.2. Always centrifuge the tubes containing the antibodies before usage. 
1.3. In principle, do not incubate two blots in the same bag. 
1.4. Never touch the blot with bare hands. Use gloves and move the blots with tweezers. 
1.5. The following procedure should be considered only for the small gels (see SOP12.1). 
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2. Migration on gels. 
 
Percentage of acrylamide Separation 
  
8% 40-200 kDa 
10% 30-200 kDa 
12% 20-200 kDa 
4-20% 7-250 kDa 
8-16% 15-250 kDa 
  
 
 
3. Transfer to membranes. 
3.1. After migration, proteins are transferred to nitrocellulose filters (Schleicher and Schuell, BA83 0.2,µm, 
no. 401380) or PVDF membranes. Instruction on how to do this can be found in the same drawer as the 
material used for the transfer and for the SDS-PAGE (see SOP 12.1). 
3.2. Transfer buffers. 
David has recently tested the two following buffers. According to him, transfer buffer II works better. 
 
Composition of transfer buffer I. 
Chemicals Stock solution Final 
concentration 
Source/Company Code/quantities 
     
CAPS 1M pH11 10 mM Acros 172621000 (100 g) 
Methanol  10% Fluka 65543 (5 l) 
     
CAPS 1M stock solution (500 ml): 110 g CAPS (MW 221.3) and 20 g NaOH in water. The pH should be 11. 
Store in the dark at 4°C. 
Prepare the transfer buffer (5 liters) directly in the transfer tank (50 ml CAPS 1M, 500 ml methanol, and water 
up to 5 liters). 
Methanol evaporation ensures that the buffer does not heat too much. Therefore the transfer buffers cannot be 
used too many times. Without methanol, the buffer would boil during the transfer! 
Transfer o/n at 600 mA. 
 
Composition of the transfer buffer II. 
Chemicals 10X stock (1 liter) Final concentration 
(1X transfer buffer) 
Source/Company Code [quantities] 
Tris 30.2 g 1 mM Biosolve ltd 20092388 [4 kg] 
Glycine 144 g 8 mM ACROS 120070050 [5 kg] 
SDS 10 ml of a 10% 
solution in water 
0.001% Biosolve ltd 19822359 [0.5 kg] 
Prepare the transfer buffer 1X (5 liters) directly in the transfer tank. 
Add 500 ml of the 10X buffer, 1 liter of methanol and water up to 5 liters. 
Transfer 5 hours at 660 mA. 
 
Currently the situation with the transfer buffers is like this: they are located above the sink were other materials 
for the transfer can also be found (sponges, etc.), There are several bottles of 10x transfer buffer. In order to 
make 1x transfer buffer, mix 100 ml of the 10X preparation with 700ml of water and 200ml of some alcohol 
(methanol or ethanol). 
 
 
3.3  After preparing the transfer tank, place the top on and plug it into a power supply machine (make 
sure that the plus and minus plugs are connected right: you do not want your proteins to be released 
on the wrong side directly into the transfer buffer). Transfer is usually preformed at 250 mA (constant 
amperage) for one hour or one hour and twenty minutes. 
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3.4 Check if the protein markers have been transferred (one should see the markers on the membrane and 
not on the gel). 
 
 
 
4. This protocol should be used when there are no particular problems to get a strong signal 
 
4.1. Ponceau S Stain for Western blots. 
Background. This is a rapid and reversible staining method for locating protein bands on Western blots.  Sensitivity is somewhat 
less than Coomassie blue and produces reddish pink stained bands; minor components may be difficult to resolve.  The stain is 
useful because it does not appear to have a deleterious effect on the sequencing of blotted polypeptides and is therefore one 
method of choice for locating polypeptides on Western blots for blot-sequencing.  The stain binds strongly to nylon-based filter 
media but is fine for nitrocellulose and PVDF membranes.  Incubate the membrane for up to an hour in staining solution with 
gentle agitation.  Rinse the membrane in distilled water until the background is clean.   The stain can be completely removed from 
the protein bands by continued washing.  Stain solution can be re-used up to 10 times.  
How we use it in the laboratory. Incubate the blot in Ponceau for 2-3 min to visualize the proteins and 
to determine whether the transfer was homogeneous. With a pen, mark the position of the molecular 
weight markers. The blots are then subjected to the following incubations. 
4.2. wash 3x 20 min at room temperature with TBS/0.1% Tween 20 (TBS/Tween; found in the big tank next 
to the sink near the entrance of the laboratory). 
4.3. 45-60 min at room temperature with TBS/5% powdered milk (TBS/milk). 
4.4. overnight with the primary antibody (in TBS/milk) at 4°(in a cold room). 
4.5. 3x 20 min at room temperature with TBS/Tween. 
4.6. 45 min at room temperature with TBS/milk. 
4.7. 45 min with the secondary antibody (in TBS/milk) at room temperature (if the secondary antibody bears 
a fluorochrome sensitive to light [e.g. antibodies required for the odyssey detection; see SOP 17], make 
sure that incubation is performed in a black box ). 
4.8. 3x 20 min at room temperature with TBS/tween (in the dark). 
 
5. Detection of the secondary antibodies on films. 
5.1. This method should be used only for antibodies and antigens that do not generate strong signals. If this 
is not the case, detect the secondary antibodies with the BioRad Fluor-S imager (refer to SOP 2.0) or 
even better with the Odyssey apparatus (see SOP 17). 
5.2. Check that the developer has been turned on and is ready to be used. 
5.3. Prepare a cassette that should contain a fluorescent ladder (to position your film on the blot later on). 
5.4. Wash a glass plate thoroughly (first with soap, rinse with water and finally with ethanol). 
5.5. Prepare the ECL reagent by mixing equal volumes of solutions I and II. You need about 1 ml for each 
10 cm2 of your blot. 
5.6. Cut some Kappak plastic sheet that will be used to contain your blot during the exposure to films. Seal 
it but leave one side open. 
5.7. Take the blot with tweezers and touch some absorbing paper with one of its corner to remove the liquid 
in excess. Place the blot on the glass plate with the transferred proteins up. Pour the ECL reagent on the 
blot. Check that the whole surface is covered and wait one minute. 
5.8. With tweezers, transfer the blot in the Kappak bag. Remove the bubbles and seal the bag. Using 
absorbing paper, remove the liquid on the exterior of the bag. Place the bag in the cassette as close as 
possible to the fluorescent ladder. Tape the bag on one side. 
5.9. Immediately, go to the dark room with the sealed blot, the films and a cassette. Place a film on the blot. 
Close the cassette. Wait one minute. Remove the first film that you insert in the developer. While the 
first film develops, place a second one on the blot and close the cassette. When the first film comes out, 
check the intensity of the signal. If it is weak, expose the second film for 5-15 min. If it is too strong, 
develop the second film immediately (it will of course be too dark too) and expose a third film to 5-15 
seconds. If the film has to be exposed for 1-2 seconds, tape it on the other side of the cassette. This will 
ensure that when you close the lids, the film will not move. Note again that if the signal is strong, you 
should not use this technique (see point 3.1). 
5.10. Keep all the films (the overexposed ones are often used to position the molecular weight markers). All 
the films should be labeled (do it immediately) with the date, the experiment number, the exposure 
time, the type of ECL used, and the experimental conditions for each lane. Also try (when possible) to 
identify the bands on your blots. 
 
6. Detection of the secondary antibodies with the BioRad Fluor-S imager. 
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6.1. Refer to SOP 2.0. 
6.2. In this case also, the images obtained should be labeled: date, the experiment number, the exposure 
time, the type of ECL used, and the experimental conditions for each lane. Also try (when possible) to 
identify the bands on your blots. 
 
7. Quantitation of the ECL signal. 
7.1. In principle, quantitation should not be performed using films because the signal on films is not linear 
(you need more that one photon to active the silver grains) and saturates rapidly. 
7.2. If possible, quantitation should be performed using the BioRas Fluor-S imager. Please refer to SOP 2.0. 
 
8. Detection of the secondary antibodies using the Odyssey system (Licor). 
8.1. Refer to SOP 17. 
 
9. No signal 
9.1. Increase the incubation with the antibodies: o/n incubation with the first antibody and 2-4 hours with the 
secondary antibody. Perform the incubations at 4°C. 
9.2. Reduce the “stringency” of the incubation buffer. Milk containing buffer can possibly quench a fraction 
of the antibody. The following buffers are ranked from highest to lowest stringency: milk-containing 
buffer, BSA containing-buffer, tween-containing buffer, PBS or Tris buffer. 
 
10. How to store antibodies. 
10.1. It is possible to reuse antibodies many times and this should be done whenever the antibody is rare and 
not available commercially. The solution containing the antibody needs to contain 0.05% azide (NaN3) 
and 10 mM EDTA. 
 
11. Very important: after completion of the Western blot procedure, always store the nitrocellulose membranes 
in Kappak bags at -20°C for further potential use. 
 
___________________________________________________________________________________ 
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Reagents 
 
 
 
Chemicals/medium Source/Company Code/quantities 
   
JETstar maxi Genomed 20 prep (#220020) 
Isopropanol   
Glycerol   
Tris   
EDTA   
 
TE: Tris 10 mM pH 7.4, EDTA 1 mM. 
___________________________________________________________________________________ 
 
 
 
Bacteria culture 
 
1. For most plasmids, inoculate 250 ml of LB with the appropriate antibiotic (see SOP 8.0) with: 
- a tip that has touched a colony on an Agar plate 
- a few ml of a mini-prep culture 
- a chunk of a glycerol stock taken with a yellow tip 
2. Incubate o/n at 37°C in a shaker. 
3. If required, take 1 ml of the culture to prepare a glycerol stock (put this one ml in an Eppendorf tube, 
centrifuge in an Eppendorf centrifuge at 4’000 rpm for 5 min, discard the supernatant and resuspend 
the pellet in 300-500 µl of a sterile 10% glycerol solution; store at –70°C). 
 
Maxi prep 
 
1. Principle. 
The procedure employs a modified alkaline/SDS method to prepare the cleared lysate. After 
neutralization, the lysate is applied onto a JETstar column and the plasmid DNA is bound to the anion 
exchange resin. Washing the resin removes RNA and all other impurities. Afterwards, the purified 
plasmid is eluted from the column and finally concentrated by alcohol precipitation. 
The supplier says that the JETstar purified plasmid DNA is of a higher quality than 2 x CsCl purified 
plasmid DNA. 
The expected yield for a maxi column is between 300-500 µg of DNA. 
 
2. Centrifuge the cultures in 250 ml bottles at 5’000 rpm for 5-10 min at 4°C using the GSA rotor in the 
Sorvall RC-5B centrifuge. Check that the rotor is clean before and after use. Clean if necessary and 
always remove any liquid present. 
3. Place the column on the “blue cow”. Add 30 ml of solution E4 in the column and let flow by gravity. 
4. Note: RNAse must be added to solution E1 prior to its first use. Just poor the lyophilized RNAse 
powder into bottle E1 and mix. Add the sticker indicating that the RNAse has been added, the date and 
your name. 
Discard the supernatant. Resuspend the pellet in 10 ml of solution E1. 
5. Add 10ml of solution E2 and mix gently. Incubate 5min at room temp on a rocker (Rocker lnotech; 
shake 9, timer 5, frequency 17). 
6. Add 10 ml of solution E3 and mix immediately by inverting the bottle 5 times. Transfer to a 50 ml blue 
Falcon tube (do not use yellow Falcon tube since they are more fragile and may break during the 
centrifugation). Centrifuge at 9’000 rpm for 10 min at 20°C using the SLA 600TC rotor in the Sorvall 
RC-5B centrifuge. 
7. Poor the supernatant on the column and let flow by gravity. Wash the resin with 60 ml of solution E5. 
8. Place the column on a 50 ml blue Falcon tube and secure the column on the tube with tape. Add 15 of 
solution E6 and let flow by gravity. 
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9. Add 10.5 of isopropanol. Mix and incubate on ice for at least 1 hour (alternatively, the tube can be 
stored o/n at –20°C). 
10. Centrifuge at 10’000 rpm for 30 min at 4°C using the SLA 600TC rotor in the Sorvall RC-5B 
centrifuge. Discard the supernatant being very careful not to loose the pellet that is not always firmly 
adherent (sometimes not at all). 
11. Add about 20 ml of 70% ethanol. Centrifuge at 10’000 rpm for 10 min at 4°C using the SLA 600TC 
rotor in the Sorvall RC-5B centrifuge. Discard the supernatant as above. Aspirate all the residual drops 
with a long white tip. 
12. Resuspend the pellet in 500 µl of TE. 
13. Measure the concentration with the spectrophotometer using a 1/100 dilution in a quartz cuvette. One 
OD at 260 nm corresponds to 50 µg/ml of DNA. The ratio between the OD at 260 nm and the OD at 
280 nm should be between 1.8 and 2.0. 
14. Write down the concentration of the maxi prep in the plasmid files as well as on the tube. 
 
___________________________________________________________________________________ 
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Materials and reagents 
1. coverslips keep in ethanol 100% 
Materials and reagents Source/Company Code/quantities 
   
PBS 10 X 
 
? ? 
0.2% TX-100 in PBS 
 
 
 
 
 
 
PBS 1X, 3% 
paraformaldehyde, 
3% sucrose 
  
Gelatin Fluka 48722 (500 g) 
Mounting medium   
Antibody   
   
 
1.1. Preparation of a PBS/0.1% gelatin solution (500 ml). 
Add 0.5 g gelatin and 50 ml PBS 10X to 450 ml ddH2O in a glass bottle. Autoclave and store at 4°C. 
 
 
 
2. List of antibodies  
 
Name of Ab Name of 
epitope or 
antigen 
Origin of 
Ab 
Source 
 
Company or 
source 
Dilution 
      
 
___________________________________________________________________________ 
Procedure 
 
Preparation of coverslips 
 
Growing cells on coverslips 
1. In a sterile hood, take a coverslip from the ethanol bottle with tweezers. Set fire to the ethanol by passing 
quickly the coverslip over the flame. When all the ethanol has burnt and evaporated, place it in the 
appropriate culture plastic-ware. If required, coat the wells and the coverslips with PBS/0.1% gelatin for at 
least 10 minutes. Remove the PBS/gelatin if present and add the cells to the wells. Transfect or infect the 
cells if required. 
 
Immunocytochemistry 
1. Fill the required number of wells of 6-well plates with ~3ml PBS 1X (these 6-well plates can be used over 
and over). With tweezers, transfer the coverslips to the 6-well plates (face up). This can be performed under 
a sterile hood with sterile devices if the rest of the cells (i.e. cells not on the coverslips) have to be kept in 
culture. 
2. After this step, the procedure can be continued on the bench. Use ~20°C solutions (solutions that have been 
kept at room temperature). 
3. Aspirate the PBS 1X and put gently 3ml of PBS 1X, 2% paraformaldehyde, 3% sucrose. Incubate 15 min in 
the dark (fixation step). 
4. Wash very carefully with 3 ml PBS 1X. 
5. Add very carefully 3ml 0.2% TX-100 in PBS 1X. Incubate the coverslips 10 min in the dark. 
(permeabilization of the membrane) 
6. Wash very carefully with 3 ml PBS 1X. 
7. Put 3 ml of sterile filtered serum-containing medium for 15 min in the dark (old sera can be used; filtrate the 
medium through 0.2 µm Millipore filter). These media are kept in the cold room. Take what is needed for 
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the experiment (do not forget to include volumes used to dilute the antibodies) under a sterile hood and work 
according to cell culture standards. 
8. Place some parafilm on a clean portion of the bench. Stretch the parafilm and fix it on the table with tape. 
9. Dilute the first antibody in filtered medium and place 50 µl drops on the parafilm (1 drop per coverslip). 
10. Take the coverslips with tweezers, remove the excess medium by touching a Kleenex tissue with the edge of 
the coverslip, and place the coverslip on the drop, face down. 
11. Cover the coverslips with a lid (typically the top part of a foam box used for the shipping of frozen 
biological goods ) with paper tapped on the interior side that must be moistened with water to reduce the 
extent of evaporation of the medium containing the antibodies. Incubate one hour. 
12. Prepare a small becher containing PBS 1X. 
13. Place 50 µl drops containing the second antibody (or any kind of labeling reagent) on a stretched parafilm 
(see #8-9). 
14. Take the coverslips with tweezers, remove the excess medium by touching a Kleenex tissue with the edge of 
the coverslip, hold the coverslip ~5 seconds in the PBS-containing becher, remove the excess liquid and 
place the coverslip on the drop, face down. Cover with a lid as described in #11 and incubate for a further 
hour. 
15. Take the coverslips with tweezers, remove the excess medium by touching a Kleenex tissue with the edge of 
the coverslip and place the coverslips face-up into the 6-well plate still filled with the filtered serum-
containing medium. 
16. Perform 6 incubations with PBS 1X in the dark. The incubations should last at least 20 min (preferably 30 
min). If the coverslips float up (which happens especially during the last washes), push them to the bottom 
of the wells with the tweezers. 
17. Clean the required number of slides to mount the coverslips. 
18. For each coverslip, place 2 µl of mounting medium on the slide (up to four coverslips can be mounted per 
slide). 
19. Take the coverslips with tweezers, remove the excess medium by touching a Kleenex tissue with the edge of 
the coverslip and place the coverslips face-down onto the drops of mounting medium. 
20. With a long white tip connected to the vaccum, remove the excess of mounting medium trying not to move 
the coverslips. 
21. Put some nail polish around the coverslips. 
22. Let the nail polish dry a few hours (typically o/n). 
23. Gently remove the dried PBS on the coverslips with a wet piece of Kleenex tissue. 
24. The coverslips can now be analyzed with the appropriate imaging system. 
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Introduction. 
In molecular biology, reverse transcription polymerase chain reaction (RT-PCR) is a laboratory 
technique for amplifying a defined piece of a ribonucleic acid (RNA) molecule. The RNA strand is first 
reverse transcribed into its DNA complement or complementary DNA, followed by amplification of 
the resulting DNA using polymerase chain reaction. This can either be a 1 or 2 step process. 
Polymerase chain reaction itself is the process used to amplify specific parts of a DNA molecule, via 
the temperature-mediated enzyme DNA polymerase. 
Reverse transcription PCR is not to be confused with real-time polymerase chain reaction which is also 
marketed as RT-PCR. 
The present SOP only describes the reverse transcription part of the procedure. 
 
RNA isolation. 
 
 Day 0 
1. Add 500 μl of TRI reagent (for 105 to 3 x 107 cells) to the cells and scrape them. Incubate at 
room temperature for 5 minutes. 
2. Add 200 μl of Chloroform, vortex and incubate 5 minutes at room temperature. 
3. Spin 15 minutes at maximum speed (13’000 rpm in the Eppendorf centrifuge 5415R; 16’100 x 
g). 
4. Transfer the aqueous phase into a new tube, add 500 μl of isopropanol, mix by inverting the 
tube a few times and put at -20°C o/n. 
 
 Day 1 
1. Spin 20 minutes at high speed (13’000 rpm in the Eppendorf centrifuge 5415R; 16’100 x g). 
At this stage if you do not see the pellet, add 40 μl of NaCl 5 M, mix by inverting the tube a 
few times and spin down again 15 minutes. 
2. Aspirate the isopropanol. 
3. Wash with 800 μl of ethanol 70%. 
4. Place the tubes in the thermomixer (Eppendorf Thermomixer Comfort, it is located in the lab) 
at 60°C for 10 minutes without shaking to let them dry. 
5. Resuspend the pellet in 50 μl of high quality water. 
6. Quantitate the RNA using the Eppendorf Biophotometer located in the lab. Push button n°9 to 
select the program to quantitate RNA, take the quartz cuvette QS 1.000  (usually located next 
to the Biophotometer), fill the cuvette with 200 μl of TE pH 8.0 and add 2 μl of your RNA. 
Mix. Click on the button labelled “Dilution” and enter the dilution (2:200). Proceed with the 
quantitation. Do not forget to do first the blank by  filling the same cuvette with 200 μl of TE 
and subsequently clicking on the button labelled ‘Blank’. You will get 260 nm values. An 
A260 reading of 1.0 is equivalent to ~40 μg/ml single-stranded RNA. 
Note that measuring the 260 nm/280 nm absorbance ratio of your samples is not a very informative method to monitor 
the purity of your preparation (despite what is written in some protocols) (Glasel, 1995). Note also that this ratio is 
influenced by the pH and ionic strength of the solution. As pH increases, the A280 decreases while the A260 is 
unaffected. This results in an increasing A260/A280 ratio (Wilfinger et al., 1997). Because water often has an acidic 
pH, it can lower the A260/A280 ratio. It is recommended to use a buffered solution with a slightly alkaline pH, such 
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as TE (pH 8.0), as a diluent (and as a blank) to assure accurate and reproducible readings. An example of the variation 
in A260/A280 ratio at different pH values is shown below 
 
BLANK/DILUENT A260/A280 ratio 
 
DEPC-treated water (pH 5-6) 1.60 
Nuclease-free water (pH 6-7) 1.85 
TE (pH 8.0) 2.14 
 
7. To have a better idea of the quality of your RNA, run it on an agarose-formaldehyde gel as 
follows: 
a. Melt 0.5 g of agarose in 37 ml of H2O, cool down a little bit, add 5 ml of 10x MOPS 
buffer and 8.75 ml of formaldehyde 36.5 %. 
b. RNA loading: prepare a mix composed of a few micro litres of your RNA 
(corresponding more or less to 500 ng), one fifth of the final volume with 5X RNA 
denaturing buffer, and water (usually up to a final volume of 10 μl). 
c. Perform electrophoresis in 1x MOPS. 
d. If your RNA preparation is good, you should see 2 bands, the highest one 
corresponds to the 28S RNA, the lowest one to the 18S RNA. 
 
 
 
Reverse Transcription 
0.5-1.0 μg total RNA 
1.0 µl of a 500 ng/µl oligo dT solution in water. 
The Olido dT primer is purchased from Microsynth; you have to sent an e-mail to the following address: 
administration@microsynth.ch asking for Random Hexamer D(N)6. Once you receive the tube (the quantity received is indicated 
on the datasheet), dissolve the oligo dT in water to get a concentration of 500 ng/µl. The oligo dT solution can be stored at -80 °C 
(alternatively, if you use them quite often, you can store some aliquots at -20 °C). For the delivery you can write in the e-mail 
your customer number, like that they automatically know your delivery address). 
Add water to 11 μl. 
3 minutes at 70°C and then keep on ice 
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Prepare the mix according to the table below. The buffer 5x, the DTT, the dNTPs, the RNAsin, and the 
reverse transcriptase come from the Superscript II Reverse Transcriptase Kit. 
Reagent μl 
    
dNTPs 10 mM each 5 
RNAsin 0.5 
Buffer 5x  5 
DTT 2 
Superscript reverse transcriptase 0.5 
H20 1 
    
Total 14 
 
Add the RNA to the mix and perform an incubation at 39ºC for 1 hour followed by 15 minutes at 70ºC. 
Your cDNA is now ready to be amplified by PCR. 
 
************************************** 
 
Materials and reagents Source/Company Code 
Agarose Eurogenetec EP-0010-10 
β-mercaptoethanol  Sigma M6250 
Bromophenol blue Fluka 18030 
EDTA Fluka 03620 
Ethidium Bromide Acros 170960010 
Formamide (25 M) Fluka 47670 
Formaldehyde 36.5% (13.2 M) Fluka 47629 
Ficoll Pharmacia Biotech 17-0400-01 
Guanidinium Thiocyanate  AppliChem 593-84-0 
MOPS (morpholinopropanesulphonic acid) Sigma M3183 
N-Lauryl Sarcosil sodium  Sigma L9150 
NaOH Fluka 71690 
Phenol (water saturated) EUROBIO GEXPHE01-0U 
RNA sin Promega N211A 
SDS Sigma L4390 
Sodium Acetate  Sigma S288 
Sodium Citrate  Sigma C8532 
dATP Promega U120D 
dGTP Promega U121D 
dCTP Promega U122D 
dTTP Promega U123D 
Superscript II Reverse Transcriptase Kit ( Buffer 5x, DTT 
and Superscript reverse transcriptase) Invitrogen 18064-014 
 
TRI solution (1.7 M guanidinium thiocyanate, 0.1 M sodium citrate, 0.25% sarcosyl, 0.05 M β-
mercaptoethanol, 0.1M sodium acetate) 
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Mix 10 ml guanidinium thiocyanate 4 M, 352 μl sodium citrate 0.75 M (pH 7), 528 μl sarcosyl 10% 
and 76 μl β-mercaptoethanol 14.3 M for a total volume of 10.9 ml. 
Place 10 ml of this mixture in a new tube, add 1 ml 2 M sodium acetate pH 4 and 10 ml of water-
saturated phenol. This is the final TRI solution that is good for at least 2 month at 4°C. 
 
10x MOPS buffer (0.2 M MOPS, 50 mM sodium acetate and 5 mM EDTA) 
200 ml of  MOPS 1M 
25 ml of sodium acetate 2M pH 4 
5 ml of EDTA 1 M 
Up to 1 liter with water 
The buffer is adjusted to pH 7.0 with 1 M NaOH and sterilised by autoclaving. Keep at 4 º C protected 
from light. 
 
Ethidium bromide 1mg/ml solution. 
Ethidium bromide is prepared under the chemical hood (wear gloves, protection glasses and mask) by 
dissolving the appropriate amount of powder in water; the solution is then stored at 4 º C. After 
preparing the solution wrap the tube with aluminium paper because EtBr is sensitive to light. 
 
FESB solution (Ficoll 10%, EDTA 10 mM, SDS 0.5% and bromophenol blue 0.02%) x 10 ml 
5 ml of Ficoll 20%   
100 μl of EDTA 1 M 
250 μl  of SDS 20% 
2 mg of bromophenol blue. 
 
RNA denaturing buffer 5x (Formaldehyde 2.6 M, Formamide 12.5 M, 2% Ficoll, 2mM EDTA, 
0.1%SDS, 0.004% bromophenol blu , ethidium bromide 40 μg/ml, in MOPS 1x) 
For ~1 ml 
200 μl of formaldehyde 36.5 %. 
500 μl of formamide. 
100 μl of MOPS 10x buffer. 
40 μl of ethidium bromide 1 mg/ml 
200 μl of FESB solution. 
Store at -20 °C. 
 
Tris-EDTA (TE) buffer  (10 mM Tris; 1 mM EDTA; pH 8.0)  
1 M Tris pH 8.0  1 ml   
0.5 M EDTA pH 8.0  0.2 ml   
H2Odd 98.8 ml   
Autoclave 
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Introduction. 
In molecular biology Cell Fractioning is a laboratory technique used to break cells and separate their 
molecular and structural components. Cell Fractioning can be divided in two steps: Homogenization 
and Fractionation. The Homogenization phase, whose purpose is to break the cell, is obtained either by 
the osmotic alteration of the media where cells are broken open through the utilization of an hypotonic 
buffer or by mechanical disruption. The Fractionation phase relies on the utilization of centrifugations 
at different speeds and times to separate cellular components on the basis of their size. 
 
Cell Fractioning (Nuclei/Cytoplasm). 
 
Day 0 
Spread at least 2.106 in a 10 cm plate. If you want to look at the localization of one or more exogenous 
protein transfect your cells according to either SOP 1.0 or SOP 3.0, depending on the cell type with 
which you are working. 
 
Day 1 
1. Wash your 10 cm plate with PBS. 
2. Add 400 μl of lysis buffer 0.5% Triton X-100. 
3. Scrape cells and incubate on ice for 20 minutes. 
4. Centrifugate at 13.000 rpm (16’100 x g) in the Eppendorf centrifuge 5415R located in the lab. 
5. Transfer the supernatant (membrane/cytoplasm fraction) into a new Eppendorf tube and keep 
the pellet. 
6. Quantitate the protein concentrations of your samples using the Eppendorf Biophotometer 
located in the lab (see SOP 13.0 [Bradford]). 
7. After completing the quantitation, add the loading buffer according to the amount of protein 
you want to load. At this point your Cytoplasmic fraction is ready to be loaded or 
alternatively you can store it at -20 °C. 
8. Rinse the pellet representing the nuclear/mithocondrial fraction with the lysis buffer once and 
resuspend in the lysis buffer containing 0.5% SDS. Shear the released genomic DNA by 
sonication. The sonicator (Heischer DmbH) is now located downstairs, in a room that is in 
front of Peter Clark’s group cell culture room. The settings you have to use are the followings: 
Cycle (representing the number of cycles per second): 0.8-0.9. 
Amplitude: 80% 
9. Once there you have to insert the metallic tip of the sonicator inside your Eppendorf tube and 
press the black button located on the top of the sonicator for 10 seconds. Two sonications are 
enough to completely break the DNA. After each sonication place the sample back on ice for a 
few seconds. Before processing the next sample, wash the metallic tip of the sonicator first 
with ethanol 70% and then with water. Dry the tip with a clean tissue. 
10. After sonication, centrifuge at 13.000 rpm  (16’100 x g) in the Eppendorf centrifuge 5415R 
and transfer the supernatant in a new Eppendorf. 
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11. Quantitate the protein concentrations of your samples using the Eppendorf Biophotometer 
located in the lab (see SOP 13.0 [Bradford]). 
12. After completing the quantitation, add the loading buffer according to the amount of protein 
you want to load. At this point your Nuclear fraction is ready to be loaded or alternatively 
you can store it at -20 °C. 
 
Cell Fractioning (Nuclei, Mitochondria, Cytoplasm and Membrane) 
Day 0 
Start from at least 10.106 using 10 cm plates. If you want to look at the localization of one or more 
exogenous protein transfect your cells according to either SOP 1.0 or SOP 3.0, depending on the cell 
type with which you are working. 
 
Day 1 
1. Wash your 10 cm plate with PBS. 
2. Add 300 μl of hypotonic lysis buffer. 
3. Scrape cells and incubate on ice for 20 minutes. 
4. Break mechanically the cells with a Dounce homogenizer. 
5. Centrifugate at 300 x g 5 minutes at 4 °C in the Eppendorf centrifuge 5415R to pellet nuclei. 
6. Transfer the supernatant in a new eppendorf and wash the pellet twice with the hypotonic lysis 
buffer. For each wash add 250 μl of hypotonic lysis buffer, centrifugate at 300 x g and discard 
the supernatant. 
7. Resuspend the pellet in 200 μl of  hypotonic lysis buffer + Triton X100 1%. 
8. Sonicate as described above.  
9. Centrifugate 10 minutes at 13.000 rpm  (16’100 x g). 
10. Discard the supernatant, risuspend the pellet, that represents the nuclear fraction, in 250 μl of  
lysis buffer 0.5% Triton X-100 containing 0.5% SDS and pass through a 26 gauge niddle 
several times to break. 
11. Sonicate 5 times 15 seconds. 
12. Centrifugate 10 minutes at 13.000 rpm  (16’100 x g). 
13. Quantitate the protein concentrations of your samples using the Eppendorf Biophotometer 
located in the lab (see SOP 13.0 [Bradford]). 
14. After completing the quantitation, add the loading buffer according to the amount of protein 
you want to load. At this point your Nuclear fraction is ready to be loaded or alternatively 
you can store it at -20 °C. 
15. For the mitochondrial fraction start from point number 5. After transferring the supernatant in 
a new Eppendorf tube, centrifugate at 10’000 x g in the Eppendorf centrifuge 5415R located 
in the lab for 10 minutes at 4 °C to pellet mithocondria. 
16. Transfer the supernatant in a new Eppendorf tube and resuspend the pellet in 200 μl of 
hypotonic lysis buffer + Triton X-100 1%.  
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17. Sonicate as described above. 
18. Quantitate the protein concentrations of your samples using the Eppendorf Biophotometer 
located in the lab (see SOP 13.0 [Bradford]). 
19. After completing the quantitation, add the loading buffer according to the amount of protein 
you want to load. At this point your Mitochondrial fraction is ready to be loaded or 
alternatively you can store it at -20 °C. 
20. Take the supernatant you transferred in a new Eppendorf tube (point number 10) and 
centirfugate at 100’000 x g 1.5 hours at 4 °C. For this centrifugation, you have to use the ultra-
centrifuge named Centrikon T-108 located in the P2 lab. The rotor, ‘Kontron 18425’, is 
located in the fridge in front of Romano Regazzi’s lab. Tubes that suit the rotor are provided 
from Beckman and the maximum volume you can put in the tubes is 1 ml. After the 
centrifugation (as well as before using it) clean it with ethanol 70% and water. Do not forget 
to put the rotor back to its storage place. 
21. Transfer the supernatant in a new Eppendorf tube. 
22. Quantitate the protein concentrations of your samples using the Eppendorf Biophotometer 
located in the lab (see SOP 13.0 [Bradford]). 
23. After completing the quantitation, add the loading buffer according to the amount of protein 
you want to load. At this point your Cytoplasmic fraction is ready to be loaded or 
alternatively you can store it at -20 °C. 
24. Resuspend the pellet in 150 μl of  hypotonic lysis buffer + Triton X100 1%. 
25. Sonicate as described above. 
26. Quantitate the protein concentrations of your samples using the Eppendorf Biophotometer 
located in the lab (see SOP 13.0 [Bradford]). 
27. After completing the quantitation, add the loading buffer according to the amount of protein 
you want to load. At this point your Membrane fraction is ready to be loaded or alternatively 
you can store it at -20 °C. 
 
Materials and reagents Source/Company Code 
TRIS (Trizma base) Sigma T1503 
Triton X-100 Fluka 93426 
NaCl Acros 207790050 
Glycerol Fluka 49780 
MgCl2 MERCK TA 808932 
KCl Fluka 60130 
SDS (sodium dodecyl sulphate) Sigma L4390 
HEPES AppliChem A3724 
Centrifuge tubes 11 x 34 mm Beckman 343778 
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Lysis buffer  0.5%  Tr iton X-100 (0.5%  Tr iton X-100, 50 mM Tr is-HCl pH 7.5, 137 mM NaCl, 
10%  glycerol, 0.5%  Tr iton X-100) 
For 10 ml 
5 ml of Tris-HCl pH 7.5 1M 
274 μl of NaCl 5M 
1 ml of glycerol 100% 
50 μl of Triton X-100 
Up to 10 ml with water 
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 Hypotonic lysis buffer (10 mM Hepes pH 7.4, 10 mM MgCl2 , 42 mM KCl) 
For 10 ml 
200 μl of Hepes pH 7.4 500 mM 
100 μl of MgCl2 1 M 
420 μl of KCl 1 M 
Up to 10 ml with water 
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Immunoprecipitation (IP) is the technique to precipitate a protein antigen out of solution using 
an antibody that specifically binds to that particular protein. It is useful when an interaction 
between two or more proteins has to be detected. 
Immunoprecipitation is not a difficult technique to carry out, it only requires the choice of a 
suitable lysis buffer and appropriate beads. 
The choice of the lysis buffer is critical because it should allow a proper cell membrane 
solubilisation without denaturing protein, when an interaction between two proteins is the 
ultimate purpose of the immunoprecipitation. Indeed denaturation might alter protein native 
three-dimensional structure thereby affecting the interaction occurring between the proteins of 
interest. 
The choice of beads depends on the isotype of the chosen antibody. 
 
Experimental protocol 
 
Lysis buffer preparation: 
IP lysis buffer should always contain: 
- One agent that buffers the pH change induced by lysed cells. Two buffer agents are 
commonly used: 
Tris-HCl pH 7.4 or HEPES-KOH pH 7.4 
- NaCl at concentration between 0 and 1 M to ensure osmotic shock for cell breaking. 
- Detergent to solubilise proteins. Detergents can be classified into two groups: Ionic and non-
ionic. Ionic detergents include sodium dodecyl sulphate (SDS) and deoxycholate, they are 
strong detergent but they also are denaturing agent that might affect the native structure of the 
protein and binding with other proteins. When it is important to retain native protein:protein 
interaction it is better to use non-ionic detergents such as NP-40 or Triton X-100. Non-ionic 
detergents are less efficient for protein solubilisation. Non-ionic detergents should be used at 
concentrations ranging from 0.1 up to 2% whereas ionic detergents should be used at 
concentration ranging from 0.01 to 0.5%. The final choice of detergent and concentration as 
well as of salt concentration is quite empirical. Researchers may have to test different 
conditions before succeeding in co-immunoprecipitating proteins of interest. 
For example a protein complex may require ionic detergents to be solubilised, but an excess 
of detergent might denature the native protein structures disrupting in this way the specific 
protein-protein interaction. In this case the co-immunoprecipitation of the proteins of interest 
would not be possible anymore. 
In the tables below are shown some physical and chemical properties of commonly used 
detergents. 
 
 
176
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Three commonly used lysis buffer for immuno/co-immunoprecipitation are now described. 
 
‘RIPA-like’ lysis buffer 
150 mM NaCl 
50 mM Tris-HCl pH 7.4 
0.25% Sodium Deoxycholate 
1 mM EGTA (Protease inhibitor) 
1 mM Na3VO4 (Phosphatase inhibitor) 
1 mM NaF (Phosphatase inhibitor) 
Supplemented with protease inhibitor cocktail 
 
Lysis buffer 1% NP-40 
50 mM Tris-HCl pH 7.4 
150 mM NaCl 
1% NP-40 
1 mM EGTA 
1 mM Na3VO4 
1 mM NaF 
1 mM MgCl2 
Supplemented with protease inhibitor cocktail. 
 
Lysis buffer 1% Triton X-100 
See lysis buffer 1% NP-40 and replace the NP-40 with Triton X-100.  
 
Choice of beads 
The commonly so-called beads for immunoprecipitation are composed of protein A or G 
coupled to a matrix. The most used matrices are sepharose and agarose. Protein G and A are 
bacterial proteins from Group G Streptococci and Staphylococcus aureus, respectively. When 
coupled to a matrix, protein G and protein A create useful, easy to-use media for routine 
purification of antibodies; in other words they are able to bind the Fc region of an 
immunoglobulin. This is the reason why they are largely employed for immunoprecipitation. 
In the table below are indicated the affinities of the different immunoglobulin classes for 
protein G and A. 
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Immunoprecipitation 
1) 20 µl of beads (G or A according to the isotype and the antibody type) per 
immunoprecipitation are transferred to an eppendorf tube and washed 3 times with washing 
buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40). For each wash, 1 ml of washing 
buffer is added to the eppendorf tube, which is then centrifuged at maximum speed in the 
Eppendorf centrifuge (5415R) located in the lab and previously cooled down to 4°C. 
2) After the last wash, the beads are resuspended in 500 µl of washing buffer and 1 to 2 µg of 
antibody is added. 
3) Samples are incubate 2 hours at 4°C with rotation. 
4) Beads are washed 3 times with washing buffer and after the last wash 500 µg to 1 mg of 
cellular lysate is loaded onto the beads. 
5) Sample is incubated 2 hours at 4 °C with rotation. 
6) Immunocomplexes are washed 3 times with washing buffer and resuspended in 2X sample 
buffer. The samples can be kept at -20 °C until further use. 
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 7) Optional: samples are boiled 10 minutes at 95 °C. Boiling is not always useful and may 
even sometimes alter migration of given proteins. 
 
 
 
Reagents 
Materials and reagents Source/Company Code 
Deoxycholic acid Acros 218590250 
Τris  Sigma T1503 
NaCl Acros 207790050 
NaF Acros 409910250 
EGTA Acros 201295000 
NP-40 Acros 205330500 
Protein G sepharose Amersham 17-0618-01 
Protein A agarose Roche 1134515 
Protease inhibitor cocktail tablets Roche 04693132001 
NP-40 (IGEPAL) Sigma I3021 
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